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Background: Heart failure (HF) affects around 500,000 people in the UK. HF medications are frequently
underprescribed and B-type natriuretic peptide (BNP)-guided therapy may help to optimise treatment.
Objective: To evaluate the clinical effectiveness and cost-effectiveness of BNP-guided therapy compared
with symptom-guided therapy in HF patients.
Design: Systematic review, cohort study and cost-effectiveness model.
Setting: A literature review and usual care in the NHS.
Participants: (a) HF patients in randomised controlled trials (RCTs) of BNP-guided therapy; and (b) patients
having usual care for HF in the NHS.
Interventions: Systematic review: BNP-guided therapy or symptom-guided therapy in primary or
secondary care. Cohort study: BNP monitored (≥ 6 months’ follow-up and three or more BNP tests
and two or more tests per year), BNP tested (≥ 1 tests but not BNP monitored) or never tested.
Cost-effectiveness model: BNP-guided therapy in specialist clinics.
Main outcome measures: Mortality, hospital admission (all cause and HF related) and adverse events;
and quality-adjusted life-years (QALYs) for the cost-effectiveness model.
Data sources: Systematic review: Individual participant or aggregate data from eligible RCTs. Cohort
study: The Clinical Practice Research Datalink, Hospital Episode Statistics and National Heart Failure
Audit (NHFA).
Review methods: A systematic literature search (five databases, trial registries, grey literature and
reference lists of publications) for published and unpublished RCTs.
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Results: Five RCTs contributed individual participant data (IPD) and eight RCTs contributed aggregate data
(1536 participants were randomised to BNP-guided therapy and 1538 participants were randomised to
symptom-guided therapy). For all-cause mortality, the hazard ratio (HR) for BNP-guided therapy was 0.87
[95% confidence interval (CI) 0.73 to 1.04]. Patients who were aged < 75 years or who had heart failure
with a reduced ejection fraction (HFrEF) received the most benefit [interactions (p = 0.03): < 75 years vs.
≥ 75 years: HR 0.70 (95% CI 0.53 to 0.92) vs. 1.07 (95% CI 0.84 to 1.37); HFrEF vs. heart failure with
a preserved ejection fraction (HFpEF): HR 0.83 (95% CI 0.68 to 1.01) vs. 1.33 (95% CI 0.83 to 2.11)].
In the cohort study, incident HF patients (1 April 2005–31 March 2013) were never tested (n = 13,632),
BNP tested (n = 3392) or BNP monitored (n = 71). Median survival was 5 years; all-cause mortality was
141.5 out of 1000 person-years (95% CI 138.5 to 144.6 person-years). All-cause mortality and hospital
admission rate were highest in the BNP-monitored group, and median survival among 130,433 NHFA
patients (1 January 2007–1 March 2013) was 2.2 years. The admission rate was 1.1 patients per year
(interquartile range 0.5–3.5 patients). In the cost-effectiveness model, in patients aged < 75 years with
HFrEF or HFpEF, BNP-guided therapy improves median survival (7.98 vs. 6.46 years) with a small QALY gain
(5.68 vs. 5.02) but higher lifetime costs (£64,777 vs. £58,139). BNP-guided therapy is cost-effective at a
threshold of £20,000 per QALY.
Limitations: The limitations of the trial were a lack of IPD for most RCTs and heterogeneous interventions;
the inability to identify BNP monitoring confidently, to determine medication doses or to distinguish
between HFrEF and HFpEF; the use of a simplified two-state Markov model; a focus on health service costs
and a paucity of data on HFpEF patients aged < 75 years and HFrEF patients aged ≥ 75 years.
Conclusions: The efficacy of BNP-guided therapy in specialist HF clinics is uncertain. If efficacious, it would
be cost-effective for patients aged < 75 years with HFrEF. The evidence reviewed may not apply in the UK
because care is delivered differently.
Future work: Identify an optimal BNP-monitoring strategy and how to optimise HF management in
accordance with guidelines; update the IPD meta-analysis to include the Guiding Evidence Based Therapy
Using Biomarker Intensified Treatment (GUIDE-IT) RCT; collect routine long-term outcome data for
completed and ongoing RCTs.
Trial registration: Current Controlled Trials ISRCTN37248047 and PROSPERO CRD42013005335.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 21, No. 40. See the NIHR Journals Library website
for further project information. The British Heart Foundation paid for Chris A Rogers’ and Maria Pufulete’s
time contributing to the study. Syed Mohiuddin’s time is supported by the NIHR Collaboration for
Leadership in Applied Health Research and Care West at University Hospitals Bristol NHS Foundation
Trust. Rachel Maishman contributed to the study when she was in receipt of a NIHR Methodology
Research Fellowship.
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Plain English summary
Heart failure (HF) affects about 500,000 people in the UK. A hormone secreted by the heart [B-typenatriuretic peptide (BNP)] is raised in people with HF; higher BNP indicates more severe HF. People with
HF may benefit from BNP being measured regularly, as doctors can increase medication doses to lower
BNP. However, more intensive treatment may cause side effects. It is uncertain whether or not BNP
monitoring works for patients and whether or not it represents value for money to the NHS.
In step 1, we combined the results of previous studies of BNP monitoring to determine which patients
benefit from BNP monitoring. In step 2, to overcome the limitation that studies recruited patients who
were mainly younger and healthier, we analysed data that were collected routinely in the NHS that
described people diagnosed as having HF between 1 April 2005 and 31 March 2013 and their health
outcomes. In step 3, we combined findings from steps 1 and 2 to find out how the cost-effectiveness of
BNP monitoring varies according to patients’ characteristics.
We found that BNP monitoring is cost-effective in patients who are < 75 years old and have poor heart
function. However, the effectiveness was not related to the reduction in BNP achieved or more intensive
medication. BNP monitoring is not effective in older patients or those with good heart function. BNP
monitoring was carried out in non-UK hospitals using a variety of methods, for example at different time
intervals and with different target levels. In the UK, general practitioners care for NHS patients with HF
unless they need hospital treatment. Therefore, it is not clear how BNP monitoring should be implemented
and whether or not it would work in the NHS.
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Scientific summary
Background
Heart failure (HF) affects ≈500,000 people in the UK and is associated with a poor prognosis; up to 40%
of newly diagnosed patients die within 1 year. HF is one of the most costly conditions treated in the NHS,
consuming about 2% of the NHS budget. The most common causes for HF are ischaemic heart disease
and high blood pressure.
Treatment is complex. Many drugs are indicated for HF, and national and international guidelines
recommend increasing drug doses to target, or maximally tolerated, levels. One reason for poor prognosis
is because some doctors prescribe less intensive treatment to avoid potential side effects, and B-type
natriuretic peptide (BNP)-guided therapy may help to optimise treatment. Surveys have shown poor
confidence in diagnosing and managing HF among general practitioners (GPs), cardiologists and HF nurses.
Objective
This study aimed to evaluate the clinical effectiveness and cost-effectiveness of BNP-guided therapy
(BNP monitoring) compared with symptom-guided therapy (usual care) in patients with HF.
Design
The study had three components: a systematic review and meta-analysis of individual participant data
(IPD) and aggregate data; an analysis of a historic cohort of patients with HF in the UK; and a lifetime
cost-effectiveness model to evaluate the cost per quality-adjusted life-year (QALY) gained by BNP-guided
therapy versus symptom-guided therapy.
Setting
Systematic review
The setting for the systematic review was randomised controlled trials (RCTs) of BNP-guided therapy versus
symptom-guided therapy in specialist HF clinics.
Cohort study
The setting for the cohort study was primary and secondary care, characterised by data from the sources
used to create the cohort.
Participants
Systematic review
The systematic review was carried out in participants with HF aged > 18 years in eligible RCTs of BNP-guided
therapy versus symptom-guided therapy in primary or secondary care. We characterised participants by age
(< 75 vs. ≥ 75 years), sex, New York Heart Association (NYHA) class (class I/II vs. class III/IV), type of HF [heart
failure with a reduced ejection fraction (HFrEF) vs. heart failure with a preserved ejection fraction (HFpEF)],
diabetes status, BNP level [≤ vs. >median across all trial participants but separately for BNP and N-terminal
pro-B-type natriuretic peptide (NT-proBNP)] and cause of HF (ischaemic/non-ischaemic).
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Cohort study
The cohort study was carried out in UK patients who have incident HF managed in general practices
contributing to the Clinical Practice Research Datalink (CPRD) and patients in the National Heart Failure
Audit (NHFA).
Interventions
Systematic review
Trial participants received treatment guided by serial BNP or NT-proBNP measurements (BNP-guided
therapy) or treatment guided by clinical assessment (symptom-guided therapy) in primary or secondary care.
Cohort study
Patients were classified as BNP monitored (≥ 6 months of observation time and three or more BNP tests
and two or more tests per year), BNP tested (one or more BNP test but not meeting criteria for BNP
monitored) or never tested (reference group; no BNP test recorded in the CPRD) based on the rate of BNP
testing. In the NHFA data set, admissions were classified according to whether or not a BNP test was
carried out during the admission.
Cost-effectiveness model
The intervention was BNP-guided therapy provided in a specialist clinic.
Main outcome measures
The outcomes of interest for the review and cohort study were all-cause mortality, HF-related death,
cardiovascular death, all-cause hospital admission, HF-specific hospital admission, adverse events and
quality of life. The outcome for the cost-effectiveness model was QALYs.
Data sources
Systematic review
Existing RCTs were identified by the review methods described below. IPD were sought for all included
RCTs. Aggregate data were extracted from publications when IPD were not available.
Cohort study
We obtained CPRD GOLD data from the General Practice Research Database through the CPRD; these
data are linked with Hospital Episode Statistics (HES) inpatient and outpatient data sets and the Office for
National Statistics mortality data set. We also obtained data from the NHFA for patients with unscheduled
admissions to a participating hospital. The NHFA provides clinical information, test results, medications and
diagnoses during admission, which are not captured in HES. NHFA were not linked with the CPRD cohort
because this link had not been performed previously and required additional approvals.
Cost-effectiveness model
Estimates of model parameters were obtained from the review and the cohort study. Estimates of utility
were obtained from the literature.
Review methods
We searched MEDLINE (via Ovid) from 1950 to 9 June 2016, EMBASE (via Ovid) from 1980 to 2016, The
Cochrane Library, Web of Science (Citations Index and Conference Proceedings) databases for published
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RCTs, the World Health Organization International Clinical Trials Registry Platform and Current Controlled
Trials for ongoing RCTs. Reference lists of full-text papers were reviewed and grey literature was searched
for unpublished studies. Study selection, data extraction and risk-of-bias assessment were carried out
in duplicate.
Results
Systematic review
Five RCTs contributed IPD and eight RCTs contributed aggregate data for one or more outcomes; 3074
patients who had HF were randomised (1536 to BNP-guided therapy and 1538 to symptom-guided
therapy). Hazard ratios (HRs) for BNP-guided therapy were 0.87 for all-cause mortality [95% confidence
interval (CI) 0.73 to 1.04], 0.97 for hospitalisation for any cause (95% CI 0.85 to 1.10) and 0.78 for
HF-specific admission (95% CI 0.65 to 0.95).
For all-cause mortality, there were significant interactions between treatment and age (p = 0.034) and
between treatment and type of HF (p = 0.026). BNP-guided therapy was beneficial for trial participants who
were < 75 years old (HR 0.70, 95% CI 0.53 to 0.92) but not for trial participants who were ≥ 75 years old
(HR 1.07, 95% CI 0.84 to 1.37) and for trial participants who had HFrEF (HR 0.83, 95% CI 0.68 to 1.01) but
not for trial participants who had HFpEF (HR 1.33, 95% CI 0.83 to 2.11). There was no interaction between
treatment strategy and age or left ventricular ejection fraction for other outcomes, but stratum-specific
estimates were consistent with those for all-cause mortality, suggesting benefit of BNP-guided therapy for
participants who are aged < 75 years or with HFrEF.
There was no statistically significant interaction between treatment strategy and age, sex, NYHA class,
diabetes or baseline BNP/NT-proBNP for any outcome.
Most RCTs provided no data on adverse events, precluding any meta-analysis, but some reported that
there were no apparent harms of BNP monitoring.
Cohort study
A total of 17,095 patients had incident HF between 1 April 2005 and 31 March 2013; this number
accrued linearly over time. We classified 13,632, 3392 and 71 patients, respectively, as never tested, BNP
tested and BNP monitored. Patients classified as BNP monitored were older, more likely to be female and
less likely to be overweight or obese; similar proportions in the three groups had any comorbidity but
there appeared to be differences for specific morbidities. There was no obvious pattern in the timing or
frequency of BNP tests in the monitored group. The number of BNP tests increased slightly faster than the
number of patients.
Overall, 49% of patients died during follow-up. The crude death rate was 141.5 (95% CI 138.5 to 144.6)
per 1000 person-years. Median survival was 5 years. The death rate was higher in the BNP-monitored
group than in the BNP-tested and never tested groups (186.5 vs. 130.6 and 186.5 vs. 143.9 per 1000
patient-years, respectively). The percentages of patients alive at 1, 2, 3 and 4 years after HF diagnosis were
84%, 74%, 64% and 56% in the never-tested group, 85%, 76%, 67% and 60% in the BNP-tested group
and 86%, 72%, 57% and 44% in the BNP-monitored group. Rates of admission to hospital were also
highest for the BNP-monitored group and lowest for the BNP-tested group.
Across the cohort, there was an average of 17 GP consultations per year (17 per year in BNP-tested and
never tested groups; 22 per year in the BNP-monitored group) but only 40% of patients had GP
consultations coded as HF or with HF-specific symptoms. There were no obvious differences between
groups in relation to different classes of medication, although a higher proportion of patients in the
BNP-monitored group appeared to be prescribed medications.
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The NHFA data described 163,244 admissions in 130,433 patients between 1 January 2007 and
31 March 2013. The characteristics of patients in the NHFA were broadly similar to those of patients in
the CPRD cohort; NHFA patients were slightly older and had more comorbidities or previous events, such
as myocardial infarction, percutaneous coronary intervention (PCI) or coronary artery bypass grafting
surgery. Most patients (97%) in the NHFA data set met the definition for incident HF admission. Median
survival time in the NHFA cohort was 2.2 years shorter than in the CPRD cohort. The admission rate in
patients with an incident HF admission was 1.1 per year [interquartile range (IQR) 0.5–3.5]; 17% were
readmitted during follow-up, with a median of 1 readmission (IQR 1–2). BNP tests were carried out during
10,114 admissions (6%), increasing from 0% to 10% over the period analysed.
Cost-effectiveness model
B-type natriuretic peptide-guided therapy is more costly but more effective than symptoms-guided therapy
over the lifetime of patients who are < 75 years and have any type of HF. If the relative reduction in
mortality is sustained for 4 years, median survival is approximately 1.5 years longer in patients who receive
BNP-guided therapy (7.98 vs. 6.46 years). The difference in mean QALYs is smaller (5.68 vs. 5.02),
reflecting the imperfect health of survivors and discounting of health gained in future years. Lifetime costs
are substantially higher in patients who receive BNP-guided therapy (£64,777 vs. £58,139), as the potential
for decreased hospitalisation observed in RCTs is more than offset by the costs of BNP testing, medications
and health care during the extended survival period. The positive incremental net monetary benefit (iNMB;
£6426, 95% CI £2401 to £10,075) indicates that BNP-guided therapy is cost-effective in this patient
subgroup at the £20,000 per QALY threshold used by the National Institute for Health and Care Excellence
(NICE). The evidence that BNP-guided therapy is cost-effective was stronger for patients with HFrEF than
for those with HFpEF.
There is some evidence that BNP-guided therapy has the potential to be cost-effective in older patients
with HFrEF. The estimated QALY gain (2.39 vs. 2.20) and iNMB is relatively small (£2267, 95% CI –£1524
to £6074) but there is a relatively high probability (0.88) that BNP-guided therapy is cost-effective at the
NICE £20,000 per QALY threshold.
Limitations
Systematic review
The main limitation of the systematic review was the inability to obtain IPD from most trials included in a
previous meta-analysis, which restricted the subgroup analyses that could be conducted; we could not
combine IPD subgroup estimates with other reported subgroup effects for all subgroups.
Other limitations were a result of features of the included RCTs. There was heterogeneity in the BNP-
monitoring and symptom-guided therapy interventions, predominant recruitment of patients < 75 years of
age with HFrEF and who are without comorbidities constrained application of the results to a broader HF
population and, in most of the RCTs, clinicians and participants were not blinded to treatment.
Cohort study
The main limitation of the cohort study was uncertainty about whether or not patients classified as BNP
monitored were in fact monitored, given the diversity in the patterns of BNP tests recorded. A proportion
of patients with short follow-up were classified as BNP tested but might have received BNP monitoring.
Serial BNP tests in the CPRD could have arisen from monitoring, cross-sectional testing to check HF
severity, or testing in relation to hospital admissions or outpatient appointments.
We could not determine medication doses accurately in the CPRD therapy data set, preventing any
investigation of changes in medication in patients classified as BNP monitored.
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We were unable to distinguish between patients with HFrEF and those with HFpEF because Read Codes
were not used consistently. The linkage between CPRD GOLD and the NHFA data could not be performed
in time; the NHFA data set would have provided more detailed clinical information on medications and
types of HF.
Some HF patients in the UK are managed in community HF clinics or at home by HF specialist nurses.
Community care databases are not linked with CPRD GOLD. Therefore, data for these patients were
missing from the CPRD GOLD data set.
Cost-effectiveness model
The model used a highly simplified two-state Markov model to track costs and patient outcomes. A more
complex model tracking dysfunction would provide a more realistic representation of disease progression.
Our model may lead to poor estimates of cost-effectiveness if BNP-guided therapy has a large effect
(positive or negative) on functional decline among survivors, but RCTs have reported that monitoring
makes no difference to quality of life.
Our analyses focus on costs to the health service, rather than wider costs falling on social care or patients
and families. BNP-guided therapy may be more cost-effective from a broader societal perspective if, for
example, it results in fewer admissions to residential or nursing homes.
The available evidence limited our ability to draw conclusions about cost-effectiveness in HFpEF patients
who are aged < 75 years and HFrEF patients aged ≥ 75 years. There was also no evidence on all-cause
hospitalisation stratified by patient subgroup.
Conclusions
The efficacy of BNP-guided therapy implemented in specialist HF clinics is uncertain, although, if efficacious, it
would be cost-effective among HF patients similar to those recruited to the RCTs and who were < 75 years of
age or who had HFrEF. Implemented in specialist clinics, it may also be efficacious and cost-effective in patients
< 75 years of age with HFpEF or in patients ≥ 75 years with HFrEF, but this is more uncertain.
The applicability of this evidence to HF patients in the UK is uncertain because UK patients are not usually
managed in specialist clinics, because there is evidence that clinical outcomes are worse in patients
managed in primary care and because differences in BNP levels or HF medications between groups in RCTs
were not associated with the magnitude of the benefit from BNP-guided therapy. Moreover, BNP-guided
therapy was implemented in diverse ways in RCTs and it is not clear how it should best be implemented.
Future work
The systematic review could not identify an optimal monitoring strategy, and no group of researchers has
defined one. Future research should attempt to do so, for example through a formal consensus process
involving relevant stakeholders.
In the RCTs, HF medications increased in both BNP-guided and symptom-guided therapy groups,
suggesting that HF management outside the RCTs was suboptimal. Research is needed to identify ways to
optimise management of HF in accordance with current guidelines.
Depending on the findings from the above research, there might be a need for a large pragmatic RCT of
BNP monitoring in the UK, evaluating the consensus-based optimal monitoring strategy in a clinical setting
that has optimised HF management.
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Most of the uncertainty about the cost-effectiveness of BNP monitoring is caused by wide CIs for the effect
sizes, particularly in patient subgroups not well represented in RCTs. The uncertainty could be reduced by
including results from the Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT)
trial in an updated IPD meta-analysis. This trial was recently terminated early for futility (https://dcri.org/
dcri-announces-halt-guide-trial/; accessed 7 March 2017), but the results would almost certainly shift pooled
effect estimates closer to no effect.
The cost-effectiveness model would also benefit from more evidence about the sustainability of the
treatment effect for BNP monitoring. This could be achieved by research to collect routine data on
long-term mortality and hospitalisation in completed and ongoing RCTs.
Finally, there is surprisingly little research on the economic impact of HF on health systems, families and
societies. Future research is required, particularly on residential care needs, informal care needs and
productivity losses due to HF in order to better judge the economic case for interventions such as
BNP-guided monitoring.
Trial registration
This trial is registered as ISRCTN37248047 and PROSPERO CRD42013005335.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. The British Heart Foundation paid for Chris A Rogers’ and Maria Pufulete’s
time contributing to the study. Syed Mohiuddin’s time is supported by the NIHR Collaboration for
Leadership in Applied Health Research and Care West at University Hospitals Bristol NHS Foundation Trust.
Rachel Maishman contributed to the study when she was in receipt of a NIHR Methodology Research Fellowship.
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Chapter 1 Introduction
Background and definition of the clinical problem
Heart failure (HF) is a complex syndrome in which the heart is unable to pump blood around the body at
the right pressure. It affects around 500,000 people in the UK,1 most of whom are older, with an
estimated prevalence of 6–10% in those aged > 65 years,2 increasing to 14% in those aged > 85 years.3
The prevalence is expected to increase as a result of the ageing population and the improved survival of
people with ischaemic heart disease. The prognosis of patients with HF is poor; up to 40% of newly
diagnosed patients die within 1 year.4,5 One of the reasons for the poor prognosis is that many patients are
not treated in accordance with guidelines and do not receive the optimal doses of available medications.6
Heart failure markedly impairs quality of life. HF signs and symptoms, which get progressively worse over
time, include fluid retention, shortness of breath and fatigue, especially on exertion.7 HF is one of the most
costly conditions to manage in the NHS, accounting for 5% of all emergency medical admissions and
consuming about 2% of the annual NHS budget.8 Global estimates indicate that, annually, HF results in
direct care costs of US$65B and lost productivity costs of US$43B owing to morbidity and premature
mortality.9 Health-care costs increase sharply at the end of life and are dominated by hospital care.10
The most common causes of HF are ischaemic heart disease and high blood pressure. Other causes include
congenital heart defects, genetic disease of the heart muscle, cardiac arrhythmia and alcohol misuse.
There are two main types of HF. HF caused by left ventricular systolic dysfunction (LVSD) occurs because
the left ventricle of the heart becomes weak and does not contract properly. This type of HF is referred to
as heart failure with a reduced ejection fraction (HFrEF). The other type of HF, referred to as heart failure
with a preserved ejection fraction (HFpEF), is caused by the left ventricle becoming stiff, which makes it
difficult for the heart chamber to fill with blood. Of patients with HF, just over half have predominantly
HFrEF and just under half have predominantly HFpEF. However, there is no agreement on the cut-off point
that defines low ejection fraction, and a range between < 35% and < 50% has been used in clinical trials
to classify patients as having HFrEF or HFpEF. Patients with HFrEF and those with HFpEF have different
demographic and clinical characteristics. Patients with HFpEF tend to be older, are more likely to be
women and are more likely to have hypertensive heart disease, renal failure, anaemia, atrial fibrillation and
obesity. Patients with HFrEF are more likely to have ischaemic heart disease, dilated cardiomyopathy and
hyperlipidaemia. Rates of morbidity and mortality are similar in both groups.
Pharmacological treatment for HF is complex, and includes angiotensin-converting enzyme inhibitors
(ACEis), angiotensin receptor blockers (ARBs), beta-blockers and mineralocorticoid receptor antagonists.
These drugs are currently administered at doses defined by clinical trials. National and international
guidelines recommend up-titration of these drugs to target (or maximally tolerated) doses, but this is
difficult to achieve in practice given the number of drugs involved and the fact that the sequence of
addition and up-titration is based largely on clinician judgement. However, many patients receive
suboptimal treatment because some clinicians are reluctant to increase medication doses after the initial
clinical improvement because they want to avoid potential side effects such as kidney failure and low
blood pressure.
There are significant gaps and variation in medical care of HF patients in the UK.11 Patients who are
discharged from hospital following an acute HF episode are largely managed in primary care. Surveys have
highlighted that general practitioners (GPs), cardiologists and HF nurses lack confidence in diagnosing and
managing HF (particularly HFpEF), and awareness of the relevant evidence base for care and GPs’ personal
preferences and organisational care pathways varies.12,13
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The health technology being assessed: B-type natriuretic
peptide-guided therapy
Biomarkers such as natriuretic peptides [B-type natriuretic peptide (BNP) or its derivative N-terminal
pro-B-type natriuretic peptide (NT-proBNP), collectively referred to here as BNP] have been used as a more
objective means of assessing HF severity and to prompt the appropriate titration of HF therapies. BNP is a
hormone secreted in the ventricular myocardium during periods of increased ventricular stretch and wall
tension. BNP levels reflect cardiac function. BNP levels are raised in patients with HF, with concentrations
rising in line with the severity of symptoms [New York Heart Association (NYHA) class]. BNP is, therefore,
useful for ruling out HF14,15 and for risk stratification; for every 100 ng/l increase in BNP, there is a
corresponding 35% relative increase in the risk of death.16 BNP testing is recommended by the National
Institute for Health and Care Excellence (NICE) as an essential part of the diagnostic pathway for HF, and it
has been shown to be cost-effective for diagnosis in both primary and secondary care.8
Treating HF with appropriate drugs leads to a reduction in BNP levels.17,18 Therefore, the use of BNP test
results to guide up-titration of medication has been proposed as an objective means of achieving optimal
therapy in patients with HF. The NICE 2010 guidelines8 recommended monitoring with BNP for some
groups of patients (e.g. those in whom up-titration is problematic and those who have been admitted to
hospital). However, it is currently unknown whether or not any HF patient group in the UK receives serial
BNP monitoring and, if they do, whether or not implementing serial BNP monitoring in practice has
changed patient management and improved clinical outcomes.
Several randomised controlled trials (RCTs) have assessed whether or not the use of serial BNP tests to
guide up-titration of medication improves clinical outcomes compared with symptom-guided therapy.
The RCTs were heterogeneous in design. Most used a BNP-lowering strategy, for which a BNP target
was set (a single target for all patients or an individualised target) and HF therapy was intensified to lower
or maintain BNP at the prespecified target. Other RCTs have used a BNP-monitoring strategy, with the
treating clinician being allowed to intensify therapy based on serial BNP results or if BNP increases by a
certain proportion above a patient’s baseline value, but without setting a BNP target. Data from RCTs
using a BNP-lowering strategy have been pooled in six aggregate data meta-analyses19–24 and one
individual participant data (IPD) meta-analysis.25 All of these analyses showed that health outcomes were
better in patients in the BNP-lowering group than in patients in the symptom-guided therapy group.
There is uncertainty about the balance of benefit and harm of BNP-guided therapy in the broader spectrum
of patients who make up the UK HF population (as opposed to the population included in RCTs). In elderly
patients with multiple comorbidities, the risks of adverse outcomes from intensified therapy may outweigh
any benefits. For example, up-titration of diuretics, ACEis and beta-blockers may worsen clinical outcomes
in elderly patients by causing hypotension and aggravating renal failure.
Rationale for the study
The overall aim of this study was to evaluate the clinical effectiveness and cost-effectiveness of BNP-guided
therapy compared with symptom-guided therapy (usual care) in patients with HF. The study included three
components: a systematic review and meta-analysis of IPD and aggregate data; an analysis of a cohort of
patients with HF that is geographically representative of patients with HF being managed in primary and
secondary care in the UK; and a lifetime cost-effectiveness model to evaluate the cost per quality-adjusted
life-year (QALY) gained by BNP-guided therapy versus symptom-guided therapy in patients with HF.
The systematic review and meta-analysis included all RCTs, regardless of BNP-monitoring strategy.
This differs from all previous meta-analyses, which have focused only on trials that used a BNP-lowering
strategy. The meta-analysis was conducted in accordance with the methods recommended by the IPD
Meta-analysis Methods Group of Cochrane26 and other published guidelines.27 We supplemented the
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systematic review and meta-analysis with a cohort study created by linking data from the Clinical Practice
Research Datalink (CPRD), Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality
register. We were concerned that the RCTs included in meta-analyses did not represent the wider UK HF
population. The RCTs had highly selected populations (younger patients; more men than women; patients
with HFrEF, high baseline BNP levels and no significant comorbidities), none was conducted in the UK and
all but one were conducted in secondary care settings. These features are not representative of the
broader UK population with HF (medical outpatients or patients in primary care) or the context in which
GPs and clinicians in the UK want to use BNP monitoring.
The NICE 2010 guidelines recommend further research on cost-effectiveness.8 The evidence on the
cost-effectiveness of BNP-guided therapy includes (1) economic evaluations conducted alongside RCTs
evaluating cost-effectiveness within the follow-up period of the trials28,29 and (2) model-based analyses
based on evidence from one30,31 or more32 RCTs, extrapolating costs and outcomes to the lifetime of
patients. We conducted a model-based cost-effectiveness analysis of BNP-guided monitoring in recently
hospitalised patients with HF. We aimed to extend previous economic evaluations in two ways. First, we
exploited recent IPD meta-analyses,25,33 including the analyses presented in this report, in estimating the
relative effect of BNP-guided therapy. Among the advantages of IPD meta-analysis is the opportunity to
investigate the (cost-)effectiveness of BNP-guided therapy in subgroups of patients who are not analysed
consistently or not reported in the original RCT publications.34 Second, we used linked data from the
CPRD, HES and ONS to inform key parameters of the model. In particular, we used these data to estimate
the NHS costs of care for patients with HF who are stable and managed in primary care compared with the
costs of those who are admitted to hospital.
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Chapter 2 B-type natriuretic peptide-guided
therapy for heart failure: systematic review and
meta-analysis of individual participant data and
aggregate data
Aims and objectives
The main aim of the meta-analysis was to determine the clinical effectiveness of BNP-guided therapy
versus standard care. The specific objectives were to:
l estimate the effect of BNP-guided therapy on clinical outcomes
l estimate the extent of effect modification for key outcomes including all-cause mortality and hospital
admission for clinically important subgroups
l quantify the extent to which improved outcomes are explained by up-titration of medication and/or
reduction in BNP levels
l combine adverse event and discontinuation data to describe the safety of BNP-guided therapy in
patients with HF.
Methods
The protocol for the systematic review and meta-analysis has been reported in detail elsewhere35 and is
registered with the PROSPERO register of systematic reviews as CRD42013005335 (www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42013005335; accessed 1 December 2016).
Study eligibility criteria
The meta-analysis comprised all RCTs of BNP-guided therapy for HF. The study population was all patients
aged > 18 years who were being treated for HF in primary or secondary care and who received treatment
guided by serial BNP or NT-proBNP measurements (BNP-guided therapy) or treatment guided by clinical
assessment (symptom-guided therapy).
Outcomes
The outcomes of interest were all-cause mortality, death related to HF, cardiovascular death, all-cause
hospital admission, hospital admission for HF, adverse events and quality of life.
Search methods for identification of studies
The search strategy is shown in Appendix 1. Published systematic reviews19–24 were initially used to identify
relevant trials. The following electronic databases were searched: MEDLINE (via Ovid) from 1950 to 9 June
2016; EMBASE (via Ovid) from 1980 to week 23 2016; The Cochrane Library; and Web of Science
(Citations Index and Conference Proceedings). The World Health Organization International Clinical Trials
Registry Platform (http://apps.who.int/trialsearch/; accessed 1 December 2016) and Current Controlled
Trials (www.controlled-trials.com; accessed 1 December 2016) were searched to identify trials in progress.
Reference lists of all full-text papers were reviewed and other grey literature was checked (www.opengrey.eu;
accessed 8 June 2016) to ensure that no unpublished study was missed.
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Study selection
Two members of the review team independently triaged the titles and abstracts identified by the search.
The remaining papers had clear inclusion criteria applied to them. Disagreements about study inclusion
were resolved by discussion with a third review author. All trials excluded from the review were given
reasons for exclusion. No language restriction was applied.
Establishing the individual participant data collaboration
Authors of eligible RCTs were invited to join the collaboration. Corresponding authors were sent the IPD
meta-analysis protocol with a cover letter explaining the study. Other RCT investigators were contacted if a
corresponding author failed to respond.
Quality assessment
Randomised controlled trials were assessed as having low, unclear or high risk of bias in accordance
with recent Cochrane guidelines.36 For blinding and incomplete outcome data, risk of bias was assessed
separately for the prespecified outcome domains (all-cause mortality, cause-specific mortality, adverse
events and quality of life). All-cause mortality was separated from cause-specific mortality because
cause-specific mortality may have risk of bias depending on whether or not the person assigning the
cause of death is blinded to the allocated intervention. RCT authors were asked to provide a study
protocol, if available.
Two members of the review team independently assessed the risk of bias in each included RCT from all
available information using the domain-based evaluation tool described in the Cochrane Handbook for
Systematic Reviews of Interventions.37 Disagreements were resolved by discussion with a third review
author. All authors of relevant unpublished RCTs were contacted to request data.
Data collection
Individual participant data were sought from all included RCTs (see Appendix 2 for the list of variables
requested) and collated into a single database. Data were requested for all randomised patients. The
formal data dictionary for the data set (a table of information about the data elements) and data collection
schedule (time points at which data were collected) were also requested. Detailed study information was
collected using a standardised data collection form (see Appendix 3).
Data checking
All data sets were checked for consistency against the original publication reports and discrepancies were
discussed and clarified with authors through e-mail communication. When clarification was not provided
by the authors, assumptions were made regarding the data and these were documented.
Statistical analysis
All analyses (see the IPD meta-analysis statistical analysis plan, which is available from the authors) were
performed on an intention-to-treat basis. The primary outcome of all-cause mortality, defined as the time
from randomisation to death from any cause, was analysed by survival methods. A hazard ratio (HR) was
estimated using Cox regression modelling for each RCT. The HRs were combined across RCTs using
random-effects meta-analysis38 and heterogeneity was assessed using the I2 test statistic. A fixed-effects
meta-analysis was also performed as a secondary analysis.
Subgroup effects were determined by estimating a treatment-by-covariate interaction term for each RCT
and combining the HRs for the subgroup-specific HRs as for the main analysis.39 Covariates defining
subgroups were age (< 75 years vs. ≥ 75 years), sex, NYHA class (class I/II vs. class III/IV), type of HF [HFrEF
vs. HFpEF, based on left ventricular ejection fraction (LVEF), < 40% in studies providing IPD and < 45% in
studies providing aggregate data], diabetes status, BNP level (median or lower vs. higher than the median
across all trial participants, with separate medians calculated for trials that reported BNP and NT-proBNP;
cause of HF (ischaemic/non-ischaemic), previous atrial fibrillation, body mass index (BMI) and systolic blood
pressure (SBP). The age cut-off point was chosen for consistency and to allow easy comparison with the
SYSTEMATIC REVIEW AND META-ANALYSIS
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meta-analysis by Troughton et al.25 Participants in recent HF trials focusing specifically on the effect of
therapies in the elderly [e.g. Irbesartan in Patients with Heart Failure and PRESERVEd Ejection Fraction
(I-PRESERVE); Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors
with Heart Failure (SENIORS); Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD); Evaluation of
Losartan in the Elderly Study (ELITE); Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF)]40–44
had a mean age of 73–76 years, and it is generally accepted that patients above this age range represent
elderly patients with HF. For the LVEF cut-off point, the clinicians on our team suggested that we use the
lower limit of normal LVEF (40%) used in clinical practice. For RCTs that did not provide IPD, HR estimates
from published reports (for both the main effects and subgroup effects) were combined with HR estimates
derived from the IPD. For the subgroup analyses, the HRs and associated 95% confidence intervals (CIs)
for the interaction effect were derived from the subgroup-specific HRs with 95% CIs. Stratum-specific
treatment effects for all-cause mortality (age and type of HF) and HF-specific admission (type of HF) were
available from a previous IPD meta-analysis33 that included seven RCTs. Interactions were calculated and
pooled as an aggregate estimate with additional trials which had contributed IPD for this study. For age
and sex, our analysis included an ‘aggregate’ interaction estimate from one RCT [Trial of Intensified versus
Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (Time-CHF); subgroup effects
reported by the triallists] for outcomes not reported in the previous IPD.
All of the analyses were prespecified and carried out in accordance with the statistical analysis plan, except
for the way in which interaction estimates from the previous IPD were combined to estimate some
subgroups more precisely. The decision to include the estimates from the previous IPD meta-analysis
prioritises greater precision of the revised estimates over exact adherence to our prespecified statistical
analysis plan. Two RCTs contributed IPD to the study and were also included in the previous meta-analysis;
for one, data to the end of follow-up were used for the overall analysis and data up to 90 days (used for
the previous meta-analysis) were used for the previously reported subgroup effects.
The relationship between the size of the treatment effect and the change in BNP values was investigated
by plotting the ratio of change in BNP values (in the BNP-guided therapy group compared with the
symptom-guided therapy group) against the hazard rate for each study with data available. The ratio of
change in BNP values was calculated as:
exp½ln(median BNP at end of follow-up in BNP-guided therapy group)
− ln(median BNP at baseline in BNP-guided therapy group)
exp½ln(median BNP at end of follow-up in symptom-guided therapy group)
− ln(median BNP at baseline in symptom-guided therapy group)
. (1)
For the three studies providing IPD, the ratio of change was also calculated using the patient-specific
change from baseline; after logarithmic transformation of all BNP values, the median change from baseline
was calculated in each treatment group and the ratio of the exponents of medians was calculated. All
analyses were conducted using Stata® version 14.0 (StataCorp LP, College Station, TX, USA), using the
‘ipdmetan’ command.45
Inclusion of aggregate data
For RCTs that did not provide IPD, aggregate data were included. Estimates of HRs from reports of studies
not providing IPD46 were combined with estimated HRs derived from the IPD.
Sensitivity analysis
The following sensitivity analyses (SAs) were conducted: restricting the analysis to RCTs that defined a BNP
target and restricting the analysis to trials with good allocation concealment, as this has been shown to be an
important source of bias in RCTs.47,48 A SA including only RCTs that had a low risk of bias across all domains
was planned; however, no RCT met this condition and therefore these analyses were not carried out.
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Checking for publication and data availability bias
Funnel plots were used to investigate association between the precision of the effect size and effect size
(which could be because of publication bias or ‘small study effects’),49 including and excluding RCTs for
which IPD were unavailable.
Changes to the study from the protocol stage
A major difficulty we faced when establishing the IPD collaboration was that an IPD meta-analysis of
BNP-guided therapy had already been published in abstract form by Troughton et al.50 We sought to
establish a collaboration with Professor Troughton and colleagues over a period of 15 months. We initially
asked for the data for the RCTs included in their meta-analysis, allowing us to carry out the analyses; then
we proposed that they should do the analyses to our analysis plan; tried to reach a compromise over the
proposed analyses (with them doing the analyses); and asked for the pooled estimates from subgroup
analyses that had already been carried out.51 None of these proposals was successful and, therefore, we
were unable to obtain IPD, or the results of subgroup analyses, from most RCTs included in the IPD
meta-analysis by Troughton et al.25,33 Consequently, we were unable to perform the subgroup analyses
specified in the protocol.35
Other changes to the study from the protocol stage include:
l A meta-analysis on cause-specific mortality outcomes was not conducted, as there were only two
studies (IPD) with data on cause of death.
l Meta-analyses on adverse event and quality of life were not conducted because no IPD studies
provided adverse event data and only one provided quality-of-life data.
l The following subgroup analyses were specified but could not be performed because the data were
not available from most studies: previous atrial fibrillation (there were only two RCTs with data, The
Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting (STARBRITE) trial52
and Anguita et al.53); BMI [there were only two RCTs with data, Use of PeptideS in Tailoring hEart
failure Project (UPSTEP)54 and NorthStar55 (the STARBRITE trial52 also provided BMI but had many
missing data)]; SBP (there were only two RCTs with data, NorthStar55 and STARBRITE;52 Shochat et al.56
also provided SBP but had many missing data); cause of HF (ischaemic/non-ischaemic, there were only
two RCTs with data, STARBRITE52 and NorthStar;55 Anguita et al.53 also provided cause of HF data but
correspondence suggested that some of these data were not accurate).
Results
Figure 1 shows the flow of studies through the review process. The literature search identified 2502
abstracts, which were screened for eligibility, 70 of which were screened as full-text articles. There were
23 RCTs eligible for inclusion (one was translated from Spanish):
l Nineteen RCTs involved long-term BNP monitoring in patients with stable HF, defined as monitoring
extended beyond the index hospital admission when a participant was recruited (most RCTs recruited
patients following an acute admission to hospital and stabilisation). Five studies provided IPD. Of the
14 RCTs that did not provide IPD, eight provided estimates of HRs for one or more of the outcomes of
interest in the published report (or these were available from the analyses of Troughton et al.25,33), two
had not finished recruiting at the time of writing this report and four had not published the results in
full so aggregate data were not available. In total, data from 13 RCTs involving long-term BNP
monitoring were used in the analysis.
SYSTEMATIC REVIEW AND META-ANALYSIS
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l Four RCTs involved short-term BNP monitoring, defined as monitoring in hospital during the index
admission (in patients hospitalised for an acute HF episode). Only one RCT provided IPD. The remaining
three RCTs had been published only as abstracts and estimates of HRs for the outcomes of interest
were not available. Therefore, a meta-analysis of RCTs evaluating short-term monitoring could not be
carried out.
Records identified through database
searching (date of search 8 June 2016)
(n = 4750)
Records after duplicates removed
(n = 2502)
Full-text articles and unpublished studies
(abstracts, posters) assessed for eligibility
(n = 70)
Records screened
(n = 2502)
Studies eligible for inclusion
(n = 23)
Records excluded
(n = 2432)
Excluded, with reasons
(n = 47)
• Different population, n = 1
• Not relevant, n = 1
• Erratum, n = 1
• Clinical trial update, n = 1
• Publication relating to the same 
   study, n = 28
• Editorial, n = 1
• Reviews, n = 3
• Duplicate publications, n = 8
• Unable to obtain PhD thesis, n = 1
• Single drug titration, n = 2
IPD requested [studies using 
short-term (in-hospital) 
BNP monitoring]
(n = 4)
IPD obtained
(n = 1)
Meta-analysis not carried out
IPD requested (studies using 
long-term BNP monitoring)
(n = 19)
IPD obtained
(n = 5)
Total included in meta-analysis (IPD + aggregate, n = 13)
IPD not obtained
(n = 3)
• Unable to make contact 
   with study authors, n = 2
• Refused to participate, 
   n = 1
• Refused to participate but 
   aggregate data available, n = 8
• Refused to participate and 
   aggregate data not available, n = 2
• Unable to make contact with 
   study authors, n = 2
• Study still recruiting, n = 2
IPD not obtained
(n = 14)
Additional records identified 
through other sources
(n = 37)
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. One eligible
study,57 published in abstract form in 2015, was identified at a late stage (June 2016) and therefore could not be included.
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Study characteristics
Table 1 shows the characteristics of the long-term BNP monitoring RCTs eligible for inclusion in the
meta-analysis. Of the 13 studies included in the meta-analysis, eight were conducted in Europe (none in
the UK),53–55,59,61–63,65 two were conducted in New Zealand,58,64 two were conducted in North America52,66
and one was conducted in Israel.56 Only one RCT63 [Swedish Intervention study – Guidelines and
NT-proBNP AnaLysis in Heart Failure (SIGNAL-HF)] was conducted in primary care; 12 were conducted in
hospital HF clinics, with most of these recruiting patients during or straight after hospitalisation for HF.
Two different types of BNP-guided therapy were identified.
1. BNP-lowering strategy: a BNP target (single target or individual target) was set and HF therapy was
intensified to lower BNP to the prespecified target.
2. BNP-monitoring strategy: a BNP target was not set; the treating clinician was allowed to intensify
therapy using serial BNP information or when BNP increased by a certain proportion from a patient’s
baseline value, that is, value at randomisation or previous visit.
Eleven RCTs used a BNP-lowering strategy52–54,58,59,61–66 and two used a BNP-monitoring strategy.55,56 Of the
11 RCTs that used a BNP-lowering strategy, eight set a single target (BNP 100–300 pg/ml; NT-proBNP
400–2200 pg/ml),53,54,58,59,61,64–66 two of which stratified by age (< 75 years and ≥ 75 years),54,59 and three
set an individual BNP target (BNP level at discharge, reduction of 50% from baseline).52,62,63 Treatment
algorithms in the BNP group differed slightly between studies but all were based on stepwise titration of
therapy according to clinical guidelines. In the two RCTs that used a BNP-monitoring strategy, clinicians
intensified treatment if BNP increased by > 30% from randomisation visit (NorthStar55) or previous clinic
visit (Shochat et al.56). In the control group, five studies52,53,58,59,64 used an algorithm designed to achieve a
target HF score based on signs and symptoms (e.g. Framingham HF score and NYHA class), and in six
studies61–63,65,66,69 therapy was entirely at the clinician’s discretion.
Risk of bias in included studies
Figure 2 and Table 2 show risk of bias for the included RCTs by risk of bias and outcome domains. None
of the RCTs had a low risk of bias across all domains. Ten out of 13 RCTs (77%)52–55,59,61–63,65,66 were rated
as having a high risk of bias in at least one domain. Three out of 13 RCTs (23%)56,58,64 were rated as
having unclear risk of bias; one of these studies56 provided IPD but no study protocol and was published as
an abstract only, so its risk of bias could not be fully assessed. The main factor that contributed to having a
high risk of bias was the lack of blinding (of participants and care-giving clinicians), which could lead to
differential departure from the intended intervention (performance bias). For some outcomes, outcome
assessors were blinded. For risk of bias from incomplete outcome data and selective outcome reporting,
we assessed only RCTs that had contributed aggregate data.
Participant characteristics
Patient characteristics are shown in Table 3. In the IPD data set, the average age of participants was
70 years; over one-third were aged ≥ 75 years. Three-quarters of patients were men. Most patients had
LVSD (median LVEF, 30%); only 8% of patients had LVEF > 40%. The majority of patients (> 80%)
had NYHA class II or III. The patients in studies providing aggregate data had similar characteristics.
Table 4 shows the baseline concentrations of NT-proBNP, BNP and other biomarkers for patients in
included studies. The severity of HF at baseline (as indicated by BNP or NT-proBNP levels) differed between
studies: one study recruited patients with mild HF (Anguita et al.,53 BNP 100 pg/ml) while other studies
recruited patients with more severe HF (BNP> 400 pg/ml or NT-proBNP > 2000 pg/ml, e.g. STARBRITE52
and UPSTEP54). Table 5 shows the comorbidities of patients in the included studies. Among the studies
providing IPD, about half of all patients had hypertension and a previous myocardial infarction (MI) and
just over one-third were diabetic. The proportions of patients with these comorbidities were similar in
studies providing aggregate data.
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Table 6 summarises the studies that were included in the meta-analysis for each outcome.
Primary outcome
Across all RCTs, 254 out of 1399 patients (18%) in the BNP groups and 290 out of 1399 patients (21%)
in the control groups died during follow-up. Median follow-up in the five RCTs52–56 that provided IPD was
18 months [interquartile range (IQR) 8–27 months]. There was a small reduction in the hazard of death
from any cause in the BNP-guided therapy group compared with the symptom-guided therapy group
(HR 0.87, 95% CI 0.73 to 1.04) (Figure 3). There was no significant heterogeneity between RCTs (see
Figure 3). The SA excluding the two RCTs that did not use a BNP-lowering strategy did not substantially
alter this finding (HR 0.86, 95% CI 0.71 to 1.04).
Only three RCTs52,59–61 were found to have good allocation concealment. The SA combining the effect
estimates from these three RCTs showed no difference in the hazard of death between groups (HR 0.93,
95% CI 0.60 to 1.44). In all meta-analyses, the results from the fixed-effects meta-analyses did not differ
from the reported results for the random-effects meta-analyses.
Secondary outcomes
Across six RCTs52–56,59,60 with data on all-cause hospitalisation, a total of 285 out of 493 patients (58%) in
the BNP group had at least one hospital admission, compared with 281 out of 491 patients (57%) in the
control group. BNP-guided therapy did not reduce the hazard of hospitalisation from any cause (HR 0.97,
95% CI 0.85 to 1.10) (Figure 4). The results did not differ in the analysis restricted to studies that used a
BNP-lowering strategy (HR 0.95, 95% CI 0.81 to 1.11). Of the three studies with good allocation
concealment, only two52,59,60 provided data on all-cause hospitalisations and the SA was not performed.
TABLE 6 Summary of studies included for each outcome analysed
Study Mortality (all cause) Hospitalisation (all cause) Hospitalisation for HF
Studies providing IPD
Anguita et al.53 ✓ ✓ ✓
NorthStar55 ✓ ✓ ✓
Shochat et al.56 ✓ ✓ ✓
STARBRITE trial52 ✓ ✓
UPSTEP54 ✓ ✓ ✓
Studies providing aggregate data
Christchurch pilot58 ✓ ✓
Time-CHF59,60 ✓ ✓ ✓
Berger et al.61 ✓ ✓
PRIMA62 ✓ ✓
SIGNAL-HF63 ✓ ✓
BATTLESCARRED64 ✓ ✓
STARS-BNP65 ✓ ✓
PROTECT66 ✓
PRIMA, Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and
mortality?; PROTECT, ProBNP Outpatient Tailored Chronic Heart Failure Therapy.
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Data source and study number HR (95% CI)
Number of
patients Weight
IPD
Anguita53
NorthStar55
Shochat56
STARBRITE trial52
UPSTEP54
Subtotal (I2 = 0.0%; p = 0.656)
Aggregate
Time-CHF (HFrEF)59,60
Time-CHF (HFpEF)59,60
Subtotal (I2 = 42.1%; p = 0.189)
Heterogeneity between groups: p = 0.885
Overall (I2 = 0.0%; p = 0.651)
0.95 (0.43 to 2.09)
0.93 (0.72 to 1.19)
1.35 (0.83 to 2.20)
0.80 (0.45 to 1.43)
0.93 (0.69 to 1.24)
0.96 (0.81 to 1.13)
60
407
119
130
268
984
2.7%
26.1%
7%
4.9%
19.6%
60.3%
0.91 (0.72 to 1.15)
1.27 (0.82 to 1.97)
1.02 (0.75 to 1.38)
499
123
622
31.2%
8.5%
39.7%
0.97 (0.85 to 1.10) 1606 100%
1
Favours symptom-guided therapyFavours BNP-guided therapy
20.50.250.125 4 8
FIGURE 4 All-cause hospitalisation: unadjusted individual HRs with 95% CIs for five studies providing IPD and one
study providing aggregate data. Meta-analysis HR (95% CI) presented both within IPD and aggregate data sources
and overall. HR for all-cause hospitalisation was available only for TIME-CHF: HFrEF59 and HFpEF60; no HR could be
obtained for the remaining studies that did not provide IPD.
Data source and study number HR (95% CI)
Number of
patients Weight
IPD
Anguita53
NorthStar55
Shochat56
STARBITE trial52
UPSTEP54
Subtotal (I2 = 0.0%; p = 0.0558)
Aggregate
Christchurch pilot58
Time-CHF (HFrEF)59,60
Time-CHF (HFpEF)59,60
Berger61
PRIMA62
SIGNAL-HF56
BATTLESCARRED64
STARS-BNP65
Subtotal (I2 = 19.9%; p = 0.272)
Heterogeneity between groups: p = 0.456
Overall (I2 = 2.4%; p = 0.423)
0.97 (0.24 to 3.87)
1.10 (0.71 to 1.69)
0.46 (0.17 to 1.22)
0.68 (0.21 to 2.14)
1.03 (0.62 to 1.71)
0.96 (0.71 to 1.28)
60
407
118
130
268
983
1.6%
15.7%
3.2%
2.3%
11.5%
34.4%
0.15 (0.02 to 1.16)
0.68 (0.45 to 1.02)
1.82 (0.83 to 4.00)
1.00 (0.54 to 1.85)
0.78 (0.53 to 1.15)
1.12 (0.38 to 3.28)
0.94 (0.54 to 1.63)
0.61 (0.23 to 1.63)
0.85 (0.66 to 1.09)
69
499
123
188
345
250
242
220
1936
0.7%
17.3%
4.9%
7.9%
19.2%
2.6%
9.8%
3.2%
65.6%
0.87 (0.73 to 1.04) 2919 100%
1
Favours symptom-guided therapyFavours BNP-guided therapy
20.50.250.125 4 8
FIGURE 3 All-cause mortality: unadjusted individual HRs with 95% CIs for five studies providing IPD and seven
studies providing aggregate data. Meta-analysis HR (95% CI) presented both within IPD and aggregate data
sources and overall. Time-CHF reported results separately for patients with HFrEF59 and patients with HFpEF.60
HR for all-cause mortality was not available for the PROTECT study.66
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Data on the number of patients with HF-specific hospitalisations were available from only three RCTs
providing aggregate data (Time-CHF,59,60 Berger et al.61 and STARS-BNP65) and four RCTs providing IPD.53–56
Across these studies, 245 out of 882 patients in the BNP groups (28%) were hospitalised for HF at
least once, compared with 311 out of 879 patients (35%) in the symptom-guided therapy groups. In a
meta-analysis of the effect of BNP-guided therapy on the hazard of hospitalisation as a result of HF,
BNP-guided therapy reduced the hazard (four RCTs provided IPD53–56 and eight provided aggregate
data;58–66 HR 0.78, 95% CI 0.65 to 0.95) (Figure 5). The results did not differ in the SA restricted to studies
that used a BNP-lowering strategy (HR 0.76, 95% CI 0.60 to 0.96). The SA with respect to allocation
concealment was again not performed because there were only two RCTs59–61 classified as having a low
risk of bias. No data were available for the other prespecified secondary outcomes (death related to HF,
cardiovascular death, adverse events and quality of life).
In all meta-analyses, the results from the fixed-effects meta-analyses did not differ from the results from
the random-effects meta-analyses.
Subgroup analyses
Subgroup analyses for age and LVEF included RCTs for which we had IPD combined with estimates
reported by Brunner-La Rocca et al.33 on the basis of the IPD that were available to them (ensuring that
data for no trial were included twice). Otherwise, the subgroup analyses were restricted to the three RCTs
that provided IPD and, for sex, one RCT that provided aggregate data (Time-CHF59,60).
Data source and study number HR (95% CI)
Number of
patients Weight
IPD
Anguita53
NorthStar55
Shochat56
UPSTEP54
Subtotal (I2 = 0.0%; p = 0.976)
Aggregate
Christchurch pilot58
Time-CHF (HFrEF)59,60
Time-CHF (HFpEF)59,60
Berger61
PRIMA62
SIGNAL-HF56
BATTLESCARRED64
PROTECT66
STARS-BNP65
Subtotal (I2 = 55.6%; p = 0.021)
Heterogeneity between groups: p = 0.167
Overall (I2 = 40.4%; p = 0.064)
1.10 (0.45 to 2.71)
0.88 (0.56 to 1.37)
0.89 (0.50 to 1.56)
0.91 (0.63 to 1.31)
0.91 (0.71 to 1.16)
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407
118
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852
3.8%
9.8%
7.5%
11.8%
32.8%
0.71 (0.23 to 2.23)
0.68 (0.50 to 0.92)
1.64 (0.89 to 3.01)
0.62 (0.38 to 1.02)
1.00 (0.68 to 1.47)
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FIGURE 5 Heart failure hospitalisation: unadjusted individual HRs with 95% CIs for five studies providing IPD and
eight studies providing aggregate data. Meta-analysis HR (95% CI) presented both within IPD and aggregate data
sources and overall.
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There was a significant interaction between treatment and age (< 75 vs. ≥ 75 years) for all-cause mortality
(based on four RCTs52,53,55,56 for which we had IPD and seven RCTs54,58–64 contributing to the estimates
reported by Brunner-La Rocca et al.,33 z = 2.119; p = 0.034) (Figure 6). BNP-guided therapy was beneficial
for trial participants who were < 75 years old (HR 0.70, 95% CI 0.53 to 0.92) but not for trial participants
who were ≥ 75 years old (HR 1.07, 95% CI 0.84 to 1.37). Interactions were not significant for any of the
other outcomes investigated. This is likely to be because Brunner-La Rocca et al.33 did not fully report
age-specific estimates for other outcomes; consequently, our estimates of the interaction for other outcomes
were less precise. Nevertheless, age-specific estimates for all outcomes were consistent, with younger
patients benefiting more from BNP-guided therapy than older patients for all outcomes (Figures 7 and 8;
see also Figure 16).
There was also a significant interaction between treatment strategy and LVEF for all-cause mortality
(based on four RCTs for which we had IPD, including one available to Brunner-La Rocca et al.33 and
six additional RCTs contributing to the estimates reported by Brunner-La Rocca et al.;33 z = 2.228; p = 0.026).
BNP-guided therapy appeared to be beneficial for trial participants with HFrEF (HR 0.83, 95% CI 0.68 to 1.01)
but not for trial participants with HFpEF (HR 1.33, 95% CI 0.83 to 2.11). There was no evidence of an
interaction between treatment strategy and LVEF for HF-related hospitalisation (based on two RCTs for which
we had IPD53,55 and seven additional RCTs contributing to the estimates reported by Brunner-La Rocca et al.;33
z = 1.246; p = 0.213) or for other outcomes. Stratum-specific estimates for HF-related hospitalisation were
consistent with those for all-cause mortality, suggesting benefit of BNP-guided therapy for trial participants
with HFrEF (HR 0.81, 95% CI 0.68 to 0.96) but not for trial participants with HFpEF (HR 1.07, 95% CI 0.73
to 1.57) (see Figure 6).
There were no significant interactions between the treatment strategy and any of the other covariates
investigated in the subgroup analyses for all-cause mortality (sex, p = 0.29, six RCTs;52–56,59 NYHA class,
p = 0.98, three RCTs;54–56 diabetes, p = 0.55, five RCTs;52–55,59 baseline BNP/NT-proBNP, p = 0.60, five
RCTs52,54–56,59) or all-cause hospitalisation (age, p = 0.31, six RCTs;52–56,59 sex, p = 0.10, six RCTs;52–56,59 NYHA
class, p = 0.95, four RCTs;53,54,56,59 LVEF, p = 0.89, three RCTs;53,55,60 diabetes, p = 0.35, five RCTs;52–55,59
baseline BNP/NT-proBNP, p = 0.81, five RCTs).52,54–56,59
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FIGURE 6 All-cause mortality subgroup analysis: (a) younger vs. (b) older age (< 75 vs. ≥ 75 years). All-cause
mortality: unadjusted individual HRs with 95% CI for four studies providing IPD and seven studies included in a
previous IPD meta-analysis (aggregate). (continued )
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FIGURE 7 All-cause hospitalisation subgroup analysis: (a) younger vs. (b) older age (< 75 vs. ≥ 75 years). All-cause
hospitalisation: unadjusted individual HRs with 95% CIs for five studies providing IPD and one study providing
aggregate data. Meta-analysis HR (95% CI) presented both within IPD and aggregate data sources and overall.
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There were no significant interactions between treatment strategy and any of the other covariates
investigated in the subgroup analyses for HF hospitalisation (sex, p = 0.80, five RCTs;53–56,59 NYHA class,
p = 0.59, four RCTs;53–56 diabetes, p = 0.27, four RCTs;53–55,59 baseline BNP, p = 0.75, four RCTs54–56,59).
For sex, the treatment effect estimates for all three outcomes investigated were of a similar magnitude in
men and women (Figures 9–11).
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FIGURE 8 Heart failure hospitalisation subgroup analysis: (a) younger vs. (b) older age (< 75 vs. ≥ 75 years). HF
hospitalisation: unadjusted individual HRs with 95% CIs for five studies providing IPD and one study providing
aggregate data. Meta-analysis HR (95% CI) presented both within IPD and aggregate data sources and overall.
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FIGURE 9 All-cause mortality subgroup analysis: (a) men vs. (b) women. All-cause mortality: unadjusted individual
HRs with 95% CIs for five studies providing IPD and one study providing aggregate data. Meta-analysis HR (95% CI)
presented both within IPD and aggregate data sources and overall.
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FIGURE 10 All-cause hospitalisation subgroup analysis: (a) men vs. (b) women. All-cause hospitalisation: unadjusted
individual HRs with 95% CIs for five studies providing IPD and one study providing aggregate data. Meta-analysis
HR (95% CI) presented both within IPD and aggregate data sources and overall.
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For NYHA class (class I/II vs. class III/IV), the treatment effect estimates were similar in the two NYHA class
strata for all outcomes investigated (Figures 12–14).
Of the five studies providing IPD, only two (Anguita et al.53 and NorthStar55) included patients with LVEF
> 40%, with 63 patients across the two trials. LVEF subgroup estimates for all-cause mortality were
available for seven studies54,58–64 providing aggregate data from the recently published subgroup analysis by
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FIGURE 11 Heart failure hospitalisation subgroup analysis: (a) men vs. (b) women. HF hospitalisation: unadjusted
individual HRs with 95% CIs for four studies providing IPD and one study providing aggregate data. Meta-analysis
HR (95% CI) presented both within IPD and aggregate data sources and overall.
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FIGURE 12 All-cause mortality subgroup analysis: (a) good vs. (b) poor NYHA class (class I/II vs. class III/IV). All-cause
mortality: unadjusted individual HRs with 95% CIs for three studies providing IPD, with meta-analysis HR and
95% CI.
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FIGURE 13 All-cause hospitalisation subgroup analysis: (a) good vs. (b) poor NYHA class (class I/II vs. class III/IV).
All-cause hospitalisation: unadjusted individual HRs with 95% CIs for four studies providing IPD, with meta-analysis
HR and 95% CI.
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Brunner-La Rocca et al.33 Figures 15–17 show the treatment effect estimates in the LVEF strata for all
outcomes investigated. For all-cause mortality, the treatment effect estimate for the lower LVEF subgroup
(< 40% in studies providing IPD and < 45% in studies providing aggregate data) suggested a protective
effect of BNP-guided therapy (HR 0.83, 95% CI 0.68 to 1.01), which was not evident in the higher LVEF
subgroup (HR 1.33, 95% CI 0.83 to 2.11). This effect was largely driven by one RCT (Time-CHF59,60); when
this RCT was excluded from the analysis, the protective effect in the lower LVEF subgroup was attenuated
(HR 0.89, 95% CI 0.71 to 1.11). For HF hospitalisation, the treatment effect suggested a protective effect
of BNP-guided therapy in the lower LVEF subgroup (HR 0.78, 95% CI 0.64 to 0.96) but no protective
effect in the higher LVEF subgroup (HR 1.61, 95% CI 0.95 to 2.71). For diabetic status, only one study59
providing aggregate data included estimates for any outcome by diabetes status (non-diabetic vs. diabetic).
Diabetes status was available from four studies providing IPD.52–55 The treatment effect estimates for the
two strata are shown in Figures 18–20. Although the interaction between treatment strategy and
diabetes status was not significant, Figure 20 suggests a protective effect of BNP-guided therapy on HF
hospitalisations in non-diabetic patients.
For baseline BNP subgroups (above vs. below the median BNP at baseline), data were combined for four
studies providing IPD52,54–56 and one study providing aggregate data.59 The treatment effect estimates were of
a similar magnitude in the low- and high-baseline-BNP groups for all outcomes investigated (Figures 21–23).
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FIGURE 14 Heart failure hospitalisation subgroup analysis: (a) good vs. (b) poor NYHA class (class I/II vs. class III/IV).
HF hospitalisation: unadjusted individual HRs with 95% CIs for four studies providing IPD, with meta-analysis HR
and 95% CI.
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FIGURE 15 All-cause mortality subgroup analysis: (a) reduced vs. (b) preserved LVEF (≤ 40% vs. > 40% for IPD
studies and ≤ 45% vs. > 45% for aggregate studies). All-cause mortality: unadjusted individual HR with 95% CIs for
four studies providing IPD and six studies included in a previous IPD meta-analysis (aggregate). (a) Reduced LVEF;
and (b) preserved LVEF. The individual estimates shown in the aggregate subgraph were reported previously.60
This previous IPD meta-analysis also included estimates for STARBRITE trial and UPSTEP but IPD were available for
these RCTs.
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Changes in B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide
from baseline to end of follow-up
B-type natriuretic peptide/NT-BNP levels at baseline and end of follow-up were available for 8 out of
13 RCTs (three IPD52,53,56 and five aggregate,58,62–64,66 Table 7). In five of these BNP/NT-BNP levels fell in both
groups.58,62–64,66 In three RCTs,62–64 the decrease in BNP/NT-BNP was greater in the symptom-guided therapy
group than in the BNP-guided therapy group. In one RCT (Shochat et al.56), NT-BNP levels had increased by
the end of follow-up in both groups.
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FIGURE 16 All-cause hospitalisation subgroup analysis: (a) reduced vs. (b) preserved LVEF (≤ 40% vs. > 40% for IPD
studies and ≤ 45% vs. > 45% for aggregate studies). All-cause hospitalisation: unadjusted individual HRs with
95% CIs for four studies providing IPD, with meta-analysis HR and 95% CI.
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Figure 24 shows a scatterplot of the HR (and 95% CI) for all-cause mortality versus the ratio of the change
in BNP/NT-proBNP from baseline between BNP-guided therapy and symptom-guided therapy groups for all
studies. There was no consistent relationship between the change in BNP from baseline between groups
and the HR for all-cause mortality for the same trial. The studies that provided evidence for a relationship
(i.e. studies with the most extreme HRs for mortality favouring BNP guided-therapy and in which BNP fell
substantially more in the BNP-guided group than in the symptom-guided group) provided least weight in
the meta-analysis. Calculating the relative change between groups using IPD (for studies that provided IPD)
provided even less evidence for a relationship.
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FIGURE 17 Heart failure hospitalisation subgroup analysis: (a) reduced vs. (b) preserved LVEF (≤ 40% vs. > 40% for
IPD studies and ≤ 45% vs. > 45% for aggregate studies). HF hospitalisation: unadjusted individual HRs with 95% CIs
for two studies providing IPD and seven studies included in a previous IPD meta-analysis (aggregate).
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Medication changes
The numbers of patients on each medication at baseline were available for all but one RCT that provided
IPD (Shochat et al.56) (Table 8). Two RCTs providing IPD (Anguita et al.53 and NorthStar55) and one RCT
providing aggregate data [Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure
IMprove heart fAilure morbidity and mortality? (PRIMA)62] also provided numbers of patients on different
medications at the end of follow-up. In these three RCTs, the proportion of patients on different
medications at baseline and end of follow-up were similar in the BNP-guided therapy group and control
group. Medication doses were provided in only one RCT (Anguita et al.53). Therefore, it was not possible to
carry out an analysis investigating the association between the changes in medication and outcomes.
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FIGURE 18 All-cause mortality subgroup analysis: (a) diabetic vs. (b) non-diabetic. All-cause mortality: unadjusted
individual HRs with 95% CIs for four studies providing IPD and one study providing aggregate data. Meta-analysis
HR (95% CI) presented both within IPD and aggregate data sources and overall.
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Adverse events
None of the IPD studies or aggregate data studies provided data on adverse events. Therefore, it was
not possible to assess the safety of BNP-guided therapy. However, six out of eight studies58,59,62,63,65,66
providing aggregate data reported that there were no significant differences in adverse events between
the BNP-guided and symptom-guided treatment groups.
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FIGURE 19 All-cause hospitalisation subgroup analysis: (a) diabetic vs. (b) non-diabetic. All-cause hospitalisation:
unadjusted individual HRs with 95% CIs for four studies providing IPD and one study providing aggregate data.
Meta-analysis HR (95% CI) presented both within IPD and aggregate data sources and overall.
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Quality of life
Only one IPD study55 provided quality-of-life data at baseline. However, the study publication reported
no differences in quality of life (using the Minnesota Living with Heart Failure questionnaire) between
BNP-guided therapy and symptom-guided therapy groups (p = 0.09). None of the other IPD studies
provided any data on quality of life. Five out of eight aggregate data studies58,59,62,64,66 reported quality of
life; four of these58,59,62,64 showed no difference between BNP-guided therapy and symptom-guided
therapy groups, although one66 found greater improvement in quality-of-life scores among patients in the
BNP-guided therapy group.
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FIGURE 20 Heart failure hospitalisation subgroup analysis: (a) diabetic vs. (b) non-diabetic. HF hospitalisation:
unadjusted individual HRs with 95% CIs for four studies providing IPD and one study providing aggregate data.
Meta-analysis HR (95% CI) presented both within IPD and aggregate data sources and overall.
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Funnel plots to assess small study effects
Funnel plots were generated for each outcome to visualise the risk of small study effects arising from
differential risk of reporting biases and methodological quality by sample size (Figures 25–27). Formal
statistical tests of funnel plot asymmetry were not carried out, given the small number of RCTs
contributing to each plot. None of the plots suggested marked asymmetry.
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FIGURE 21 All-cause mortality subgroup analysis: (a) high vs. (b) low BNP at baseline (≤median vs. >median).
All-cause mortality: unadjusted individual HRs with 95% CIs for four studies providing IPD and one study providing
aggregate data. Meta-analysis HR (95% CIs) presented both within IPD and aggregate data sources and overall.
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Data source and study number
(b)
HR (95% CI)
Number of
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Subtotal (I2 = 25.6%; p = 0.258)
Aggregate
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Overall (I2 = 9.1%; p = 0.354)
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FIGURE 22 All-cause hospitalisation subgroup analysis: (a) high vs. (b) low BNP at baseline (≤median vs. >median).
All-cause hospitalisation: unadjusted individual HRs with 95% CIs for four studies providing IPD and one study
providing aggregate data. Meta-analysis HR (95% CI) presented both within IPD and aggregate data sources
and overall.
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Data source and study number
(a)
HR (95% CI)
Number of
patients Weight
IPD
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Data source and study number
(b)
HR (95% CI)
Number of
patients Weight
IPD
NorthStar55
Shochat56
UPSTEP54
Subtotal (I2 = 16.0%; p = 0.304)
Aggregate
Time-CHF (HFrEF)59,60
Subtotal (I2 = .%; p = .)
Heterogeneity between groups: p = 0.783
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0.87 (0.67 to 1.12) 655 100%
1
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20.50.250.125 4 8
FIGURE 23 Heart failure hospitalisation subgroup analysis: (a) high vs. (b) low BNP at baseline (≤median vs. >median).
HF hospitalisation: unadjusted individual HRs with 95% CIs for four studies providing IPD and one study providing
aggregate data. Meta-analysis HR (95% CI) presented both within IPD and aggregate data sources and overall.
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Summary of findings
Our meta-analyses, including up to 3074 patients with HF (1536 randomised to BNP-guided therapy and
1538 randomised to symptom-guided therapy), showed that BNP-guided therapy reduced the hazard of
death from any cause by 13% (HR 0.87, 95% CI 0.73 to 1.04) and the hazard of hospital admission for
HF by 22% (HR 0.78, 95% CI 0.65 to 0.95). These results are consistent with those of a previous IPD
meta-analysis by Troughton et al.25 (including 11 trials, 2000 patients, also in the present analysis, but
excluding HFpEF participants recruited to the TIME-CHF) RCT,60 which showed an 18% reduction in the
hazard of death from any cause (HR 0.82, 95% CI 0.67 to 1.00) and a 26% reduction in the hazard of
hospital admission for HF (HR 0.74, 95% CI 0.60 to 0.90).
The results from our subgroup analyses showed more benefit of BNP-guided therapy in patients < 75 years
old and patients with HFrEF, which is consistent with the analyses reported by Troughton et al.25 and
Brunner-La Rocca et al.33
There were significant interactions between treatment strategy and age, and between treatment strategy
and type of HF, for all-cause mortality. These interactions were not significant for any of the other
outcomes investigated, although age-specific and type of HF-specific estimates for all outcomes were
consistent with the findings for all-cause mortality. The interaction between treatment strategy and type of
HF was largely driven by one RCT (Time-CHF); when this RCT was excluded from the analysis, the
protective effect in the HFrEF subgroup was considerably attenuated.
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Ratio of change in BNP/NT-proBNP from baseline for
BNP-guided therapy group compared with
symptom-guided therapy group
Favours
BNP-guided
therapy
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therapy
0.25
0.15
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Anguita53
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PRIMA61
BATTLESCARRED64
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FIGURE 24 Relationship between HRs for all-cause mortality and the ratio of the change in BNP/NT-proBNP from
baseline between the BNP-guided therapy group and symptom-guided therapy group. Filled circles represent the
ratio of the change calculated using aggregate data and open circles represent the ratio of the change calculated
using IPD when available; the change in the position on the x-axis for three trials shows how the effect estimates
change with the two analyses methods, while the position on the y-axis remains the same.
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There also appeared to be a protective effect of BNP-guided therapy on HF hospitalisations in non-diabetic
patients (HR 0.76, 95% CI 0.58 to 0.98), which was not evident in diabetic patients (HR 0.93, 95% CI
0.67 to 1.30), although the test of interaction for this analysis was not statistically significant.
Unlike Brunner-La Rocca et al.,33 we could not investigate the interaction effect of treatment strategy and
age controlling for the interaction effect of treatment strategy and type of HF because we had IPD for a
minority of the RCTs. Brunner-La Rocca et al.33 reported that the interactions were independent but noted
that the interaction of treatment strategy with type of HF was explained by comorbidities, in particular
renal failure.
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FIGURE 26 Funnel plot with pseudo 95% confidence limits for the secondary outcome of all-cause hospitalisation.
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FIGURE 25 Funnel plot with pseudo 95% confidence limits for the primary outcome of all-cause mortality.
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FIGURE 27 Funnel plot with pseudo 95% confidence limits for the secondary outcome of HF hospitalisation.
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Chapter 3 B-type natriuretic peptide
(or N-terminal pro-B-type natriuretic peptide) testing
and monitoring in patients with chronic heart failure:
a population-based cohort study in the Clinical
Practice Research Datalink
Aims and objectives
The aim of the cohort study was to characterise a representative cohort of English patients with HF and to
evaluate the clinical effectiveness of BNP-guided therapy compared with usual care in patients with chronic
HF. The specific objectives were to:
l create a cohort of HF patients from routinely collected data sets [CPRD, National Heart Failure Audit
(NHFA), ONS, HES] and profile their longitudinal care pathway, from diagnosis, through treatment,
to outcome
l classify patients in the cohort according to their history of BNP testing
l estimate the effect of BNP-guided therapy on clinical outcomes compared with usual care
l estimate the effect of BNP-guided therapy in predefined subgroups of HF patients (e.g. by age group,
sex, type of HF, severity of HF, baseline BNP levels)
l derive summary resource use statistics to characterise the cohort to be used to inform parameter
estimates in a cost-effectiveness model of BNP monitoring in primary and secondary care in the UK.
Methods
This was a retrospective population-based longitudinal cohort study. The cohort was created by linking
data from the CPRD, HES and ONS mortality.
Data sources
The CPRD includes all data from the General Practice Research Database, which was established in 1987.
It contains anonymised longitudinal primary care records, usable for research purposes, from over
13 million patients in the UK (from 684 GP practices in England, Wales, Scotland and Northern Ireland).
The geographical distribution of the GP practices participating in the General Practice Research Database
is representative of the UK population (www.cprd.com/home; accessed 1 December 2016). The CPRD
GOLD data set contains details of consultations, diagnoses, interventions, test results, prescriptions and
referrals. Coded data are provided as several data sets (clinical, referral, test and therapy data sets). The
data set includes a combination of coded data (coded at the time of entry, usually by the GP) and free text
associated with the coded entries: the free text has been either typed by the GP or obtained from hospital
letters. CPRD GOLD includes data from about 8% of the UK population. GP practices that contribute data
to the CPRD are each assigned an up-to-standard (UTS) date, that is, the date after which the data
submitted by the practice are considered to meet assigned data quality standards. Only data submitted
after the UTS date were used for analysis.
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CPRD GOLD is linked with the HES inpatient data set, which contains details of all hospital admissions in
England, including dates of admission and discharge and main diagnoses. The CPRD recently established
linkage with the HES outpatient data set, which contains details of outpatient appointments and the
clinical diagnoses these relate to. CPRD GOLD is also linked with the ONS mortality data set, which
contains the date and cause of death (from the death certificate) for the population of England and Wales.
The linkage is performed via NHS Digital (a trusted third party). GP practices submit patient data directly to
NHS Digital, which links IPD with HES and ONS via the patient’s NHS number, sex and partial date of birth.
Only about 40% of GP practices that contribute to the CPRD have given approval for their data to be
linked with HES. NHS Digital submits patient data to the CPRD with pseudonym identifiers, either linked
with HES/ONS or not linked (for GP practices that have not given approval for linkage).
Additional planned linkage
The original application also proposed linking the CPRD GOLD data source with the NHFA (January 2007
and March 2013), which contains data on the care and treatment of patients who have an unscheduled
admission to a participating hospital resulting from HF. The NHFA provides information that is not captured
in HES, including detailed clinical information, test results, medications and diagnoses during admission.
The data items are collected by NHFA in order to audit adherence to national guidance on the care and
treatment of patients with HF by participating hospitals. The planned flow of data is shown in Figure 28.
Study population
The study population was identified in CPRD GOLD. Patients were included in the study if they had a
HF diagnosis between 1 April 2005 and 31 March 2013 with no HF diagnosis in the preceding year
(i.e. incident HF), had at least 1 year of UTS follow-up before HF diagnosis and had a linked HES and/or
ONS record. HF patients from GP practices that did not participate in the HES/ONS linkage programme
were excluded.
Incident HF was defined from Read Codes, which are a hierarchical clinical coding system of over 80,000
terms that are used in general practice in the UK. In the absence of any established algorithm for
NHS 
Digital
linkage
CPRD
2005–13
NICOR/NHFA
2007–13
CPRD cohort 
(HF and no HF 
but > 1 BNP test)
pseudonym 
identifiersa
Study-specific
patient identifiers +
clinical data
(HESb/ONS linked)
Study-specific
patient identifiers +
clinical data
(HES/ONS linked)
NHFA/NICOR
patient
identifiers
Study-specific 
patient identifiers
UoB
First data 
flow
Second 
data flow
Third 
data flow
FIGURE 28 Flow of data for the planned linked cohort. NICOR, National Institute for Cardiovascular Outcomes
Research; UoB, University of Bristol. a, GP practices submit pseudo patient identifiers and patient identifiers to NHS
Digital; b, NICOR will not provide HES data on patients linked with the CPRD.
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identifying incident HF from Read Codes, three incidence algorithms were defined, which were organised
hierarchically to have decreasing sensitivity but increasing specificity, to identify patients with HF:
1. Specific HF diagnosis codes OR symptom-specific codes, which included codes for a variety of heart
conditions that could potentially represent HF (e.g. oedema). This was the most sensitive algorithm
(cohort 1).
2. Same codes as in cohort 1 AND the presence of a BNP test or echocardiography test within 6 months
of the HF code AND more than one HF medication prescription within 6 months of HF code (cohort 2).
3. Specific HF diagnosis codes only AND the presence of a BNP test or echocardiography test within
6 months of the HF code AND more than one HF medication prescription within 6 months of HF code.
This was the most specific algorithm (cohort 3).
Algorithm 3 was used to define the main study cohort. The specific HF diagnosis codes used for algorithm 3
were based on the published Quality and Outcomes Framework guidance for coding HF in the CPRD
(www.pcc-cic.org.uk/article/qof-read-codes-v30/; accessed 22 June 2017) (Read Code lists for algorithms
1–3 together with BNP test codes, echocardiography test codes and qualifying HF medications are shown in
the statistical analysis plan, which is available from the authors, for the cohort study).
Exposures (B-type natriuretic peptide testing and B-type natriuretic peptide monitoring)
Patients were classified as BNP monitored, BNP tested or never tested based on the rate of BNP testing.
We planned to compare outcomes for the BNP-monitored and BNP-tested groups with the never-tested
group. The groups were defined as follows.
1. Never tested (reference group): no BNP tests recorded in the CPRD.
2. BNP tested: one or more BNP test (irrespective of the duration of observation for a patient in the
cohort) but not meeting criteria for BNP monitored.
3. BNP monitored: ≥ 6 months of observation time AND three or more BNP tests carried out AND two or
more tests per year.
These definitions were developed by examining the data set for serial BNP testing but before any analyses
that described outcomes by group. Different definitions were developed and the clinical members of the
team reached consensus about the definition that was most likely to represent some form of monitoring
(based on the frequency of tests per year).
Outcomes
The primary outcome measure of the study was time to all-cause mortality from diagnosis of HF. Patients
were censored either at date of death or on 1 May 2014 (the last date on which ONS data were available).
Patients who had a diagnosis of HF recorded for the first time on the same date as death were given a
survival time of 0.5 days to enable them to be included in the analysis population. The secondary outcomes
were time from diagnosis of HF to emergency in hospital admission(s)/unscheduled readmission(s), length
of hospital stay following all unscheduled admissions for HF, prescribed medications on discharge after all
unscheduled admissions for HF, new medication/s started, current medication(s) stopped, time on each
medication, annual rate of outpatient clinic and GP attendance and annual rate of HF-related investigations
(e.g. echocardiography).
Patients’ observation time was censored either at date of death or on 1 April 2014 (the last date at which
ONS data were available). Patients who experienced a secondary outcome before diagnosis of HF were
censored at that point, that is, their observation time did not contribute to measures of the frequencies of
outcomes after diagnosis.
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Emergency/unscheduled hospital admissions and HF hospital admissions were identified from HES, the
latter using International Classification of Diseases, Tenth Edition,70 codes (I11.0, I13.0, I13.2, I50, I50.0,
I50.1, I50.9) recorded against the hospital spells. Length of hospital stay for each admission was provided
in HES; admissions were grouped into continuous inpatient spells (full details are given in the statistical
analysis plan for the cohort study, which is available from the authors). Outpatient appointments were
identified from the HES outpatient data set. Multiple appointments on the same day under different
treatment specialties were treated as separate appointments; multiple appointments on the same day
under the same treatment specialty were treated as a single appointment. Outpatient appointments in
which the patient was treated under the cardiology specialty were identified. Medications were grouped
into classes (e.g. ACEis, ARBs, beta-blockers). Within each medication class, ‘courses’ of medications were
identified. A new course of medication was defined as a prescription for any medication within the class
with no prescription in the previous 6 months. The period of time for each course of medication was
calculated as the difference between the dates of the last and first prescription within the course plus
28 days (assuming an average prescription length of 28 days for all medication classes). HF-related
investigations referred to echocardiograms and BNP tests.
Comorbidities were identified from previously defined Read Codes in the CPRD (https://clinicalcodes.rss.
mhs.man.ac.uk; accessed 1 May 2016)71 in the year prior to incidence date (cohort entry). The absence of
a comorbidity Read Code was assumed to mean the patient did not have that comorbidity. The Charlson
Comorbidity Index is calculated as the sum of weights for all comorbidities recorded for the patient in
the year prior to cohort entry.72
Covariates
Confounders were specified a priori. Two groups of potential confounders were specified: patient-level
confounders (age, sex, severity of HF, degree of comorbidity classified using the Charlson Comorbidity
Index) and practice-level confounding (practice deprivation index). Severity of HF was assessed using the
NYHA classification; for patients without NYHA classification recorded in the CPRD, the severity was
treated as unknown.
Statistical analysis
The main study cohort used for the analysis was defined by algorithm 3 (HF-specific Read Codes only).
We summarised the baseline characteristics of the HF patients identified using algorithm 3 and algorithm 2
(more sensitive). We used means and standard deviations (SDs) to summarise normally distributed
continuous data and medians and IQRs to summarise continuous data that were not normally distributed.
Categorical variables were summarised as the number and percentage of patients within each category.
We also determined the baseline characteristics stratified by BNP testing groups (not tested, BNP tested
and BNP monitored).
Kaplan–Meier curves were used to compare time to all-cause mortality among the three BNP-testing
groups. For all other time-to-event outcomes, we compared the cumulative incidence function between
the BNP-testing groups, accounting for the competing risk of mortality before the event of interest.
For all secondary outcomes, including the number of events during follow-up (e.g. number of attended
GP appointments) or number of days when a particular event was experienced (e.g. time on medications,
length of hospital stay following unscheduled admissions), we calculated event rates as the number of
events experienced/number of days event experienced divided by the duration of follow-up. These data
were summarised as the number of patients with at least one event (e.g. the number of patients with a
rate over zero) and the median (IQR) rate among those with a non-zero rate. For the outcomes of
unexpected hospital admission (all cause and HF specific), we summarised the number of patients with at
least one admission, the median (IQR) number of admissions and the median (IQR) total number of days
hospitalised following all admissions.
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We summarised medication use in 6-monthly intervals from incidence to 4 years post incidence and in the
remaining follow-up time > 4 years. Within each time period, we summarised the number of patients
taking each medication class at any point and the proportion of time during the time period in which the
patient was taking the medication (calculated as the number of days taking medication during time period
divided by the number of days of follow-up within the time period). We carried out a SA for the primary
outcome in the cohort of patients defined by algorithm 2.
We characterised the cohort of HF patients in the NHFA data set but made no formal comparisons with
the cohort identified in the CPRD. Prior to analyses, we performed basic checks on the data set and
excluded any entries for which the patient identification number was unknown. When patients had
multiple admissions within the same month (the NHFA data set included only month and year of
admission), we treated the admission with the longest time to censoring as the first admission. We defined
incident HF in NHFA as an admission with no admission recorded in the previous year; if a patient met the
incidence criteria for more than one admission, the first admission at which the criteria were met was
taken as the incident admission. We summarised demographic data at the ‘incidence admission’ in tables,
the number of patients with more than one admission and the admission rate among patients with HF
incidence in NHFA. We also summarised median (IQR) time from HF incidence to mortality; patients whose
status at the end of follow-up was unknown were excluded from this analysis. Follow-up time has also
been summarised separately for the patients who were alive and deceased at the end of follow-up. All
analyses were prespecified and described in the statistical analysis plan for the cohort study.
Deviation from the planned analyses
There were two main changes to the planned cohort study, the first affecting the planned linkage for the
cohort and the second relating to the planned analyses.
It was not possible to link CPRD GOLD with the NHFA data set for this project. The CPRD’s Independent
Scientific Advisory Committee granted approval for the study, including the proposed linkage, in August
2014. However, at that time linkage agreements with specific data sets and disease registries were not in
place. The CPRD secured generic agreement from the Ethics and Confidentiality Committee to link audit
and other data sets to CPRD GOLD. It then started working on a generic agreement with relevant
organisations and data controllers for permission to link to its data sets [including but not restricted to the
National Institute for Cardiovascular Outcomes Research (NICOR) and the Healthcare Quality Improvement
Partnership, which manage and commission the NHFA, respectively].
The approval process was too slow for the timeline of the study. Therefore, the CPRD attempted to expedite
it by applying for study-specific approval outside of the generic agreement to fast track our study for
bespoke approval. Healthcare Quality Improvement Partnership granted the study-specific approval and the
final application for linkage was made to NHS Digital, the trusted third party that was to perform the linkage.
However, this coincided with the moratorium on processing of applications and the implementation of new
governance procedures by NHS Digital and the standard agreements used by the CPRD and Healthcare
Quality Improvement Partnership did not meet NHS Digital’s new governance requirements. Further
clarification and amendments of existing agreements were required. Given that the process of seeking
approval for the planned linkage had been ongoing for almost 2 years, that there was no indication from the
CPRD or NHS Digital about how long approvals would take and that the project was overdue, we decided
not to pursue the linkage between CPRD GOLD and the NHFA.
We had already applied to NICOR to use the NHFA data set for the study and requested the data set while
the applications for linkage between NHFA and CPRD GOLD were ongoing. NICOR provided the unlinked
NHFA data set to the study team.
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As described previously, we explored different definitions for classifying patients to BNP exposure groups.
The final classification resulted in a very small number of patients being classified as BNP monitored,
relative to the size of the overall cohort. Therefore, the formal analyses comparing outcomes between
groups (detailed in the statistical analysis plan, which is available from the authors) were not conducted.
We decided that these analyses would be misleading: the treatment effects for the BNP-monitored cohort
would be extremely imprecise, the treatment effects for the larger BNP-tested cohort were not relevant to
the objectives of the study and the characteristics of exposure groups suggest that the BNP-monitored
group is highly selected for reasons that we were not able to identify.
Results
Study population and characteristics
Figure 29 shows the total number of patients with HF identified in the CPRD using the three HF incidence
algorithms. A total of 40,073 patients met the inclusion criteria for incident HF using algorithm 1. Of these,
20,367 patients met the inclusion criteria for incident HF using algorithm 2 and 17,095 met the inclusion
criteria for incident HF using algorithm 3 (main study cohort). There was a steady increase in the
cumulative number of patients identified with incident HF in the CPRD over time (Figure 30), indicating
that the rate at which new patients accrued to the cohort was constant. The number of BNP tests
increased slightly faster over time than the number of patients (Figure 31).
Patients with HF (2005–14) 
in CPRD
(n = 72,437)
Linked with HES and ONS
(n = 44,766)
Met any incidence definition
(n = 40,120)
Incidence algorithm 1
(n = 40,073)
Incidence algorithm 2
(n = 20,367)
Incidence algorithm 3
(n = 17,095)b
Excluded: no linkage with
HES/ONS available
(n = 27,671)
Excluded
(n = 4646)
• Patient does not have 
   unique ID in HES, n = 468
• Patient did not meet any
   incidence definition,
   n = 4178a
FIGURE 29 Flow diagram of the study population with HF defined using three incidence algorithms. a, Includes
52 patients who met incidence definition 1 but were aged < 18 years at time of incidence; b, There were 47 patients
who had incident HF in the main cohort but did not meet the criteria for incident HF using algorithms 1 and 2.
These patients had HF symptom Read Codes in the year prior to the HF-specific Read Code, preventing them from
having 1 year free from Read Codes when including both the HF symptom and HF-specific Read Codes.
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Table 9 shows the characteristics of the main study cohort (overall and stratified by BNP testing) and the
cohort defined using incidence algorithm 2. The characteristics of the cohorts defined by algorithms 2 and 3
were very similar. There were extreme differences in the sizes of the exposure groups; 13,632 were
classified as never tested, 3392 as BNP tested and only 71 as BNP monitored. Compared with patients who
were never tested, patients who were tested were on average older and more likely to be female. Patients
who were monitored were even older and more likely to be female; in addition, a lower proportion were
classified as overweight or obese (BMI ≥ 25 kg/m2). Based on the Charlson Comorbidity Index, comorbidities
appeared to be similar between exposure groups but there were some marked differences in proportions
with specific morbidities between groups.
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Figure 32 shows the timing of BNP tests in the 71 patients identified as BNP monitored. There was no
obvious pattern in the timing or frequency of BNP tests: in some patients testing was carried out monthly
and in other patients testing was the minimum required frequency of tests that allowed them to be
classified as monitored.
Primary outcome: all-cause mortality
Of the 17,095 patients in the main study cohort, 164 (1%) were assigned a HF diagnosis only at the time
of death.
Table 10 shows the rates of death from any cause for the cohorts defined using incidence algorithms 2
and 3 (main study cohort), overall and stratified by BNP testing. Overall, in the main study cohort, 8311
out of 17,095 (49%) patients died during follow-up (median 3.0 years, IQR 1.5–5.1 years), generating a
crude death rate of 141.5 (95% CI 138.5 to 144.6) per 1000 person-years. For patients who died, the
median time (IQR) between incident HF and death was 1.9 years (0.7–3.5 years). The death rate was
higher in the small group of patients who were defined as BNP monitored than in those who were
classified as BNP tested or never tested (186.5 vs. 130.6 and 186.5 vs. 143.9 per 1000 patient-years,
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FIGURE 32 Timing of BNP tests in the BNP monitored group. Crosses represent BNP tests; filled black circles
represent the end of follow-up for each patient.
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respectively). The results were similar for the cohort defined using incidence algorithm 2. Death rates were
slightly higher in men than women across all age groups (Table 11).
Figure 33 shows the Kaplan–Meier survival curves for death from any cause in the main study cohort,
stratified by BNP testing. In the never tested group, 84% of patients were alive at 1 year after HF
diagnosis, 74% at 2 years, 64% at 3 years and 56% at 4 years. In the BNP-tested group, 85%, 76%,
67% and 60% of patients were alive at 1, 2, 3 and 4 years after HF diagnosis, respectively. In the
BNP-monitored group, 86%, 72%, 57% and 44% of patients were alive at 1, 2, 3 and 4 years post
incidence, respectively. The results of the SA using the cohort defined using algorithm 2 (more sensitive)
are consistent with those for the main study cohort.
Secondary outcome: mortality caused by heart failure and cardiovascular causes
Table 12 shows the rates of death due to HF and cardiovascular causes in the main study cohort, overall
and stratified by BNP testing. Rates of death due to HF and cardiovascular causes were higher in patients
who were monitored than in patients who were never tested (100.8 vs. 61.9 for death due to HF; 166.4
vs. 114.2 for death due to cardiovascular causes) and patients who were tested (100.8 vs. 59.1 for death
due to HF; 166.4 vs. 104.9 for death due to cardiovascular causes). The cumulative incidence of death due
to HF and death due to cardiovascular causes, stratified by BNP testing, are shown in Figures 34 and 35,
respectively. Patients who were monitored had higher cumulative incidences of deaths.
TABLE 10 Rates of death from any cause for the main study cohort and cohort defined using incidence algorithms
2 and 3 (overall and stratified by BNP testing)
Death from any cause by
BNP exposure group
Number of
deaths, n/N (%)
Patient-years of
observation
Number of
deaths
Death rate per 1000
patient-years (95% CI)
Main study cohort (defined using incidence algorithm 3)
Overall 8311/17,095 (49) 58,721 8311 141.5 (138.5 to 144.6)
Never tested 6844/13,632 (50) 47,577 6844 143.9 (140.5 to 147.3)
BNP tested 1430/3392 (42) 10,946 1430 130.6 (124.0 to 137.6)
BNP monitored 37/71 (52) 198 37 186.5 (135.1 to 257.4)
Cohort (defined using incidence algorithm 2)
Overall 9469/20,367 (46) 70,855 9469 133.6 (131.0 to 136.4)
Never tested 7706/16,074 (48) 57,072 7706 135.0 (132.0 to 138.1)
BNP tested 1716/4205 (41) 13,533 1716 126.8 (120.9 to 132.9)
BNP monitored 47/88 (53) 249 47 188.6 (141.7 to 251.0)
TABLE 11 Overall rates of death from any cause per 1000 patient-years (95% CI) in the main study cohort stratified
by age and sex
Sex
Age group (years)
< 50 50–60 60–70 70–80 > 80
Male 37 (28 to 49) 47 (40 to 54) 71 (65 to 76) 113 (108 to 119) 229 (221 to 237)
Female 32 (25 to 43) 41 (35 to 48) 62 (57 to 67) 99 (94 to 105) 201 (194 to 208)
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FIGURE 33 Kaplan–Meier survival curves for death from any cause in the main study cohort, stratified by BNP testing.
0.4
0.3
0.2
C
u
m
u
la
ti
ve
 in
ci
d
en
ce
0.1
0.0
0 2 4
Time since incidence (years)
6 8 10
Never tested
Tested
Monitored
FIGURE 34 Cumulative incidence of death due to HF in the main study cohort stratified by BNP testing.
TABLE 12 Rates of death due to HF and cardiovascular causes in the main study cohort, overall and stratified by
BNP testing
Cause of death by BNP exposure group Number of deaths, n/N (%) Death rate per 1000 patient-years (95% CI)
Death due to HF
Overall 3633/17,095 (21) 61.9 (59.9 to 63.9)
Never tested 2966/13,632 (22) 62.3 (60.1 to 64.6)
BNP tested 647/3392 (19) 59.1 (54.7 to 63.8)
BNP monitored 20/71 (28) 100.8 (65.0 to 156.3)
Death due to cardiovascular causes
Overall 6707/17,095 (39) 114.2 (111.5 to 117.0)
Never tested 5526/13,632 (41) 116.1 (113.1 to 119.3)
BNP tested 1148/3392 (34) 104.9 (99.0 to 111.1)
BNP monitored 33/71 (46) 166.4 (118.3 to 234.0)
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Secondary outcome: unscheduled hospital admissions
Table 13 shows the proportions of patients who were admitted to hospital during follow-up in the
main study cohort. Overall, admission rates were worst for the BNP-monitored group and best for
the BNP-tested group; the rates of admission were highest in the BNP-monitored group (for all-cause
hospitalisation, 651 per 1000 patient-years; for HF-related hospitalisation, 345 per 1000 patient-years) and
lowest in the BNP-tested group (438 per 1000 patient-years and 218 per 1000 patient-years, respectively,
for all-cause and HF-related admissions).
Other statistics are shown in Table 13. The pattern across groups for the number of patients hospitalised
for any cause was similar to that described above but less obviously so for hospitalisations because of HF.
Statistics involving number of days admitted are difficult to interpret because some admissions will have
resulted in death in hospital, potentially reducing the average length of admissions in the BNP-monitored
group, which had a higher death rate.
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FIGURE 35 Cumulative incidence of death due to cardiovascular causes in the main study cohort stratified by
BNP testing.
TABLE 13 Details on hospital admissions in the main study cohort, overall and stratified by BNP exposure
Unscheduled
hospital
admissions by
BNP exposure
group
Number of
patients with
≥ 1 admission,
n/N (%)
Rate of patients
with ≥ 1 admission
per 1000 patient-
years (95% CI)
Number of
admissionsa
(median, IQR)
Total number
of days in
hospital after
all admissionsa
(median, IQR)
Number of
days
hospitalised
per yeara
(median, IQR)
Unscheduled admissions for any cause
Overall 13,180/17,095 (77) 502.1 (493.6 to 510.7) 2 (1–4) 23 (8–51) 8.8 (2.8–25.4)
Never tested 10,703/13,632 (79) 518.5 (508.7 to 528.4) 2 (1–4) 23 (9–53) 9.1 (2.9–26.1)
BNP tested 2422/3392 (71) 438.4 (421.3 to 456.2) 2 (1–4) 19 (7–44) 7.7 (2.4–21.6)
BNP monitored 55/71 (77) 650.8 (499.7 to 847.7) 2 (1–4) 22 (9–58) 8.8 (2.7–27.5)
Unscheduled admissions for HF
Overall 9611/17,095 (56) 253.4 (248.4 to 258.5) 2 (1–3) 19 (8–42) 7.7 (2.5–22.8)
Never tested 7887/13,632 (58) 262.1 (256.4 to 267.9) 2 (1–3) 20 (8–43) 7.9 (2.6–23.4)
BNP tested 1682/3392 (50) 217.9 (207.8 to 228.6) 2 (1–3) 16 (7–37) 6.8 (2.3–20.4)
BNP monitored 42/71 (59) 345.3 (255.2 to 467.2) 1.5 (1–3) 18.5 (5–54) 8.6 (2.0–26.7)
a Calculated for patients with ≥ 1 admission.
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Figures 36 and 37 show the cumulative incidence of unscheduled hospital admission for all causes and
unscheduled hospital admissions for HF, respectively. Patients who were monitored were more likely to be
admitted to hospital than patients who were tested and never tested. There was a slightly lower incidence
of both all-cause and HF-related hospital admission among those who were tested than among those who
were never tested.
Secondary outcome: general practice consultations and outpatient appointments
Across the cohort, 98% of patients had at least one GP consultation (face to face or telephone). There
were an average of 17 GP consultations per year (Table 14). Patients in the BNP-tested and never tested
groups had a similar number of GP consultations (17 per year); this number was higher for patients in the
BNP-monitored group (22 per year). Only 40% of patients in the cohort had GP consultations linked to a
specific- or symptom-based HF code. The proportion of patients with at least one GP consultation linked to
HF was higher in the BNP-monitored group (66%). The rate of GP consultations among those who had at
least one consultation for HF was also higher in the monitored group (two consultations per year compared
with less than one in the never tested and tested groups).
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FIGURE 36 Cumulative incidence of unscheduled hospital admission (all cause) in the main study cohort stratified
by BNP exposure.
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FIGURE 37 Cumulative incidence of unscheduled hospital admission (HF related) in the main study cohort stratified
by BNP exposure.
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The majority of patients in the main study cohort had at least one outpatient appointment for any specialty
(92% of patients) (Table 15), with similar proportions in each of the BNP groups. Similar yearly outpatient
appointment rates were observed in the never tested and tested groups, with a slightly higher rate in the
monitored group (5.9 tests per year vs. 4.4 and 4.3, respectively). There were similar proportions of
patients in the three groups having outpatient appointments for the cardiology specialty.
Secondary outcome: heart failure-related investigations (B-type natriuretic
peptide and echocardiography tests)
The annual rates of HF-related investigations are shown in Table 16. The rate of HF-related investigations
was low, with only 52% of patients having one or more echocardiogram or BNP test recorded after cohort
entry. Only 49% of patients in the never tested group had a record of a HF-related investigation after
incidence, compared with 63% of patients in the tested group and 97% of patients in the monitored
group.
Table 17 shows the proportion of patients on different medications at the time of incident HF, overall and
stratified by BNP exposure group.
TABLE 14 Annual rate of general practice (GP) consultations (face to face and telephone) in the main study cohort,
overall and stratified by BNP exposure
GP consultations
by BNP exposure
group
Number of patients
with one or more GP
consultation, n/N (%)
Rate of GP
consultationsa
(median, IQR)
Number of patients
with one or more
GP consultation for
HF, n/N (%)
Rate of GP
consultations for
HF (median, IQR)
(specific or
symptom based)
Overall 16,818/17,095 (98) 16.7 (10.4–27.2) 6886/17,095 (40) 0.6 (0.3–1.4)
Never tested 13,428/13,632 (99) 16.6 (10.3–27.3) 5437/13,632 (40) 0.6 (0.3–1.3)
Blood pressure
tested
3319/3392 (98) 16.7 (10.7–26.7) 1402/3392 (41) 0.7 (0.4–1.7)
BNP monitored 71/71 (100) 22.4 (15.7–35.7) 47/71 (66) 1.8 (0.9–2.6)
a Calculated for patients with one or more consultation.
TABLE 15 Annual rate of attended outpatient appointments in the main study cohort, overall and stratified by
BNP exposure
OP appointments
by BNP exposure
group
Number of patients
with one or more
OP appointment
(all treatment
specialties), n/N (%)
Rate of OP
appointmentsa
(all treatment
specialties),
median (IQR)
Number of patients
with one or more
OP appointment
(cardiology
specialty), n/N (%)
Rate of OP
appointmentsa
(cardiology
specialty),
median, (IQR)
Overall 15,648/17,095 (92) 4.4 (2.1–8.3) 11,090/17,095 (65) 1.3 (0.6–2.6)
Never tested 12,509/13,632 (92) 4.4 (2.1–8.4) 8872/13,632 (65) 1.3 (0.6–2.6)
BNP tested 3073/3392 (91) 4.3 (2.1–7.7) 2171/3392 (64) 1.3 (0.6–2.5)
BNP monitored 66/71 (93) 5.9 (2.9–11.2) 47/71 (66) 1.8 (0.7–3.7)
OP, outpatient.
a Calculated for patients with ≥ 1 appointment.
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Table 18 shows how these proportions changed during time since diagnosis of incident HF. The
denominators decrease with increasing time since diagnosis of incident HF because the observation time
for an increasing proportion of cohort participants stopped because of death or loss to follow-up.
Figure 38 shows the proportion of patients taking each class of medication during 6-monthly intervals of
follow-up. There are no obvious differences between the groups in prescription of any of the classes of
medications. Although there are higher proportions of patients on medications in the monitored group,
TABLE 17 Number and proportions of patients on different medications at cohort entry by BNP exposure group
HF medications
Never tested
(n= 13,632), n/N (%)
BNP tested
(n= 3392), n/N (%)
BNP monitored
(n= 71), n/N (%)
Overall
(N= 17,095), n/N (%)
ACEis 6042/13,632 (44.3) 1544/3392 (45.5) 33/71 (46.5) 7619/17,095 (44.6)
ARBs 2088/13,632 (15.3) 582/3392 (17.2) 21/71 (29.6) 2691/17,095 (15.7)
Beta-blockers 3501/13,632 (25.7) 826/3392 (24.4) 25/71 (35.2) 4352/17,095 (25.5)
Digoxin 1927/13,632 (14.1) 500/3392 (14.7) 17/71 (23.9) 2444/17,095 (14.3)
Loop diuretics 7280/13,632 (53.4) 2110/3392 (62.2) 49/71 (69.0) 9439/17,095 (55.2)
Thiazide diuretics 1197/13,632 (8.8) 370/3392 (10.9) 7/71 (9.9) 1574/17,095 (9.2)
Hydralazine 35/13,632 (0.3) 12/3392 (0.4) 0/71 (0.0) 47/17,095 (0.3)
Isosorbide 1647/13,632 (12.1) 341/3392 (10.1) 8/71 (11.3) 1996/17,095 (11.7)
Spironolactone 1028/13,632 (7.5) 236/3392 (7.0) 9/71 (12.7) 1273/17,095 (7.4)
Eplerenone 69/13,632 (0.5) 15/3392 (0.4) 2/71 (2.8) 86/17,095 (0.5)
Amiloride 304/13,632 (2.2) 96/3392 (2.8) 0/71 (0.0) 400/17,095 (2.3)
Triamterene 11/13,632 (0.1) 2/3392 (0.1) 0/71 (0.0) 13/17,095 (0.1)
Calcium channel blockers 2600/13,632 (19.1) 794/3392 (23.4) 17/71 (23.9) 3411/17,095 (20.0)
Statins 6835/13,632 (50.1) 1674/3392 (49.4) 41/71 (57.7) 8550/17,095 (50.0)
Anticoagulants 2650/13,632 (19.4) 720/3392 (21.2) 24/71 (33.8) 3394/17,095 (19.9)
Aspirin 5590/13,632 (41.0) 1360/3392 (40.1) 30/71 (42.3) 6980/17,095 (40.8)
TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
ACEis
0–6 months
Number of patients, n/N (%) 10,087/13,632 (74.0) 2454/3392 (72.3) 45/71 (63.4) 12,586/17,095 (73.6)
Proportion of time on
medication, median (IQR)
1.0 (0.8–1.0) 1.0 (0.8–1.0) 1.0 (0.9–1.0) 1.0 (0.8–1.0)
6–12 months
Number of patients, n/N (%) 7706/11,673 (66.0) 1770/2793 (63.4) 34/66 (51.5) 9510/14,532 (65.4)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
12–18 months
Number of patients, n/N (%) 6275/9958 (63.0) 1423/2343 (60.7) 20/50 (40.0) 7718/12,351 (62.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 5272/8508 (62.0) 1188/1990 (59.7) 13/31 (41.9) 6473/10,529 (61.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 4420/7260 (60.9) 973/1659 (58.6) 12/24 (50.0) 5405/8943 (60.4)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 3702/6127 (60.4) 793/1380 (57.5) 9/18 (50.0) 4504/7525 (59.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 3055/5084 (60.1) 654/1149 (56.9) 3/13 (23.1) 3712/6246 (59.4)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.8–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 2505/4229 (59.2) 519/930 (55.8) 1/8 (12.5) 3025/5167 (58.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 2094/3478 (60.2) 413/730 (56.6) 2/7 (28.6) 2509/4215 (59.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.9–1.0) 0.5 (0.0–1.0) 1.0 (0.9–1.0)
ARBs
0–6 months
Number of patients, n/N (%) 2992/13,632 (21.9) 827/3392 (24.4) 26/71 (36.6) 3845/17,095 (22.5)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 1.0 (0.7–1.0) 1.0 (0.5–1.0) 1.0 (0.6–1.0)
6–12 months
Number of patients, n/N (%) 2627/11,673 (22.5) 699/2793 (25.0) 21/66 (31.8) 3347/14,532 (23.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
continued
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
12–18 months
Number of patients, n/N (%) 2323/9958 (23.3) 612/2343 (26.1) 17/50 (34.0) 2952/12,351 (23.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 2053/8508 (24.1) 527/1990 (26.5) 11/31 (35.5) 2591/10,529 (24.6)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 1790/7260 (24.7) 463/1659 (27.9) 9/24 (37.5) 2262/8943 (25.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 1559/6127 (25.4) 383/1380 (27.8) 8/18 (44.4) 1950/7525 (25.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 1312/5084 (25.8) 316/1149 (27.5) 7/13 (53.8) 1635/6246 (26.2)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.7–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 1123/4229 (26.6) 275/930 (29.6) 4/8 (50.0) 1402/5167 (27.1)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 982/3478 (28.2) 232/730 (31.8) 4/7 (57.1) 1218/4215 (28.9)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (0.8–1.0) 1.0 (0.9–1.0)
Beta-blockers
0–6 months
Number of patients, n/N (%) 7864/13632 (57.7) 1783/3392 (52.6) 37/71 (52.1) 9684/17,095 (56.6)
Proportion of time on
medication, median (IQR)
0.9 (0.7–1.0) 1.0 (0.7–1.0) 1.0 (1.0–1.0) 0.9 (0.7–1.0)
6–12 months
Number of patients, n/N (%) 6631/11,673 (56.8) 1421/2793 (50.9) 34/66 (51.5) 8086/14,532 (55.6)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
12–18 months
Number of patients, n/N (%) 5640/9958 (56.6) 1198/2343 (51.1) 23/50 (46.0) 6861/12,351 (55.6)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
18–24 months
Number of patients, n/N (%) 4853/8508 (57.0) 1006/1990 (50.6) 15/31 (48.4) 5874/10,529 (55.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 4136/7260 (57.0) 840/1659 (50.6) 14/24 (58.3) 4990/8943 (55.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 3473/6127 (56.7) 690/1380 (50.0) 13/18 (72.2) 4176/7525 (55.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.8–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 2898/5084 (57.0) 586/1149 (51.0) 11/13 (84.6) 3495/6246 (56.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.5–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 2407/4229 (56.9) 485/930 (52.2) 5/8 (62.5) 2897/5167 (56.1)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 2129/3478 (61.2) 409/730 (56.0) 6/7 (85.7) 2544/4215 (60.4)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0)
Digoxin
0–6 months
Number of patients, n/N (%) 3739/13,632 (27.4) 853/3392 (25.1) 22/71 (31.0) 4614/17,095 (27.0)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.7–1.0) 1.0 (0.8–1.0) 1.0 (0.7–1.0)
6–12 months
Number of patients, n/N (%) 2981/11,673 (25.5) 666/2793 (23.8) 23/66 (34.8) 3670/14,532 (25.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
12–18 months
Number of patients, n/N (%) 2501/9958 (25.1) 556/2343 (23.7) 18/50 (36.0) 3075/12,351 (24.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
continued
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
18–24 months
Number of patients, n/N (%) 2103/8508 (24.7) 477/1990 (24.0) 9/31 (29.0) 2589/10,529 (24.6)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 1776/7260 (24.5) 389/1659 (23.4) 8/24 (33.3) 2173/8943 (24.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 1480/6127 (24.2) 316/1380 (22.9) 6/18 (33.3) 1802/7525 (23.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 1227/5084 (24.1) 250/1149 (21.8) 5/13 (38.5) 1482/6246 (23.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 1046/4229 (24.7) 205/930 (22.0) 3/8 (37.5) 1254/5167 (24.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.6–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 931/3478 (26.8) 178/730 (24.4) 2/7 (28.6) 1111/4215 (26.4)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0)
Loop diuretics
0–6 months
Number of patients, n/N (%) 11,516/13,632 (84.5) 2971/3392 (87.6) 65/71 (91.5) 14552/17,095 (85.1)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (0.9–1.0)
6–12 months
Number of patients, n/N (%) 9243/11,673 (79.2) 2261/2793 (81.0) 55/66 (83.3) 11,559/14,532 (79.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
12–18 months
Number of patients, n/N (%) 7612/9958 (76.4) 1835/2343 (78.3) 41/50 (82.0) 9488/12,351 (76.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 6392/8508 (75.1) 1531/1990 (76.9) 24/31 (77.4) 7947/10,529 (75.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
24–30 months
Number of patients, n/N (%) 5322/7260 (73.3) 1276/1659 (76.9) 21/24 (87.5) 6619/8943 (74.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 4423/6127 (72.2) 1045/1380 (75.7) 17/18 (94.4) 5485/7525 (72.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 3609/5084 (71.0) 869/1149 (75.6) 11/13 (84.6) 4489/6246 (71.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.4–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 2970/4229 (70.2) 708/930 (76.1) 7/8 (87.5) 3685/5167 (71.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.4–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 2567/3478 (73.8) 582/730 (79.7) 7/7 (100) 3156/4215 (74.9)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 0.6 (0.1–1.0) 1.0 (0.9–1.0)
Thiazide diuretics
0–6 months
Number of patients, n/N (%) 1630/13,632 (12.0) 459/3392 (13.5) 10/71 (14.1) 2099/17,095 (12.3)
Proportion of time on
medication, median (IQR)
0.4 (0.1–1.0) 0.5 (0.2–1.0) 0.2 (0.1–0.6) 0.4 (0.1–1.0)
6–12 months
Number of patients, n/N (%) 810/11,673 (6.9) 234/2793 (8.4) 5/66 (7.6) 1049/14,532 (7.2)
Proportion of time on
medication, median (IQR)
1.0 (0.4–1.0) 1.0 (0.5–1.0) 0.4 (0.2–0.4) 1.0 (0.4–1.0)
12–18 months
Number of patients, n/N (%) 650/9958 (6.5) 197/2343 (8.4) 2/50 (4.0) 849/12,351 (6.9)
Proportion of time on
medication, median (IQR)
1.0 (0.5–1.0) 1.0 (0.6–1.0) 0.7 (0.3–1.0) 1.0 (0.5–1.0)
18–24 months
Number of patients, n/N (%) 525/8508 (6.2) 155/1990 (7.8) 2/31 (6.5) 682/10,529 (6.5)
Proportion of time on
medication, median (IQR)
1.0 (0.5–1.0) 1.0 (0.7–1.0) 0.2 (0.2–0.3) 1.0 (0.5–1.0)
continued
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
24–30 months
Number of patients, n/N (%) 444/7260 (6.1) 115/1659 (6.9) 1/24 (4.2) 560/8943 (6.3)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 1.0 (0.7–1.0) 0.3 (0.3–0.3) 1.0 (0.6–1.0)
30–36 months
Number of patients, n/N (%) 364/6127 (5.9) 88/1380 (6.4) 2/18 (11.1) 454/7525 (6.0)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 1.0 (0.8–1.0) 0.5 (0.1–0.9) 1.0 (0.7–1.0)
36–42 months
Number of patients, n/N (%) 298/5084 (5.9) 74/1149 (6.4) 1/13 (7.7) 373/6246 (6.0)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.5–1.0) 1.0 (1.0–1.0) 1.0 (0.7–1.0)
42–48 months
Number of patients, n/N (%) 250/4229 (5.9) 65/930 (7.0) 1/8 (12.5) 316/5167 (6.1)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.7–1.0) 0.4 (0.4–0.4) 1.0 (0.7–1.0)
> 48 months
Number of patients, n/N (%) 273/3478 (7.8) 75/730 (10.3) 0/7 (0.0) 348/4215 (8.3)
Proportion of time on
medication, median (IQR)
0.7 (0.2–1.0) 0.6 (0.2–1.0) 0.7 (0.2–1.0)
Hydralazine
0–6 months
Number of patients, n/N (%) 96/13,632 (0.7) 30/3392 (0.9) 0/71 (0.0) 126/17,095 (0.7)
Proportion of time on
medication, median (IQR)
0.7 (0.4–1.0) 0.9 (0.4–1.0) 0.7 (0.4–1.0)
6–12 months
Number of patients, n/N (%) 82/11,673 (0.7) 27/2793 (1.0) 0/66 (0.0) 109/14,532 (0.8)
Proportion of time on
medication, median (IQR)
1.0 (0.5–1.0) 1.0 (0.6–1.0) 1.0 (0.6–1.0)
12–18 months
Number of patients, n/N (%) 55/9958 (0.6) 19/2343 (0.8) 1/50 (2.0) 75/12,351 (0.6)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.3 (0.3–0.3) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 54/8508 (0.6) 17/1990 (0.9) 0/31 (0.0) 71/10,529 (0.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 52/7260 (0.7) 10/1659 (0.6) 0/24 (0.0) 62/8943 (0.7)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
30–36 months
Number of patients, n/N (%) 36/6127 (0.6) 5/1380 (0.4) 0/18 (0.0) 41/7525 (0.5)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 31/5084 (0.6) 6/1149 (0.5) 0/13 (0.0) 37/6246 (0.6)
Proportion of time on
medication, median (IQR)
1.0 (0.8–1.0) 1.0 (0.6–1.0) 1.0 (0.8–1.0)
42–48 months
Number of patients, n/N (%) 25/4229 (0.6) 4/930 (0.4) 0/8 (0.0) 29/5167 (0.6)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.8–1.0) 1.0 (0.9–1.0)
> 48 months
Number of patients, n/N (%) 35/3478 (1.0) 5/730 (0.7) 0/7 (0.0) 40/4215 (0.9)
Proportion of time on
medication, median (IQR)
0.7 (0.1–1.0) 0.4 (0.3–1.0) 0.6 (0.2–1.0)
Isosorbide
0–6 months
Number of patients, n/N (%) 2287/13,632 (16.8) 455/3392 (13.4) 11/71 (15.5) 2753/17,095 (16.1)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.8–1.0) 1.0 (0.4–1.0) 1.0 (0.7–1.0)
6–12 months
Number of patients, n/N (%) 1846/11,673 (15.8) 368/2793 (13.2) 9/66 (13.6) 2223/14,532 (15.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.7–1.0) 1.0 (1.0–1.0)
12–18 months
Number of patients, n/N (%) 1543/9958 (15.5) 314/2343 (13.4) 4/50 (8.0) 1861/12,351 (15.1)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 1301/8508 (15.3) 271/1990 (13.6) 1/31 (3.2) 1573/10,529 (14.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 1096/7260 (15.1) 226/1659 (13.6) 2/24 (8.3) 1324/8943 (14.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.6 (0.2–1.0) 1.0 (1.0–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
30–36 months
Number of patients, n/N (%) 936/6127 (15.3) 192/1380 (13.9) 2/18 (11.1) 1130/7525 (15.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 757/5084 (14.9) 158/1149 (13.8) 2/13 (15.4) 917/6246 (14.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.6 (0.2–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 617/4229 (14.6) 126/930 (13.5) 1/8 (12.5) 744/5167 (14.4)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 572/3478 (16.4) 114/730 (15.6) 0/7 (0.0) 686/4215 (16.3)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.7–1.0) 1.0 (0.7–1.0)
Spironolactone
0–6 months
Number of patients, n/N (%) 3894/13,632 (28.6) 817/3392 (24.1) 32/71 (45.1) 4743/17,095 (27.7)
Proportion of time on
medication, median (IQR)
0.8 (0.5–1.0) 0.8 (0.4–1.0) 0.7 (0.2–1.0) 0.8 (0.4–1.0)
6–12 months
Number of patients, n/N (%) 3126/11,673 (26.8) 663/2793 (23.7) 27/66 (40.9) 3816/14,532 (26.3)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.6–1.0) 1.0 (0.6–1.0) 1.0 (0.7–1.0)
12–18 months
Number of patients, n/N (%) 2496/9958 (25.1) 546/2343 (23.3) 16/50 (32.0) 3058/12,351 (24.8)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (0.7–1.0) 1.0 (0.9–1.0)
18–24 months
Number of patients, n/N (%) 2072/8508 (24.4) 446/1990 (22.4) 12/31 (38.7) 2530/10,529 (24.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.9–1.0) 0.9 (0.3–1.0) 1.0 (0.9–1.0)
24–30 months
Number of patients, n/N (%) 1696/7260 (23.4) 353/1659 (21.3) 9/24 (37.5) 2058/8943 (23.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 1353/6127 (22.1) 281/1380 (20.4) 8/18 (44.4) 1642/7525 (21.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.8–1.0) 1.0 (1.0–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
36–42 months
Number of patients, n/N (%) 1142/5084 (22.5) 243/1149 (21.1) 6/13 (46.2) 1391/6246 (22.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.9 (0.5–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 946/4229 (22.4) 195/930 (21.0) 3/8 (37.5) 1144/5167 (22.1)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.2–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 905/3478 (26.0) 200/730 (27.4) 4/7 (57.1) 1109/4215 (26.3)
Proportion of time on
medication, median (IQR)
1.0 (0.5–1.0) 0.8 (0.3–1.0) 1.0 (0.9–1.0) 1.0 (0.5–1.0)
Eplerenone
0–6 months
Number of patients, n/N (%) 309/13,632 (2.3) 61/3392 (1.8) 3/71 (4.2) 373/17,095 (2.2)
Proportion of time on
medication, median (IQR)
0.8 (0.4–1.0) 0.8 (0.3–1.0) 0.2 (0.2–1.0) 0.8 (0.3–1.0)
6–12 months
Number of patients, n/N (%) 307/11,673 (2.6) 51/2793 (1.8) 0/66 (0.0) 358/14532 (2.5)
Proportion of time on
medication, median (IQR)
1.0 (0.6– 1.0) 1.0 (0.8–1.0) 1.0 (0.7–1.0)
12–18 months
Number of patients, n/N (%) 270/9958 (2.7) 58/2343 (2.5) 0/50 (0.0) 328/12,351 (2.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.4–1.0) 1.0 (0.9–1.0)
18–24 months
Number of patients, n/N (%) 221/8508 (2.6) 42/1990 (2.1) 1/31 (3.2) 264/10,529 (2.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.6 (0.6–0.6) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 197/7260 (2.7) 30/1659 (1.8) 2/24 (8.3) 229/8943 (2.6)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.8–1.0) 0.8 (0.5–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 171/6127 (2.8) 28/1380 (2.0) 1/18 (5.6) 200/7525 (2.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
continued
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
36–42 months
Number of patients, n/N (%) 137/5084 (2.7) 30/1149 (2.6) 0/13 (0.0) 167/6246 (2.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.6–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 115/4229 (2.7) 24/930 (2.6) 0/8 (0.0) 139/5167 (2.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 120/3478 (3.5) 26/730 (3.6) 0/7 (0.0) 146/4215 (3.5)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 0.8 (0.2–1.0) 1.0 (0.5–1.0)
Amiloride
0–6 months
Number of patients, n/N (%) 483/13632 (3.5) 147/3392 (4.3) 0/71 (0.0) 630/17,095 (3.7)
Proportion of time on
medication, median (IQR)
0.4 (0.2–1.0) 0.5 (0.2–1.0) 0.5 (0.2–1.0)
6–12 months
Number of patients, n/N (%) 267/11,673 (2.3) 79/2793 (2.8) 1/66 (1.5) 347/14,532 (2.4)
Proportion of time on
medication, median (IQR)
1.0 (0.4–1.0) 1.0 (0.3–1.0) 0.8 (0.8–0.8) 1.0 (0.4–1.0)
12–18 months
Number of patients, n/N (%) 202/9958 (2.0) 57/2343 (2.4) 2/50 (4.0) 261/12,351 (2.1)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.2–1.0) 0.9 (0.9–1.0) 1.0 (0.6–1.0)
18–24 months
Number of patients, n/N (%) 177/8508 (2.1) 40/1990 (2.0) 2/31 (6.5) 219/10,529 (2.1)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.4–1.0) 0.6 (0.2–1.0) 1.0 (0.6–1.0)
24–30 months
Number of patients, n/N (%) 143/7260 (2.0) 35/1659 (2.1) 0/24 (0.0) 178/8943 (2.0)
Proportion of time on
medication, median (IQR)
1.0 (0.8–1.0) 1.0 (0.3–1.0) 1.0 (0.7–1.0)
30–36 months
Number of patients, n/N (%) 117/6127 (1.9) 24/1380 (1.7) 1/18 (5.6) 142/7525 (1.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (0.9–1.0) 0.2 (0.2–0.2) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 95/5084 (1.9) 19/1149 (1.7) 0/13 (0.0) 114/6246 (1.8)
Proportion of time on
medication, median (IQR)
1.0 (0.8–1.0) 1.0 (0.6–1.0) 1.0 (0.8–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
42–48 months
Number of patients, n/N (%) 72/4229 (1.7) 21/930 (2.3) 0/8 (0.0) 93/5167 (1.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 0.6 (0.2–1.0) 1.0 (0.7–1.0)
> 48 months
Number of patients, n/N (%) 76/3478 (2.2) 18/730 (2.5) 0/7 (0.0) 94/4215 (2.2)
Proportion of time on
medication, median (IQR)
0.9 (0.3–1.0) 0.4 (0.1–1.0) 0.9 (0.2–1.0)
Triamterene
0–6 months
Number of patients, n/N (%) 15/13,632 (0.1) 2/3392 (0.1) 0/71 (0.0) 17/17,095 (0.1)
Proportion of time on
medication, median (IQR)
0.2 (0.1–1.0) 0.1 (0.1–0.1) 0.2 (0.1–0.4)
6–12 months
Number of patients, n/N (%) 5/11,673 (0.0) 0/2793 (0.0) 0/66 (0.0) 5/14,532 (0.0)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 1.0 (0.6–1.0)
12–18 months
Number of patients, n/N (%) 5/9958 (0.1) 0/2343 (0.0) 0/50 (0.0) 5/12,351 (0.0)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 1.0 (0.6–1.0)
18–24 months
Number of patients, n/N (%) 3/8508 (0.0) 0/1990 (0.0) 0/31 (0.0) 3/10,529 (0.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 3/7260 (0.0) 0/1659 (0.0) 0/24 (0.0) 3/8943 (0.0)
Proportion of time on
medication, median (IQR)
1.0 (0.3–1.0) 1.0 (0.3–1.0)
30–36 months
Number of patients, n/N (%) 3/6127 (0.0) 0/1380 (0.0) 0/18 (0.0) 3/7525 (0.0)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 1.0 (0.6–1.0)
36–42 months
Number of patients, n/N (%) 3/5084 (0.1) 0/1149 (0.0) 0/13 (0.0) 3/6246 (0.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0)
continued
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
42–48 months
Number of patients, n/N (%) 2/4229 (0.0) 0/930 (0.0) 0/8 (0.0) 2/5167 (0.0)
Proportion of time on
medication, median (IQR)
0.7 (0.4–1.0) 0.7 (0.4–1.0)
> 48 months
Number of patients, n/N (%) 1/3478 (0.0) 0/730 (0.0) 0/7 (0.0) 1/4215 (0.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0)
Calcium channel blockers
0–6 months
Number of patients, n/N (%) 3091/13,632 (22.7) 889/3392 (26.2) 17/71 (23.9) 3997/17,095 (23.4)
Proportion of time on
medication, median (IQR)
1.0 (0.3–1.0) 1.0 (0.4–1.0) 1.0 (1.0–1.0) 1.0 (0.3–1.0)
6–12 months
Number of patients, n/N (%) 1950/11,673 (16.7) 561/2793 (20.1) 15/66 (22.7) 2526/14,532 (17.4)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (0.9–1.0)
12–18 months
Number of patients, n/N (%) 1682/9958 (16.9) 463/2343 (19.8) 11/50 (22.0) 2156/12,351 (17.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 1447/8508 (17.0) 390/1990 (19.6) 8/31 (25.8) 1845/10,529 (17.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.8–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 1237/7260 (17.0) 338/1659 (20.4) 5/24 (20.8) 1580/8943 (17.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 1049/6127 (17.1) 278/1380 (20.1) 4/18 (22.2) 1331/7525 (17.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.5–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 896/5084 (17.6) 222/1149 (19.3) 3/13 (23.1) 1121/6246 (17.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 765/4229 (18.1) 175/930 (18.8) 2/8 (25.0) 942/5167 (18.2)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.6 (0.2–1.0) 1.0 (1.0–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
> 48 months
Number of patients, n/N (%) 746/3478 (21.4) 176/730 (24.1) 3/7 (42.9) 925/4215 (21.9)
Proportion of time on
medication, median (IQR)
1.0 (0.6–1.0) 1.0 (0.6–1.0) 0.3 (0.3–0.4) 1.0 (0.6–1.0)
Statins
0–6 months
Number of patients, n/N (%) 8412/13,632 (61.7) 1930/3392 (56.9) 43/71 (60.6) 10,385/17,095 (60.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
6–12 months
Number of patients, n/N (%) 7200/11,673 (61.7) 1633/2793 (58.5) 39/66 (59.1) 8872/14,532 (61.1)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
12–18 months
Number of patients, n/N (%) 6230/9958 (62.6) 1392/2343 (59.4) 28/50 (56.0) 7650/12,351 (61.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 5382/8508 (63.3) 1199/1990 (60.3) 18/31 (58.1) 6599/10,529 (62.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 4631/7260 (63.8) 1008/1659 (60.8) 17/24 (70.8) 5656/8943 (63.2)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 3907/6127 (63.8) 853/1380 (61.8) 12/18 (66.7) 4772/7525 (63.4)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 3300/5084 (64.9) 700/1149 (60.9) 9/13 (69.2) 4009/6246 (64.2)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 2780/4229 (65.7) 572/930 (61.5) 5/8 (62.5) 3357/5167 (65.0)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
continued
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
> 48 months
Number of patients, n/N (%) 2407/3478 (69.2) 474/730 (64.9) 4/7 (57.1) 2885/4215 (68.4)
Proportion of time on
medication, median (IQR)
1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0)
Anticoagulants
0–6 months
Number of patients, n/N (%) 4444/13,632 (32.6) 1091/3392 (32.2) 26/71 (36.6) 5561/17,095 (32.5)
Proportion of time on
medication, median (IQR)
1.0 (0.7–1.0) 1.0 (0.8–1.0) 1.0 (1.0–1.0) 1.0 (0.7–1.0)
6–12 months
Number of patients, n/N (%) 3816/11,673 (32.7) 927/2793 (33.2) 23/66 (34.8) 4766/14,532 (32.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
12–18 months
Number of patients, n/N (%) 3259/9958 (32.7) 782/2343 (33.4) 17/50 (34.0) 4058/12,351 (32.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 2770/8508 (32.6) 628/1990 (31.6) 10/31 (32.3) 3408/10,529 (32.4)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 2368/7260 (32.6) 533/1659 (32.1) 8/24 (33.3) 2909/8943 (32.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 1998/6127 (32.6) 425/1380 (30.8) 6/18 (33.3) 2429/7525 (32.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 1687/5084 (33.2) 357/1149 (31.1) 4/13 (30.8) 2048/6246 (32.8)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.6–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 1423/4229 (33.6) 306/930 (32.9) 2/8 (25.0) 1731/5167 (33.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 1245/3478 (35.8) 263/730 (36.0) 2/7 (28.6) 1510/4215 (35.8)
Proportion of time on
medication, median (IQR)
1.0 (0.8–1.0) 1.0 (0.8–1.0) 1.0 (1.0–1.0) 1.0 (0.8–1.0)
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TABLE 18 Number of patients on different medications and proportion of time spent on medication during
6-monthly intervals by BNP exposure group (continued )
HF medication
Never tested
(n= 13,632)
BNP tested
(n= 3392)
BNP monitored
(n= 71)
Overall
(N= 17,095)
Aspirin
0–6 months
Number of patients, n/N (%) 7695/13,632 (56.4) 1701/3392 (50.1) 34/71 (47.9) 9430/17,095 (55.2)
Proportion of time on
medication, median (IQR)
1.0 (0.8–1.0) 1.0 (0.8–1.0) 1.0 (1.0–1.0) 1.0 (0.8–1.0)
6–12 months
Number of patients, n/N (%) 5995/11,673 (51.4) 1285/2793 (46.0) 29/66 (43.9) 7309/14,532 (50.3)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
12–18 months
Number of patients, n/N (%) 5068/9958 (50.9) 1070/2343 (45.7) 20/50 (40.0) 6158/12,351 (49.9)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
18–24 months
Number of patients, n/N (%) 4311/8508 (50.7) 907/1990 (45.6) 16/31 (51.6) 5234/10,529 (49.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
24–30 months
Number of patients, n/N (%) 3650/7260 (50.3) 764/1659 (46.1) 14/24 (58.3) 4428/8943 (49.5)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
30–36 months
Number of patients, n/N (%) 3024/6127 (49.4) 659/1380 (47.8) 10/18 (55.6) 3693/7525 (49.1)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
36–42 months
Number of patients, n/N (%) 2467/5084 (48.5) 527/1149 (45.9) 8/13 (61.5) 3002/6246 (48.1)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (0.9–1.0) 1.0 (1.0–1.0)
42–48 months
Number of patients, n/N (%) 2029/4229 (48.0) 430/930 (46.2) 5/8 (62.5) 2464/5167 (47.7)
Proportion of time on
medication, median (IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
> 48 months
Number of patients, n/N (%) 1797/3478 (51.7) 364/730 (49.9) 4/7 (57.1) 2165/4215 (51.4)
Proportion of time on
medication, median (IQR)
1.0 (0.8–1.0) 1.0 (0.7–1.0) 1.0 (1.0–1.0) 1.0 (0.8–1.0)
Denominators are the number of patients within each BNP exposure group with at least 1 day of follow-up within the
time interval.
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FIGURE 38 Proportion of patients taking each class of medication at any point during each 6-month time period,
stratified by BNP testing. (a) ACEis; (b) ARBs; (c) beta-blockers; (d) digoxin; (e) loop diuretics; (f) thiazide diuretics;
(g) spironolactone; and (h) calcium channel blockers. Solid lines, never tested group; dashed lines, tested group;
dotted lines, monitored group. Numbers of patients with follow-up during each time period in the never tested,
tested and monitored groups are: 0–6 months – 13,632, 3392, 471; 6–12 months – 11,673, 2793, 66; 12–18 months –
9958, 2343, 50; 18–24 months – 8508, 1990, 31; 24–30 months – 7260, 1659, 24; 30–36 months – 6127, 1380,
18; 36–42 months – 5084, 1149, 13; 42–48 months – 4229, 930, 8; > 48 months – 3478, 730, 7.
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the number of patients in this group is too small to reach definitive conclusions (note that, at the later time
points, follow-up data are available for only a very small number of patients).
National Heart Failure Audit
A total of 163,244 admissions were recorded across 130,433 patients in the NHFA between January 2007
and March 2013. Of the patients in the NHFA, 126,686 (97%) met the definition of incident HF admission.
The cumulative number of patients identified as having incident HF in the NHFA is shown in Figure 39.
The number of admissions recorded each month increased from 298 in January 2007 to > 3100 in 2013
(with almost 3700 in January 2013) (Figure 40). The admission rate in patients with an incident HF
admission was 1.1 per year (IQR 0.5–3.5); 17% were readmitted during follow-up, with a median of
1 readmission (IQR 1–2).
B-type natriuretic peptide tests were carried out in 10,114 admissions (6%). The proportion of
visits at which a BNP test was carried out increased from 0% at the start of the audit to 10% by
March 2013 (Figure 41).
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FIGURE 39 Cumulative number of patients identified as having incident HF in NHFA cohort.
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FIGURE 40 Number of admissions recorded in the NHFA data set per month.
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Table 19 shows demographic data and clinical characteristics of patients in the NHFA. Sex distribution,
BMI and blood pressure appear similar between patients in the NHFA cohort and those in the CPRD
cohort. The patients in the NHFA cohort appear to be older (67% of patients aged ≥ 75 years vs. 60%
in the CPRD cohort) and have more comorbidities or previous events, such as myocardial infarction,
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) surgery. However,
to some extent this is likely to be because the NHFA audit collects information on any medical history
prior to the admission, whereas the CPRD cohort reports such data only for the year prior to incident HF.
Patients had a median follow-up time of 1.1 years (IQR 0.3–2.2 years). A total of 60,677 out of 125,719
patients with incident HF were reported to have died at the end of follow-up.
Figure 42 shows the Kaplan–Meier curve for the survival time in the NHFA cohort. The median survival
time was shorter in the NHFA cohort (2.2 years) than in the CPRD cohort (5 years).
Table 20 shows the proportion of patients on each medication class on admission and at discharge from
the incident HF admission. Data were more complete for medications at discharge, but it can be seen that
the proportion of patients taking ACEis, beta-blockers, loop diuretics and spironolactone/eplerenone was
higher at discharge than at admission.
Readmissions were recorded in the NHFA for 20,949 patients (17%). Patients were readmitted once on
average (IQR 1–2), with a yearly admission rate of 1.1 admissions per year (IQR 0.5–3.5 admissions per
year) in patients who had at least one readmission.
Summary of main findings
We conducted a population-based cohort study of 17,095 patients with incident HF followed for up to
9 years (median 3 years), half of whom died during follow-up. Only 71 out of 17,095 (0.4%) of patients
were identified as having had BNP monitoring during their follow-up after diagnosis of HF. Patients
identified as ‘BNP monitored’ had higher rates of death from any cause and death related to HF or
cardiovascular causes. These patients were also more likely to be admitted to hospital, had more GP and
outpatient consultations and more HF-related investigations (echocardiography) than patients who were
identified as BNP tested and never tested. These results indicate that patients identified as BNP monitored
were a sicker group of HF patients.
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FIGURE 41 Percentage of admissions at which a BNP test was recorded per month in the NHFA data set.
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This finding does not appear consistent with the findings from our meta-analysis or that of Troughton
et al.,25 both of which suggest a benefit of BNP monitoring on clinical outcomes. However, given the very
small size of the BNP-monitored group (0.4% of the study cohort), patients classified as having been BNP
monitored may have been highly selected on grounds that were not characterised in the cohort. We also
had no definitive evidence that the patients we identified as ‘BNP monitored’ were in fact monitored
(i.e. had serial BNP tests in order to guide up-titration of medication). Therefore, we have not reported
analyses comparing groups of patients defined as BNP tested, BNP monitored and never tested.
The cohort of HF patients in NHFA was broadly comparable with the cohort identified in the CPRD but
was, on average, older and had more comorbidities and previous medical events. These differences are
consistent with NHFA patients, on average, having progressed to a more advanced stage of HF at the time
of entry into the cohort, supported by them having shorter median survival (2.2 vs. 5 years). The
proportion of admissions during which a BNP test was carried out increased from 0% at the start of the
audit to 10% by March 2013.
TABLE 19 Baseline demographic, clinical characteristics and medical history at incident HF admission in the NHFA cohort
Patient characteristics Incident HF admission (N= 126,686)
Age at incidence (median, IQR) 80 (71–86)
Aged ≥ 75 years, n (%) 84,936/126,632 (67)
Male, n (%) 69,765/126,564 (55)
BMI (median, IQR) 26.7 (22.8–31.2)
< 20 kg/m2, n (%) 1738/14,573 (12)
≥ 20 and < 25 kg/m2, n (%) 3923/14,573 (27)
≥ 25 and < 30 kg/m2, n (%) 4344/14,573 (30)
≥ 30 kg/m2, n (%) 4568/14,573 (31)
SBP (mean, SD) 128 (22)
DBP (mean, SD) 74 (17)
Medical history, n (%)
Previous MI 34976/115,940 (30)
Previous PCI 691/8007 (9)
Previous CABG 997/8166 (12)
Medical history – other
Arrhythmias, n (%) 2865/8049 (36)
CVA, n (%) 940/8523 (11)
Diabetes, n (%) 34723/119,833 (29)
Peripheral vascular disease, n (%) 559/7947 (7)
COPD, n (%) 7170/42,161 (17)
BNP/NT-proBNP measurement, n (%) 7723/126,686 (6)
BNP (median, IQR) 672 (304–1478)
NT-proBNP (median, IQR) 2727.5 (626–7572.5)
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DBP, diastolic blood pressure;
MI, myocardial infarction.
Missing data
l Age: n = 54.
l BMI: n= 112,113.
l SBP: n = 96,067.
l DBP: n = 119,344.
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TABLE 20 Medications on admission and at discharge during the incident HF admission
Medications for HF Incident HF admission (N= 126,686), n (%)
ACEis
Admission 4732/10,335 (46)
Discharge 64,155/119,936 (53)
ARBs
Admission 1477/10,085 (15)
Discharge 15,177/120,951 (13)
Beta-blockers
Admission 4641/10,006 (46)
Discharge 61,390/114,682 (54)
Loop diuretics
Admission 6646/10,375 (64)
Discharge 100,225/121,890 (82)
Thiazide diuretics
Admission 626/9851 (6)
Discharge 4331/112,302 (4)
Digoxin
Admission 1653/10,299 (16)
Discharge 23142/112,022 (21)
Spironolactone or eplerenone
Incidence 1952/10,108 (19)
End of follow-up 37,227/121,102 (31)
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FIGURE 42 Kaplan–Meier survival curves for death in the NHFA cohort.
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TABLE 20 Medications on admission and at discharge during the incident HF admission (continued )
Medications for HF Incident HF admission (N= 126,686), n (%)
Antiplatelets
Incidence 3661/7087 (52)
End of follow-up 5160/8697 (59)
Calcium channel blockers
Incidence 1313/7328 (18)
End of follow-up 1037/10,342 (10)
Statins
Incidence 3929/7388 (53)
End of follow-up 5337/10,818 (49)
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Chapter 4 A model-based cost-effectiveness
analysis of B-type natriuretic peptide monitoring in
patients with chronic heart failure in primary and
secondary care
Aims and objectives
Our objective was to synthesise the evidence on the cost-effectiveness of BNP-guided monitoring in patient
subgroups defined by age and LVEF status, thereby helping clinicians and policy-makers decide which
patients may benefit from BNP-guided therapy.
The aim of this cost-effectiveness analysis was to model the cost-effectiveness of BNP guided-therapy in
primary and secondary care in the UK using efficacy data derived from the IPD meta-analysis and resource
use data derived from the cohort study to inform key parameters of the model. The specific objectives
were to:
l identify the relative contribution of different types of care (i.e. inpatient, outpatient, primary care and
medications) to the overall cost of HF
l determine how cost differs by age (< 75 vs. ≥ 75 years), proximity to death and underlying cause of
death (circulatory vs. other).
Methods
Overview of the model
We developed a decision-analytical model to assess the cost-effectiveness of BNP-guided strategy
compared with standard clinically guided (CG) strategy for optimising medical therapy in patients with HF
and who have recently been discharged from hospital following an acute episode. We considered recently
hospitalised patients with HF because the data that we used from the IPD meta-analyses25,33 are based on
RCTs that recruited patients who had recently been hospitalised because of HF. One exception, the
SIGNAL-HF trial,63 which recruited patients with stable HF from primary care, found no improvements in
outcomes as a result of BNP-guided monitoring. We compared specialist-led BNP-guided therapy with
specialist-led CG therapy. Although two RCTs61,64 included a third arm in which usual care was provided
by a primary care physician, in common with the IPD meta-analyses,25,33 we focused on whether or not
BNP-guided therapy is a cost-effective addition to specialist-led care.
We followed the criteria for selecting an appropriate modelling approach set out by Barton et al.73 A
Markov cohort model was considered to be appropriate for this decision problem, as HF is a chronic
disease affecting patients over their remaining lifetime, patient prognoses could adequately be represented
with a relatively small number of health states and, as a non-communicable disease, interaction between
patients could be ignored. Markov models segregate patients’ possible prognoses into a series of discrete
health states over time divided into periods or cycles of equal duration. Transition probabilities determine
the movement of patients between health states at the end of each cycle. Each health state is associated
with a cost, representing NHS care costs, and a ‘utility’, representing patient health-related quality of life.
The model tracks the patient cohort over a large number of cycles to estimate cumulative costs and health
benefits based on the length of time patients spend in each health state.
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Goehler et al.,74 in a review of HF decision-analytical models, found similar numbers of models using NYHA
class (n = 9), rehospitalisation (n = 6) or alive/dead health states (n = 10) to track disease progression and
survival. They note that the choice of model structure is dependent on, among other factors, data
availability. Our choice was limited to a simplified model structure as the majority of RCTs do not measure
or report changes in NYHA class at follow-up. Our model is similar to the structure of a previous
cost-effectiveness model that was used to develop NICE clinical guidelines on the management of HF8 and
later updated with additional RCT evidence.32 We used a simple Markov process consisting of two health
states: alive and dead (Figure 43). The probability of death (pt) varied with time since initial hospitalisation
and care (BNP/CG) received. We tracked the probability of hospitalisation (rt) among survivors, which also
varied with time since initial hospitalisation and care (BNP/CG) received. This was important because
BNP-guided monitoring may reduce acute episodes and the need for hospitalisation, which would affect
the cost of care and quality of life. However, we did not model the interaction between the number of
hospitalisations and the subsequent risk of death. This was a pragmatic decision, as RCTs do not report
mortality hazard rates conditional on the number of hospitalisations. The simplicity of the two-state
Markov model is a potential limitation, which we return to in the discussion.
We estimated the average costs and health benefits of a hypothetical cohort of 1000 patients with HF over
the course of their lifetime.10 The recent literature25,33 and our own work in this project have used IPD
meta-analysis of RCTs to explore the relative effectiveness of BNP-guided monitoring in various subgroups
of the HF population including age (< 75/≥ 75 years) and LVEF (≤ 45%/> 45%) status. The evidence that
BNP-guided therapy is effective is strongest in younger patients and in those with HFrEF. The evidence is
weaker in older patients with HFpEF. Initially, we used the model to explore the cost-effectiveness of
BNP-guided therapy in two patient subgroups: (1) all HF patients aged < 75 years; and (2) all HF patients
aged ≥ 75 years. Based on evidence published in September 2015,33 we then extended the model to
explore three further subgroups: (3) HFrEF patients aged < 75 years; (4) HFpEF patients aged < 75 years;
and (5) HFrEF patients aged ≥ 75 years. We excluded older patients with HFpEF, as there is no evidence of
benefit in this subgroup of patients (HR 1.56, 95% CI 0.90 to 2.70).33
We chose a cycle length of 3 months to track changes in health. In many RCTs,58,59,64 BNP was monitored
every 3 months during follow-up and mortality differences have emerged by 3 months in IPD meta-
analyses.25,33 To estimate costs and health benefits, we assumed that transitions between health states
occur halfway through each cycle (i.e. a half-cycle correction). We assumed that the mean age of the age
subgroups (< 75 and ≥ 75 years) at the inception of treatment was 65 and 81 years, respectively.33 We
assumed that age at inception was also 65 years in the ‘HFrEF < 75 years’ and ‘HFpEF < 75 years’
subgroups and 81 years in the ‘HFrEF ≥ 75 years’ subgroup. We tracked outcomes for a period of 30 years
for all patient subgroups with age < 75 years and for a period of 15 years for all patient subgroups with
age ≥ 75 years. In all cases, this equated to a period when more than 99% of patients died in both
monitoring strategies.
We chose a UK NHS perspective for costs. HF undoubtedly has a large impact on social care, patients and
carers. However, there are no suitable data on the broader economic burden of HF in the UK. Health
benefits were quantified in terms of QALYs,10 calculated by multiplying the utility value for each health
state with the time spent in that state.75 A utility value represents a patient’s health-related quality of life
Alive
Hospitalised (rt)/not 
hospitalised (1 – rt)
1 – pt
pt
Dead
1
FIGURE 43 Markov model of disease progression.
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on a scale anchored at 0 (= death) and 1 (= perfect health). All costs and QALYs were discounted at an
annual rate of 3.5%, as recommended by NICE.76 We compared the cost-effectiveness of monitoring
strategies based on incremental net monetary benefits (iNMB). The iNMB of BNP-guided versus CG
strategies is expressed as:
iNMB = λ (QALYsBNP −QALYsCG)− (CostBNP − CostCG), (2)
where λ represents the maximum amount that the NHS is ‘willing to pay’ to gain one QALY. NICE typically
uses λ values of between £20,000 and £30,000 per QALY to identify technologies that are cost-effective
enough for use in the NHS.77 In our analyses, we used the lower figure (λ = £20,000) in calculating iNMB.
An iNMB value greater than zero indicates that BNP-guided monitoring is cost-effective. We also present
cost-effectiveness acceptability curves (CEACs) to demonstrate how the NHS ‘willingness-to-pay’ threshold
affects the probability that BNP-guided therapy is considered to be cost-effective.78
Model parameters
The model used four sets of parameters: (1) baseline probabilities, which determine the probability of
being hospitalised or of dying at each cycle in the CG group; (2) relative treatment effects expressed as
HRs and relative risks (RRs), which determine how the baseline probabilities differ in the BNP-guided
monitoring group; (3) utilities, which represent the health-related quality of life of patients in each state;
and (4) costs incurred by the NHS in each state. All model parameters are listed in Tables 21 and 22.
The sources of these data are described in the following sections.
TABLE 21 Transition probability parameters used in the model
Parameter Estimate Distribution Source
Baseline monthly hazard rate of all-cause mortality for
the first 8 years of the model (< 75 years)
0.009 LN (–4.718, 0.012 SE) CPRD–ONSa
HR (≥ 75 years vs. < 75 years) of all-cause mortality for
the first 8 years of the model
2.80 LN (1.030, 0.014 SE) CPRD–ONSa
3 monthly risk of all-cause mortality in general population Age variant Fixed ONS79
RR (HF patients vs. general population) of all-cause mortality 3.14 Beta (199, 94)
HF/ Beta (176, 410)
general population
van Jaarsveld et al.80
RR (HFpEF patients vs. HFrEF patients) of all-cause
mortality
0.78 Beta (766, 2865) HFpEF/
Beta (584, 1621) HFrEF
Nichols et al.81
BNP HR of all-cause mortality for all HF patients aged
< 75 years
0.62 LN (–0.478, 0.162 SE) Troughton et al.25
BNP HR of all-cause mortality for all HF patients aged
≥ 75 years
0.98 LN (–0.020, 0.140 SE) Troughton et al.25
BNP HR of all-cause mortality for HFrEF patients aged
< 75 years
0.68 LN (–0.386, 0.177 SE) Brunner-La Rocca et al.33
BNP HR of all-cause mortality for HFpEF patients aged
< 75 years
0.76 LN (–0.274, 0.487 SE) Brunner-La Rocca et al.33
BNP HR of all-cause mortality for HFrEF patients aged
≥ 75 years
0.87 LN (–0.139, 0.148 SE) Brunner-La Rocca et al.33
Baseline hazard rate per month of all-cause hospitalisation
(< 75 years)
0.066 LN (–2.711, 0.008 SE) CPRD–HESa
HR (≥ 75 years vs. < 75 years) of all-cause hospitalisation 1.248 LN (0.222, 0.010 SE) CPRD–HESa
BNP HR of all-cause hospitalisation 0.94 LN (–0.062, 0.062 SE) Troughton et al.25
LN, log-normal; SE, standard error.
a www.cprd.com/home (accessed 1 December 2016).
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Baseline probabilities: mortality
There are a number of potential sources of information on the baseline probability of all-cause mortality in
patients who receive CG therapy. The CG arms of the RCTs pooled in the IPD meta-analyses25,33 provide
one potential data source. A drawback of these data is that they provide evidence on survival only over the
relatively short follow-up period of the RCTs, typically up to 24 months. Survival beyond that period must
be extrapolated or estimated from other sources. A further drawback is that the largest IPD meta-analysis25
available at the start of this project provided a Kaplan–Meier survival curve but not the number of events
and number at risk at each follow-up time point. Therefore, we used a software (Version 3.9, WebPlot
Digitizer, Austin, TX, USA) to estimate, from this published survival curve, the mortality hazard in the RCT
CG arms. This process is approximate and most suited to fitting simple constant hazard functions
(e.g. exponential).
As an alternative, we used routinely collected CPRD–HES–ONS linked data from April 2005 up to the
censoring date of April 2014, including 52,122 patients, to estimate the monthly mortality rate in clinical
practice. This provides an opportunity to estimate survival over a longer time period than is available from
RCTs and to compare the fit of different parametric survival models. Arguably, it may also provide a better
estimation of the ‘real-world’ effectiveness of BNP-guided monitoring if used outside a RCT setting.
However, this requires the strong assumption that the treatment effect, derived from RCT participants, can
be generalised to the patients with HF in the CPRD–HES–ONS linked data. In our primary analysis, we used
the exponential distribution using the all-cause mortality rate obtained from the CPRD–HES–ONS linked
data to estimate survival for the first 8 years of the model. In SAs, we used two alternative survival models
to evaluate the robustness of our results: (1) the Weibull distribution for the first 8 years of the model
based on the CPRD–HES–ONS linked data as described above (SA1); and (2) the exponential distribution
for the first 2 years of the model based on data extracted from the Kaplan–Meier curve25 (SA2).
Beyond the initial period, we used age- and sex-specific ONS 2011–13 population life tables for the UK
to estimate survival,79 assuming that two-thirds of patients were male, as reported in the published IPD
meta-analysis,25 and inflating general population mortality to mortality for the HF patient population using
a RR derived from an observational study.80 Van Jaarsveld et al.80 report 32% survival at 7 years for 293
incident HF cases diagnosed in the Netherlands between 1993 and 1998, compared with 70% survival
TABLE 22 Utility, resource use and cost parameters used in the model
Parameter Estimate Distribution Source
HF utility score when hospitalised 0.66 Beta (7321, 3772) Reed et al.82
HF utility score when not hospitalised 0.77 Beta (7978, 2383) Reed et al.82
Duration of hospitalisation (days) 13.21 Gamma (1148.29, 0.01) CPRD–HES10
3-monthly cost when hospitalised (aged < 75 years), (£) 9104 Gamma (678.06, 13.43) CPRD–HES10
3-monthly cost when not hospitalised (aged < 75 years), (£) 682 Gamma (827.17, 0.82) CPRD–HES10
3-monthly cost when hospitalised (aged ≥ 75 years), (£) 8057 Gamma (1746.96, 4.61) CPRD–HES10
3-monthly cost when not hospitalised (aged ≥ 75 years), (£) 569 Gamma (1536.51, 0.37) CPRD–HES10
CG unscheduled outpatient visits (24 months) 1.1 Gamma (71.60, 0.02) PRIMA62
BNP-guided unscheduled outpatient visits (24 months) 1.4 Gamma (94.52, 0.02) PRIMA62
BNP-guided additional cost of medications (18 months), (£) 58.32 Gamma (88.42, 0.66) TIME-CHF29
Unit cost of an outpatient visit, (£) 123 Fixed DoH83
Unit cost of a BNP test, (£) 25 Fixed NICE84
DoH, Department of Health.
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among 586 age- and sex-matched control subjects without HF. These 7-year survival probabilities were
converted to 3-monthly survival probabilities.
The majority of patients recruited to trials have HFrEF. After adjusting for age, sex and other covariates,
mortality has been demonstrated to be lower in patients with HFpEF.81,85 Therefore, we adjusted survival in
the HFpEF subgroup evaluated in our model, using results from a cohort of more than 6500 patients
hospitalised for HF, which reported an adjusted 1-year mortality RR of 1.25 (95% CI 1.12 to 1.41) in
patients with HFrEF versus HFpEF.81
Relative effects: mortality
Troughton et al.25 conducted a systematic review and IPD meta-analysis to evaluate the effect of
BNP-guided monitoring on a primary outcome of all-cause mortality and secondary outcomes, including
all-cause and HF-specific hospitalisation. For the primary outcome, their meta-analysis was based on eight
RCTs,52,54,58,59,61–64 which provided IPD on 2000 patients, 994 of whom were randomised to the CG group
and 1006 were randomised to the BNP-guided group. This meta-analysis explored the interaction between
age and relative effectiveness. There were 982 patients in the younger (< 75 years) subgroup and 1018 in
the older (≥ 75 years) subgroup. The authors estimated Kaplan–Meier survival curves and HRs for all-cause
mortality in both subgroups. BNP-guided monitoring reduced all-cause mortality in the younger subgroup
(HR 0.62, 95% CI 0.45 to 0.85) but there was no evidence of a beneficial effect in the older subgroup
(HR 0.98, 95% CI 0.75 to 1.3). These findings are qualitatively quite similar to our age subgroup findings,
reported in previous sections of this report, based on six RCTs52–56,59 including 1476 patients combined with
the estimate of Brunner-La Rocca et al.:33 greater benefit of BNP-guided therapy was observed in the
younger subgroup (HR 0.70, 95% CI 0.53 to 0.92) than in the older subgroup (HR 1.07, 95% CI 0.84
to 1.37).
In a recent IPD meta-analysis, Brunner-La Rocca et al.33 explored additional age and LVEF status subgroups
based on a subset of seven RCTs54,58,59,61–64 in patients with HFrEF (n = 1580) and four RCTs60–62,64 in
patients with HFpEF (n = 296). They found the strongest evidence of a beneficial effect of BNP-guided
monitoring among younger patients (< 75 years) with HFrEF (HR 0.68, 95% CI 0.48 to 0.96, n = 881),
although the evidence was weaker among the smaller number of younger patients with HFpEF (HR 0.76,
95% CI 0.29 to 1.96, n = 96). The evidence was not conclusive in older (≥ 75 years) patients with HFrEF
(HR 0.87, 95% CI 0.65 to 1.16, n = 850) but did not exclude the possibility of a clinically important effect.
In our primary analyses, we used the relative effects reported in the Troughton et al.25 and Brunner-La
Rocca et al.33 subgroup meta-analyses to estimate cost-effectiveness, as they represent the largest IPD
meta-analyses to date. In SAs, we used relative effects from our IPD meta-analysis to assess the sensitivity
of results to the subset of RCTs selected (SA3). Long-term follow-up is not available for most RCTs. In the
TIME-CHF,86 BNP-guided therapy ceased at 18 months; over a 5-year follow-up period, the study found a
non-significant trend for continued improved survival in younger HFrEF patients with treatment guided by
BNP (HR 0.62, 95% CI 0.37 to 1.03). Very few patients were followed up for the full 5 years in TIME-CHF.
Therefore, in our primary analysis, we assumed that BNP-guided therapy would cease after 18 months and
that the relative treatment effect would end after 4 years. However, it is plausible that BNP-guided care
becomes ineffective or less effective before 4 years if, for example, compliance with BNP-guided therapy
decreases or the efficacy of BNP-guided therapy decreases with age. Equally, patients may benefit from
longer periods of BNP-guided therapy and the relative effect may extend beyond 4 years. To test the
importance of these assumptions, we performed SAs assuming that the relative effect and cost of
BNP-guided therapy ceased at 2 years (SA4) or that the relative effect and cost of BNP-guided therapy
extend for the lifetime of patients (SA5).
Baseline probabilities and relative effects: hospitalisation
For patients surviving each cycle of the model, we estimated the probability of all-cause hospitalisation.
In the CG group we used the CPRD–HES–ONS linked data, as described earlier, to estimate the monthly
hazard rate of all-cause hospitalisation. We then applied this hazard rate throughout the lifetime of
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patients in the model. Troughton et al.25 found no strong evidence that all-cause hospitalisation was
reduced in the BNP-guided monitoring arm (HR 0.94, 95% CI 0.84 to 1.07). However, HF-specific
hospitalisation was lower in the BNP-guided therapy arm (HR 0.80, 95% CI 0.67 to 0.94). In our analyses,
we modelled all-cause hospitalisation. We selected all-cause hospitalisations because this outcome is
important to patients and costly for the NHS. This is consistent with our focus on all-cause mortality and
allows for the possibility that savings through reduced HF readmissions may be partially offset by more
admissions for concomitant disorders or side effects of more intensive HF pharmacotherapy.
Neither Troughton et al.25 nor Brunner-La Rocca et al.33 reported HRs for all-cause hospitalisation stratified
by LVEF status. In the absence of evidence, we used a HR of 0.94 (0.84 to 1.07) for patients with any
type of HF reported by Troughton et al.25 to estimate the relative effect of BNP-guided monitoring on
all-cause hospitalisation since, after adjustment for covariates, there is negligible difference in the risk of
all-cause hospitalisation at 1 year (RR 1.02, 95% CI 0.95 to 1.10).81 Therefore, we used the same risk
of all-cause hospitalisation for patients with HFrEF and HFpEF.
Utility parameters
We used two utility parameters to distinguish between patients with stable HF managed in the community
and patients who are hospitalised with HF. We conducted a brief literature search to identify studies which
reported utility scores, preferably using the EuroQol-5 Dimensions, in patients with HF stratified by
hospitalisation status. The Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure
(ASCEND-HF) multinational trial82 reported utility scores among more than 6000 patients hospitalised with
acute decompensated HF and randomised to Nesiritide or placebo. EuroQol-5 Dimensions, three levels
(EQ-5D-3L) scores were collected at baseline, 24 hours, discharge and 30 days. In the placebo arm, mean
EQ-5D-3L utility scores increased from 0.55 (SD 0.29) at admission to 0.66 (SD 0.26) at 24 hours and
0.77 (SD 0.23) at discharge. EQ-5D-3L scores did not change substantially post discharge: 0.74 (SD 0.25).
In our model, we assumed that the utility score at 24 hours was representative of the average utility score
(Uh) of patients with acute decompensation during hospitalisation and that the utility score at discharge was
representative of the average utility score (Unh) among patients with stable HF who were not hospitalised. We
assumed that these two utility values were independent of monitoring strategy; therefore any improvement
in quality of life from BNP-guided monitoring strategy in the model is the result of reducing the risk of
readmission. Evidence from most RCTs59,62–64 that measured quality of life indicates no difference between
patients with BNP-guided and those with CG treatment. We assumed that utility values did not decline with
age or differ by LVEF status.
Using the CPRD–HES linked data, we estimated that patients hospitalised with HF would have a mean
(standard error) length of stay of 13.21 (0.39) days within a 3-month cycle. Therefore, the mean QALYs
gained during a 3-month (i.e. 91.31 days) cycle which included a hospitalisation (QALYh) and a 3-month
cycle with stable HF not hospitalised (QALYnh) are:
QALYh = (13:21 (Uh) + (91:31−13:21) (Unh)) / 365:25: (3)
QALYnh = 91:31 (Unh) / 365:25: (4)
Cost parameters
The model includes several cost parameters: (1) the cost of BNP and renal testing, (2) up-titration of
pharmacotherapy related to BNP monitoring, (3) unscheduled outpatient appointments, (4) the ongoing
cost of managing patients with HF in the community and (5) the costs of treating patients with HF in
hospital. BNP-guided therapy is likely to initially increase costs due to BNP testing and up-titration of
medications but this may be offset in the longer term through reduced hospital admissions. BNP-guided
therapy will also increase NHS costs if it extends survival.
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The cost of a BNP blood test is £15–25.84 We used the top end of this range (£25) in our primary analysis
to include the costs of additional renal function tests. The cumulative cost will depend on how frequently
and for how long monitoring continues. Several RCTs58,59,64 used BNP testing at approximately 3-monthly
intervals, whereas others54,62 used testing more frequently initially and then at tapered intervals. Our
default assumption was that BNP-guided monitoring would cease at 18 months.
There is mixed evidence of the effect of BNP-guided monitoring on drug utilisation. Some trials58,59,62
reported increases in doses of some drugs in the BNP-guided therapy arm, whereas others54,63,64 did not.
In the economic evaluation conducted alongside TIME-CHF,29 medication costs were 12% higher [US$747
vs. US$668; p = 0.04 (2006 values)] in the BNP-guided therapy arm over an 18-month follow-up period.
We used this incremental cost (US$79), inflated to 2013/14 values and converted to £(GBP), to estimate the
potential increase in medication costs. BNP-guided therapy may also increase the number of unscheduled
outpatient visits due to increased side effects of pharmacotherapy; however, most trials do not report this
outcome. The PRIMA trial62 found inconclusive evidence of a higher mean number of unscheduled outpatient
appointments in the BNP-guided monitoring arm than the CG arm at 2 years (1.4 vs. 1.1; p = 0.06). We used
this estimate and a unit cost of £123 per outpatient appointment.83
We estimated the costs of managing patients hospitalised with HF and with stable HF in the community,
stratified by age group, based on the CPRD–HES–ONS linked data.10 In brief, we identified 1555 adults
in England who died with HF in 2012/13. We used the CPRD–HES linked data to estimate the cost of
medications, primary and hospital health care during each 90 day period in the 5 years before death.
The mean cost of NHS care (hospital admissions, outpatient clinics, primary care consultations, medications
and investigations), for patients hospitalised and not-hospitalised, stratified by age group, are reported in
Table 22. These analyses found no strong evidence of additional NHS costs for patients with left ventricular
dysfunction (mean incremental cost £234, 95% CI –£113 to £580) and therefore we used the same
estimates in HFrEF and HFpEF subgroup analyses. All costs were estimated in 2013/14 £(GBP).
Probabilistic sensitivity analysis
We used probabilistic sensitivity analysis (PSA) to propagate the probabilistic uncertainty about each model
parameter and estimate 95% CIs around the cost-effectiveness results.87 Monte Carlo simulation was
used to draw a randomly selected estimate of each model parameter from the distribution described in
Tables 21 and 22 and calculate the iNMB. We used beta distributions to represent the uncertainty in the
probability and utility parameters because these values are typically bounded at zero and one. We used
log-normal distributions to estimate uncertainty in hazard rates and ratios. We used gamma distributions
to represent the uncertainty in the cost parameters because these values are constrained to be non-
negative but can have skewed distributions. The model was built in Microsoft Excel® 2013 (Microsoft
Corporation, Redmond, WA, USA) and programmed using Microsoft Visual Basic for Applications® 2013
(Microsoft Corporation, Redmond, WA, USA) to run the PSA. We used a conventional number of iterations
(n = 10,000) to empirically estimate the uncertainty surrounding the mean iNMBs calculated from
the model.
Deterministic sensitivity analyses
Probabilistic sensitivity analysis on model parameters does not account for all uncertainties underlying the
model. There are a number of structural assumptions that are more difficult to parameterise and test in the
PSA. Therefore, we conducted a number of deterministic SAs to evaluate the robustness of our results to
several of the assumptions made within the model. In addition to the SAs described previously, we also
tested the sensitivity of model results to a 50% decrease (SA6) and 50% increase (SA7) in the cost of
BNP testing.
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Results
Younger patients (aged < 75 years) with heart failure
Our results indicate that BNP-guided therapy is more costly but also more effective than CG therapy over
the lifetime of younger patients with any type of HF (see Table 23). If the relative reduction in mortality is
sustained for 4 years, then median survival is approximately 1.5 years longer in patients with BNP-guided
therapy (7.98 years vs. 6.46 years; Figure 44). The difference in mean QALYs is smaller (5.68 vs. 5.02; see
Table 23), reflecting the imperfect health of survivors and the discounting of health gained in future years.
Lifetime costs are substantially higher in patients with BNP-guided therapy (£64,777 vs. £58,139; Table 23),
as the potential for decreased hospitalisation observed in RCTs is more than offset by BNP testing,
medications and the costs of health care during the extended survival period.
The positive iNMB statistic (£6426, 95% CI £2401 to £10,075; see Table 23) indicates that BNP-guided
therapy is cost-effective in this patient subgroup at the £20,000 per QALY threshold used by NICE. The CI
is broad, primarily because of the uncertainty around the mortality HR from the RCT meta-analysis;
however, it does not include zero. Therefore, there is a high probability (0.99) that BNP-guided therapy is
cost-effective for this patient subgroup at the NICE £20,000 per QALY threshold (Figure 45).
TABLE 23 Primary cost-effectiveness results in five patient subgroups
Subgroup
CG BNP
iNMB (95% CI)b (£)Costa (£) QALYsa Costa (£) QALYsa
Patients aged < 75 years
All HF 58,139 5.02 64,777 5.68 6426 (2401 to 10,075)
HFrEF 58,139 5.02 63,527 5.57 5424 (987 to 9469)
HFpEF 67,694 5.86 71,097 6.23 3155 (–10,307 to 11,613)
Patients aged ≥ 75 years
All HF 26,093 2.20 25,802 2.23 869 (–2814 to 4606)
HFrEF 26,093 2.20 27,676 2.39 2267 (–1524 to 6074)
a Deterministic SAs.
b PSA.
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FIGURE 44 Survival curves for all HF patients aged < 75 years.
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Younger patients (aged < 75 years) with heart failure; stratified by left ventricular
ejection fraction status
The findings in the subgroup of younger patients with HFrEF are broadly similar to those described above
for younger patients with any HF. This is unsurprising, as the majority of younger patients (90%)33
recruited to RCTs have HFrEF. The positive iNMB statistic (£5424, 95% CI £987 to £9469; see Table 23)
indicates that BNP-guided therapy is cost-effective in this patient subgroup at the £20,000 per QALY
threshold used by NICE.
The evidence of cost-effectiveness of BNP-guided therapy is less strong for the subgroup of younger
patients with HFpEF. Median survival (9.54 vs. 8.43 years; Figure 46) and mean QALYs (6.23 vs. 5.86
QALYs; see Table 23) are estimated to be higher in patients with BNP-guided monitoring. However, the
iNMB is relatively small with a broad CI spanning zero (£3155, 95% CI –£10,307 to £11,613; see Table 23).
Nevertheless, there is a relatively high probability (0.75) that BNP-guided therapy is cost-effective for this
patient subgroup at the NICE £20,000 per QALY threshold (Figure 47).
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FIGURE 45 Cost-effectiveness acceptability curves for all HF patients aged < 75 years.
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FIGURE 46 Survival curves for HFpEF patients aged < 75 years.
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Older patients (aged ≥ 75 years) with any heart failure and heart failure reduced
ejection fraction
There is little evidence of meaningful health benefits or NHS cost savings of BNP-guided therapy among
older patients with any type of HF. The iNMB is small, with a broad CI spanning zero (£869, 95% CI
–£2814 to £4606; see Table 23). There is some evidence that BNP-guided therapy has the potential to be
cost-effective among older patients with HFrEF. However, life expectancy is much lower in this subgroup
than in younger patients, and the estimated gain in QALYs (2.39 vs. 2.20 QALYs) is therefore relatively
small. Likewise, the iNMB is relatively small and the CI spans zero (£2267, 95% CI –£1524 to £6074; see
Table 23). There is a relatively high probability (0.88) that BNP-guided therapy is cost-effective for this
patient subgroup at the NICE £20,000 per QALY threshold (Figure 48).
Sensitivity analyses
The estimated benefit of BNP-guided therapy is sensitive to assumptions about its sustained effect (Table 24).
If the relative effect and cost of BNP-guided monitoring ceases at 2 years (SA4), the estimated gains in
survival (Figure 49) and QALYs (5.39 vs. 5.02 QALYs; see Table 24) are smaller. However, because the costs
of BNP-guided monitoring also fall when survival decreases, the conclusion that BNP-guided monitoring is
probably cost-effective in younger patients (< 75 years) with HF does not change (iNMB £3395, 95% CI
£1137 to £5368; see Table 24).
If the benefit of BNP-guided therapy is sustained over patients’ lifetimes (SA5), the estimated benefit and
CI width both increase greatly (iNMB £15,033, 95% CI £4330 to £26,556; see Table 24). Plausible
changes in the unit cost of the BNP test have minimal impact on conclusions about cost-effectiveness in
this patient group (SA6, SA7; see Table 24). Different assumptions about the function form of survival,
based on the Weibull distribution (SA1) or Kaplan–Meier curve from Troughton et al.25 (SA2), also had
negligible impact on conclusions about cost-effectiveness (see Table 24). The use of the HR derived from
our IPD meta-analysis did not change the iNMB estimate greatly (SA3; see Table 24).
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FIGURE 47 Cost-effectiveness acceptability curves for HFpEF patients aged < 75 years.
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Summary of main findings
We found strong evidence that BNP-guided therapy is a cost-effective alternative to CG therapy strategy in
younger (< 75 years) patients with HFrEF and who have recently been discharged from hospital after an
acute episode. This conclusion holds even if the impact of BNP-guided therapy on mortality is assumed to
dissipate after 2 years. The additional upfront costs of BNP-guided therapy are justified by improvements
in survival in this patient subgroup. The costs of BNP-guided monitoring may be offset by fewer
hospitalisations but there is no strong evidence that BNP-guided therapy reduces all-cause hospitalisation.
We also found that BNP-guided therapy has the potential to be cost-effective in younger patients with HFpEF
and older patients (≥ 75 years) with HFrEF. However, more evidence is required before any firm conclusions can
be drawn. There were relatively few younger patients with HFpEF included in RCTs; therefore, conclusions about
clinical effectiveness and cost-effectiveness in this subgroup are tentative. Although a larger number of older
patients with HFrEF have participated in RCTs, the effectiveness of BNP-guided therapy appears to be attenuated
in this subgroup compared with younger patients with HFrEF and cost-effectiveness remains unproven.
TABLE 24 Sensitivity analyses (all HF patients aged < 75 years)
SA
CG BNP
iNMB (95% CI)b (£)Costa (£) QALYsa Costa (£) QALYsa
SA1: survival based on the Weibull distribution 59,025 5.10 66,293 5.81 6838 (2512 to 10,825)
SA2: survival based on the Kaplan–Meier curve
from Troughton et al.25
62,270 5.38 69,640 6.10 6914 (2632 to 10,847)
SA3: BNP HR based on our own IPD meta-analysis 58,139 5.02 63,117 5.53 5138 (1242 to 8680)
SA4: BNP-guided monitoring ceases at 2 years 58,139 5.02 62,008 5.39 3395 (1137 to 5368)
SA5: BNP-guided monitoring continues for lifetime 58,139 5.02 74,686 6.60 15,033 (4330 to 26,556)
SA6: low cost (£12.50) of a BNP test 58,139 5.02 64,708 5.68 6438 (2391 to 10,142)
SA7: high cost (£37.50) of a BNP test 58,139 5.02 64,846 5.68 6358 (2319 to 10,027)
a Deterministic SA.
b PSA.
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FIGURE 49 Sensitivity analysis 4: survival curves if BNP-guided monitoring ceases at 2 years.
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Chapter 5 Discussion
Main findings: study conduct
The main findings with respect to study conduct relate to challenges with data sources and data
management.
We had extreme difficulty in obtaining the IPD from RCTs that we identified for the systematic review.
We followed established recommendations for establishing an IPD collaboration, taking advice from the
Cochrane IPD meta-analysis Methods Group as well as from experts within the team. Several triallists/
participants in the first meta-analysis of BNP-guided therapy,25 led by Troughton, argued that, contrary
to our protocol, trials that did not set a BNP target should be excluded. We had addressed this issue by
specifying in our analysis plan that we would carry out a SA, excluding trials that did not set a target.
Nevertheless, Troughton et al. declined to participate. Therefore, we estimated the main effect of
BNP-guided therapy by combining IPD and aggregate data, including ‘aggregate’ estimates for key
subgroups from a previous meta-analysis in order to maximise the power of these analyses. Regrettably,
we could carry out only very limited other subgroup analyses, which had low power.
The process for obtaining the linked cohort data was complex and took much longer than expected. The
organisations responsible were not as seamlessly integrated as we had expected and the information they
provided was not always clear; ultimately, the process for gaining approval to link the CPRD data with
the NHFA data set was so protracted that we proceeded without this aspect of the linked cohort. There
were two main reasons for delay we experienced: when we started the project the linkage agreements
between CPRD GOLD and specific disease registries were not in place and later the reorganisation of the
governance arrangements in NHS Digital halted all applications for data and data linkages. When we
obtained the CPRD GOLD data, the principle of creating the longitudinal cohort worked satisfactorily.
In relation to the cohort study, in the absence of any established algorithms to identify patients with HF
and classify patients as exposed to BNP monitoring or not, we developed our own algorithms. We found
that Read Codes for HF are diverse but reasonably consistently used. We chose the most specific algorithm
for incident HF in order to have the greatest confidence that the cohort truly comprised patients with HF; it
was reassuring that a relatively small number of patients were excluded by this algorithm, compared with
the next most sensitive algorithm, and that (when we compared them) the findings for the two algorithms
were broadly similar.
Designing an algorithm to identify patients who were exposed to BNP monitoring was more challenging.
We were able to quantify the number of BNP tests for each cohort participant and rate of BNP testing. The
final algorithm we chose aimed to take into account the total number of tests, the rate of testing and the
period of observation, in order to allow for regular but infrequent tests. This algorithm classified very few
patients (< 0.5%) as monitored. Although such patients were required to have had three or more BNP
tests at a rate of two or more per year, we could not confirm that the test results were used to up-titrate
HF medication because medication doses in the CPRD were inconsistently reported. The small number of
patients classified as BNP monitored were different from patients who had never had a BNP test or who
had had fewer BNP tests: more were female and > 75 years of age and they had a lower BMI and a
differing pattern of comorbidity. Given the low frequency of BNP monitoring identified by the algorithm,
different nature of the patients classified as BNP monitored and our uncertainty about the success of the
algorithm in identifying BNP-monitored patients, we have not reported estimates of the effectiveness of
algorithm-determined BNP monitoring in the cohort.
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Main findings: study results
Systematic review and meta-analysis
There were four main findings from the systematic review and meta-analysis (the meta-analysis carried
out for this project, incorporating evidence from the Troughton et al.25 and Brunner-La Rocca et al.33 IPD
meta-analyses).
First, BNP-guided therapy appeared efficacious in reducing hospital admissions for HF. Although the
meta-analysis by Troughton et al.25 suggested a protective effect of BNP-guided therapy on all-cause
mortality, this excluded the subgroup of patients with HFpEF from the Time-CHF trial. The inclusion of this
subgroup in our analysis slightly attenuated the overall effect of BNP-guided therapy on all-cause mortality,
which became not statistically significant (p = 0.13).
Second, the benefit of BNP-guided therapy appeared to be greatest in patients < 75 years and in patients
with HFrEF. Brunner-La Rocca et al.33 appear to have considered the independent effects of the interactions
between BNP monitoring with age and type of HF, presumably fitting both interactions in one model.
They reported the efficacy of BNP monitoring for the four combinations of age and type of HF separately;
patients < 75 years with HFrEF benefited the most. They also included comorbidities in the model and
concluded that the interaction between BNP-guided therapy and age was explained by the older group
having more comorbidities.
Third, the magnitude of treatment effects for clinical outcomes observed in RCTs was not associated
with differences in BNP levels between BNP-guided and CG groups or the stringency of the BNP target in
trials that set a target. In their meta-analysis, Troughton et al.25 also showed that there were no major
differences between groups in their medications at the end of follow-up.
Fourth, BNP-guided therapy was implemented in diverse ways across trials. This is perhaps not surprising,
given that there is no established guideline describing how to monitor BNP or what the BNP target should
be. The majority of trials used a target-setting approach (reducing or maintaining the BNP level below a
defined target) but with different targets and test frequencies. The heterogeneity between trials and the
absence of an established BNP target level were the main factors responsible for our decision to include
evidence from all RCTs, regardless of the BNP monitoring approach used.
Finally, none of the studies that provided IPD included individual data for adverse events. Published original
reports of each individual study did not identify any significant differences in adverse events between
study groups.
These findings pose a paradox. On the one hand, BNP-guided therapy appears to be efficacious in the
kinds of patients with HF recruited to the RCTs that have been carried out. On the other hand, there was
no strong evidence to support the mechanism by which such a benefit is hypothesised to arise, that is,
differences in BNP changes from baseline between BNP-guided and symptom-guided therapy groups and
more aggressive up-titration of all medications for HF in the BNP-guided group compared with the
symptom-guided therapy group. Some of the key findings are discussed in more detail below.
Which groups of patients benefit from B-type natriuretic peptide-guided therapy?
The results from our subgroup analyses showed more benefit of BNP-guided therapy in patients < 75 years
old and patients with HFrEF, with significant interactions between BNP-guided therapy and age and
between BNP-guided therapy and type of HF for all-cause mortality. These interactions were also found by
Brunner-La Rocca et al.,33 which is unsurprising, as the latter’s estimates account for over 80% of the
weight in our analyses. For type of HF, the effect appeared to be substantially driven by TIME-CHF; when
this study was excluded the interaction between the treatment response on mortality and the type of HF
was no longer statistically significant (the treatment effect in the two strata converged).
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The subgroup analysis by Brunner-La Rocca et al.33 suggested that the effect of age on treatment response
disappeared when interactions between comorbidities (e.g. hypertension, renal failure, chronic obstructive
pulmonary disease) and treatment strategy allocation were considered. Similarly, in patients with HFrEF,
who formed the majority of the study populations, comorbidities, such as diabetes and chronic obstructive
pulmonary disease, attenuated the efficacy of BNP-guided therapy on mortality.
Was the treatment effect a result of decreasing B-type natriuretic peptide and
up-titration of medication?
The observed benefit in the BNP-guided therapy group could not be attributed to changes in BNP/NT-proBNP
levels during follow-up. In most of the RCTs (5/8)58,62–64,66 that described BNP/NT-proBNP levels at baseline and
end of follow-up, levels decreased in both treatment groups at the end of follow-up. The meta-analysis by
Troughton et al.25 also showed that NT-proBNP levels (available from seven studies providing IPD) fell by a
similar amount in the two groups, 35% in the BNP-guided therapy group and 32% in the symptom-guided
therapy group. There was no consistent relationship between the magnitude of the HR for all-cause mortality
and the BNP/NT-proBNP decrease (see Figure 24). The trials that showed the greatest benefit and in which BNP
fell substantially more in the BNP-guided group than in the symptom-guided group provided least weight in the
meta-analysis.
This interpretation of the lack of relationship between treatment effects and changes in BNP/NT-proBNP levels
might be criticised as naive. For example, the RCT populations had different baseline BNP/NT-proBNP levels and
the effect of BNP-guided therapy may differ according to HF severity. In addition, the dynamics of BNP levels
are complex, influenced not only by HF severity but also a multitude of factors, including demographic (age,
sex, BMI),88,89 genetic,90 and a variety of other cardiac and non-cardiac conditions (e.g. atrial fibrillation,
pulmonary hypertension, myocardial ischaemia, ischaemic stroke, pulmonary embolism, chronic kidney disease
and liver dysfunction).91 Nevertheless, these important prognostic factors should have been distributed similarly
in BNP-guided therapy and symptom-guided therapy groups in all of the RCTs by virtue of randomisation, and
proponents of BNP-guided therapy need to explain the absence of a relationship.
The proportion of patients on different HF medications was similar in both the BNP-guided therapy and
symptom-guided therapy groups at baseline and at the end of follow-up. It could not be determined
whether or not and how HF medication doses changed during follow-up because medication doses were
not available for most of the studies providing IPD. The meta-analysis by Troughton et al.25 showed no
differences between groups in the changes in medication doses from baseline to the end of follow-up,
except for ACEis and ARBs (higher doses in the BNP-guided therapy group). Treatment with ACEis and
ARBs in accordance with guidelines has been shown to reduce the risk of death and hospitalisation in both
RCTs and large registries.92–95
B-type natriuretic peptide-lowering versus B-type natriuretic peptide-monitoring
strategy
Our systematic review and meta-analyses aimed to include all RCTs that used serial BNP measurements to
guide HF therapy, regardless of the monitoring strategy used. The exclusion of two RCTs that did not use a
BNP-lowering strategy did not alter the findings of the meta-analysis. Troughton and Januzzi (R Troughton,
University of Otago/Christchurch Hospital and JL Januzzi, Harvard Medical School/Massachusetts General
Hospital, 2015, personal communication) have argued that only studies using a similar design should be
pooled because including studies that use different monitoring approaches will increase clinical
heterogeneity, leaving clinicians uncertain as to which approach to follow. A published protocol is not
available and, despite several requests, Troughton et al. were unable to provide one. Therefore, it is
unclear whether or not this was an a priori point of view when Troughton et al. carried out their first
meta-analysis. It is also unclear whether their meta-analysis was based on a systematic literature search.
There is no mention in the published meta-analysis of Troughton et al.25 of the different BNP-monitoring
strategies, although the NorthStar results were presented between Troughton’s conference presentation50
and his published meta-analysis.25
DOI: 10.3310/hta21400 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 40
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
At the outset, we disagreed with the point of view of Troughton et al. for several reasons. First, we aimed
to provide realistic treatment effect estimates given that there is no established guideline describing how
to monitor BNP or what the BNP target should be, and therefore clinicians are likely to vary in how they
use BNP levels to manage their patients (e.g. some may use BNP to check the status quo and others may
take a more stringent approach to lower BNP as much as possible or to a particular target).
Second, it can be argued that the two strategies are not fundamentally dissimilar, as both approaches will
prompt a review of the treatment a patient receives, with appropriate intensification to bring BNP down to
a set target or within the specified range (and it can be reasonably argued that the latter also represents
monitoring to a target).
Third, the RCTs that used a BNP-lowering strategy were themselves highly heterogeneous in design,
treatment strategies (in both the BNP group and the control group) and BNP/NT-proBNP cut-off points
used. This heterogeneity, combined with the fact that the optimal target is not known and that the effect
of BNP-guided therapy appears to be independent of BNP changes over time makes it difficult to argue for
the exclusion of any trials, regardless of the BNP-monitoring approach used.
Finally, we prespecified in our protocol that we intended to include all trials of BNP monitoring. We made
this decision because we are aware that UK patients with HF are managed mainly in primary care,
in which target setting may be less appropriate, and wished to avoid publication-related biases, data
availability bias and reviewer selection bias.26,37,96 These biases can lead to meta-analyses being biased
towards more favourable treatment effects96,97 and have been highlighted as a potential problem in
meta-analyses that use IPD.96 We included a SA to investigate the impact of the distinction between
BNP-guided strategies that do and do not set a target.
Risk of bias in randomised controlled trials included in meta-analyses and
systematic reviews
It is important also to consider whether or not the apparent benefits of BNP-guided therapy could have
arisen because of bias, either in the primary RCTs or through the conduct of the reviews, particularly in
view of the lack of an apparent mechanism for the benefits.
Most of the included RCTs (10/13) had unclear risk of bias because they did not report whether or not
allocation was concealed (see Table 1 and Figure 2). SAs including just the three RCTs52,59,61 that were judged
to have had concealed allocation appeared to generate attenuated effects but these analyses had low power.
Most of the included RCTs were considered to have a high risk of bias because there was a lack of
blinding of participants and the care team. This lack of blinding means that cointerventions affecting
outcomes (including all-cause mortality) could have been initiated by either the doctors or the participants
themselves, conditional on their knowledge of the allocation. (By contrast, risk of bias because of blinding
of outcome assessors was assumed to be low for all RCTs for all-cause mortality and high or unclear for
about 50% of RCTs for other outcomes.) Two RCTs were reported as double-blind58,64 and one reported
blinding patients to group allocation.59 Among the other included RCTs, ten made no attempt to blind
investigators52–55,59–63,65,66 and one was unclear,56 and two made no attempt to blind participants55,66 and
eight were unclear52–54,56,61–63,65 (see Table 2 and Figure 2).
Blinding of participants required blood samples to be taken (but not acted on) in both groups at all time
points when BNP measurements were scheduled to be used to guide management in the BNP-guided
group. The investigators of the TIME-CHF RCT described this arrangement: ‘The N-terminal BNP levels were
determined centrally at every visit in all patients, but only results of patients in the N-terminal BNP-guided
strategy group were sent to the investigators (treating physicians)’.59 The same was true in the Christchurch
pilot58 and BATTLESCARRED RCTs.64 Although no attempt to assess the success of participant blinding was
reported, it seems likely that this was successful in these three trials, meaning the reporting of quality of
life had low risk of bias.
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Blinding of doctors managing participants required objective criteria to be applied for treatment
intensification, with assessment of a participant’s status against the criteria by an independent physician
not otherwise involved in managing the participant’s care. This arrangement is described for the
Christchurch pilot and for the BATTLESCARRED RCTs: ‘Heart failure scores ≥ 2.0 triggered escalation of
drug therapy according to a pre-set algorithm . . . For the NT-proBNP group, adjustments in medications
and additional follow-up visits were triggered by a NT-proBNP level > 150 pmol/l and/or a heart failure
score ≥ 2.0 according to instructions by 1 investigator (JGL) who did not undertake the clinical
assessments’.64 No attempt to assess the success of investigator blinding was reported.
It is striking that in the Christchurch pilot58 and BATTLESCARRED RCTs,64 both of which blinded both
investigators and participants, treatment effects spanned almost the total range of the effects across trials
(HR 0.15 and 0.94; these estimates were extracted from a previous IPD meta-analysis),25 accepting that the
former estimate was extremely imprecise.
Neither previous meta-analysis reported that it was based on a protocol or carried out a systematic
literature search.25,33 Importantly, without protocols, one cannot be sure that study eligibility criteria,
outcomes and analyses were prespecified. Most of the reported effects took no account of multiple testing
and were of borderline statistical significance (0.05 > p > 0.01), the exceptions being stratum-specific
estimates for HF admission or a composite outcome of HF admission or death. The magnitude of the
reported benefits of BNP-guided therapy (HRs around 0.8–0.9) are likely to be clinically important and,
based on the cost-effectiveness model we report, very likely to be cost-effective for younger patients with
HFrEF. However, there remains considerable uncertainty about the size of the effects and the extent to
which they may be a result of bias.
Cohort study of patients with incident heart failure
The cohort of patients with incident HF provided a detailed description of the natural history of English
patients with HF and informed the cost-effectiveness model, primarily in relation to the costs of managing
patients with HF.
Three nested algorithms, designed to have differing sensitivity and specificity for incident HF, were applied.
The main cohort findings were based on the most specific algorithm, which included only patients with
one or more specific HF diagnosis codes. This algorithm yielded only slightly fewer patients with incident
HF (15%) than the intermediate algorithm, which also included patients with HF symptom codes; both
these algorithms also required patients to have a code for an investigation or test for HF and to have been
prescribed a medication indicated for HF.
The cohort study provided a comprehensive description of incident HF patients in the UK, through
follow-up in primary and secondary care (CPRD GOLD data linked with hospital data). We were able to use
the cohort data to estimate the incidence of adverse clinical outcomes in patients with HF and describe
patterns of BNP testing in HF patients in the UK. New patients with incident HF accrued to the cohort at a
constant rate over time, suggesting that GPs use the Read Codes for HF in a consistent manner. The rate
of BNP testing appeared to increase to some extent over time. The median longevity (death from any
cause) following diagnosis with HF was about 4.5 years.
Across all follow-up, patients had about one unscheduled admission to hospital every 2 years. In a
separate publication10 we used the CPRD data to identify a subset of 1555 adults in England who died
with HF in 2012/13 and described the pattern of resource over time; this analysis showed that admissions
were not spread evenly during follow-up but increased in frequency substantially as patients’ health
deteriorated. In this subset of patients, we also estimated the cost of medications, primary and hospital
health care and derived cost estimates for the cost-effectiveness model. We also presented data for the
cohort of patients with unscheduled hospital admissions in the NHFA. The cohorts were comparable with
respect to demographic and baseline clinical characteristics.
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This is the first study which has attempted to identify BNP monitoring in a cohort of HF patients from routinely
collected data. The algorithm for classifying patients according to their BNP test exposure classified very few
patients (< 0.5%) as monitored. The small number of patients classified as BNP-monitored also appeared to be
different from patients who had never had a BNP test or who had had fewer BNP tests: more were female and
> 75 years of age and they had a lower BMI and a differing pattern of comorbidity.
There were only five Read Codes that identified a BNP test in the CPRD, all of which are specific for BNP;
therefore, it is likely that BNP tests were identified consistently and accurately. The algorithms for defining
BNP exposure, in particular BNP-monitored patients, was developed with input from all clinical members of
the study team. However, this task was hampered by the fact that there is currently no accepted definition
of BNP monitoring on which we could base our algorithm (see Strengths and limitations of the study).
Model-based cost-effectiveness analysis
There were two main findings of the cost-effectiveness analysis:
1. BNP-guided therapy is a cost-effective alternative to symptom-guided therapy in younger (< 75 years)
patients with HFrEF and who are recently discharged from hospital after an acute episode. This finding
remains true even if the effect of BNP-guided therapy on mortality is limited to 2 years.
2. BNP-guided therapy is cost-effective, despite the costs of BNP-guided monitoring, over a longer period
of time, because more QALYs accrue with longer survival. BNP-guided therapy might reduce
hospitalisations but there is insufficient evidence to conclude that this is the case.
We compared our own findings with those of previous economic evaluations of BNP-guided monitoring
in patients with HF (Table 25). The largest prospective economic evaluation was conducted alongside
TIME-CHF.29 The RCT reported that more patients with HFrEF survived to 18 months (mean age 76 years)
with BNP-guided therapy, although the CI included one result (HR 0.68, 95% CI 0.45 to 1.02) that was
not statistically significant.59 The economic evaluation estimated higher costs (US$384, 95% CI –US$3462
TABLE 25 Previous economic evaluations
Author Study design Patients Interventions Outcomes Results
Sanders-van
Wijk et al.29
CUA alongside
TIME-CHF
n = 438;
≥ 60 years;
LVEF ≤ 45%
1. Symptom
guided;
2. NT-proBNP
guided
QALYs at
18 months;
2006 payer
costs
QALYs: 0.91 (BNP), 0.87 (SG),
difference 0.05 (95% CI –0.02
to 0.11). Costs: US$16,792 (BNP),
US$16,364 (SG), difference US$384
(95% CI –US$3462 to US$4803)
Adlbrecht
et al.28
CEAs alongside
Berger et al.61
trial
n = 190;
LVEF < 40%
or CTR> 0.5
1. UC;
2. HNC;
3. BNP
Mortality at
18 months;
2005 payer
costs
Mortality: 45% UC; 24% HNC;
17% BNP. Costs: €12,450 UC;
€12,391 HNC; €9674 BNP
Morimoto
et al.31
CUA Markov
model
35–85 years;
LVEF ≤ 40%
1. CG group;
2. BNP group
QALYs at
18 months;
2002 costs
QALYs: 1.07 (BNP), 0.94 (CG).
Costs: US$20,737 (BNP),
US$19,723 (CG)
Moertl et al.30 CUA Markov
model
LVEF < 40%
or CTR> 0.5
1. UC;
2. HNC;
3. BNP
QALYs up
to 20 years;
2010 health-
care costs
QALYs: 2.36 (UC); 3.04 (HNC);
3.20 (BNP). Costs: €36,110 (UC);
€38,653 (HNC); €35,155 (BNP)
Laramée et al.32 CUA Markov
model
Chronic HF
due to LVSD
and other
subgroups
1. Clinical
assessment;
2. NP
monitoring
QALYs over
lifetime;
2011 NHS
and social
service costs
QALYs: 4.85 (CA); 5.19 (NP).
Costs: £12,869 (CA); £13,972 (NP)
CA, clinical assessment by a specialist; CEA, cost-effectiveness analysis; CTR, cardiothoracic ratio; CUA, cost–utility analysis;
HNC, home-based nurse care; NP, natriuretic peptide; SG, symptom guided; UC, usual care.
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to US$4803; after excluding residential costs), longer survival (0.07 life-years, 95% CI 0.00 to 0.14
life-years) and higher QALYs (0.05 QALYs, 95% CI –0.02 to 0.11 QALYs) in patients with BNP-guided
therapy.29 The authors concluded that BNP-guided therapy had a high probability of being cost-effective
but note that this probability was lower in older patients.
Laramée et al.32 published the only UK-based economic model of BNP-guided therapy, developing previous
work included in the NICE HF clinical guidelines.8 Their analysis is based on aggregate data, rather than
IPD, from six RCTs.58,59,62,64–66 The structure of their model is similar to ours but the key model parameter
estimates differ, particularly those we derived from our analyses of the CPRD data. They concluded that
BNP-guided therapy is most probably cost-effective in patients with HFrEF and in younger patients
with HF from any cause. An acknowledged limitation of their analysis is that they could not explore
cost-effectiveness in patients with HFpEF.
Our study, using pooled IPD across several RCTs, was able to explore patient subgroups further than
previous economic evaluations. Our findings are in agreement with previous work that BNP-guided therapy
is a cost-effective alternative to CG therapy in younger (< 75 years) patients with HFrEF. Our analysis
suggests that BNP-guided therapy has the potential to be cost-effective in younger patients with HFpEF and
older patients (≥ 75 years) with HFrEF. However, it would be unreasonable to conclude that BNP-guided
therapy may be efficacious in these patients, given the small number of patients with HFpEF and patients
≥ 75 years of age who were recruited into the RCTs and the fact that BNP monitoring can work only
through optimising HF therapy but current HF drugs appear not to improve outcomes in HFpEF patients.98
There is also uncertainty with respect to what constitutes an optimal BNP-monitoring strategy. The trials
were heterogeneous in how BNP-guided therapy was administered and to date no group of researchers
has defined an optimal strategy. In addition, we have no strong evidence of an association between
the magnitude of the change in BNP levels during follow-up between groups and the size of the clinical
effect, which suggests that the intervention may not be responsible for the observed effects (as there
appears to be no mechanism for the efficacy of the intervention). Most of the RCTs also had a high risk
of performance bias.
Patient and public involvement and engagement
Patients and the public were not actively involved in identifying the research question for our project
because it had been prioritised by the NHS as a commissioned research programme. Nevertheless, during
the later stages of the application, we included Peter Billingham, who is the chairperson of the Avon,
Gloucestershire, Wiltshire and Somerset Cardiac and Stroke Network Cardiac Patients and Carers Group,
as a co-applicant. Mr Billingham has a history of cardiovascular disease and HF. We invited him to join the
study to help us understand the perspective of patients with HF, interpret the findings of the study and
disseminate the results.
During the course of the study, the newly appointed patient and public involvement and engagement
(PPI&E) lead for the Cardiovascular Biomedical Research Unit co-ordinated further PPI&E for this study. We
invited a small group of current HF patients so that we could talk to them about our project and gain their
insight and opinions about aspects of HF management that are important to patients with HF.
We enlisted the help of the HF specialist nurse at the University Hospitals Bristol NHS Foundation Trust to
identify patients to invite to the group. However, shortly after initiating the work, the specialist nurse left
her post and was not immediately replaced. Once we had compiled most of the study findings, we invited
patients to a focus group in order to elicit their perspectives on the emerging findings and to discuss their
views about disseminating the results of the study.
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Patient and participant involvement focus group
Four participants attended the focus group. All four were male and in their late fifties or older. Although
each was living with a HF diagnosis, they were in reasonably good health. Three of the participants
brought their partners with them and each (partner) fully participated in the group discussion. The
discussion was facilitated by the PPI&E lead, one of the authors (Maria Pufulete), a cardiovascular research
nurse (Kim Wright) and a second author, whose role was primarily to record minutes of the discussion
(Rachel Maishman).
Participants shared the following details of their histories.
l Participant A: this participant’s pathway started when he fainted and was admitted to hospital for tests.
He had a number of follow-ups over the subsequent years to determine what was wrong with him
and, gradually, the term ‘heart failure’ started to be used to describe his condition. The participant said
that his GP had never really been involved in the management of his HF and that he was usually seen
in the pacing clinic or by specialist HF nurses at the hospital.
l Participant B: the participant said that he had had a bad experience with the GP in relation to his
diagnosis. Initially, he was treated for a variety of other conditions (e.g. asthma, hay fever). Eventually,
the participant demanded to be referred to hospital, where he was immediately diagnosed. The
participant has no regular follow-ups at the GP and said that all of his HF management takes place in
the hospital. The participant said that he has only regular follow-up appointments because he is in a
drug trial with scheduled visits.
l Participant C: the participant noticed that he was unwell because his physical fitness was not as good
as usual. The participant was then diagnosed after an admission to hospital. He has not been back to
the GP since the diagnosis and all follow-up is with a specialist HF nurse at the local health centre.
The participant has follow-ups every 2–3 weeks and occasional consultations at the hospital with a
cardiologist specialising in HF. He is currently trying different medications to find the best combination
for him.
l Participant D: the participant has been to see the GP only a couple of times about his HF. The
participant was diagnosed following a referral by his GP to a cardiologist. He sees the cardiologist every
12 months to check his medications. The participant was also in the same trial as participant B.
Participants’ views on B-type natriuretic peptide-monitoring
Participants were asked whether or not they would be happy having BNP tests at regular follow-ups to
guide medication changes.
They said that they would welcome an objective way of saying whether the medication was working or
not. One participant said that the blood test would be a good idea and that, in terms of weighing up
‘better heart condition’ versus ‘increased side effects from more intensive drug treatment’, he would like
the results of the test in order to guide the recommendation to change treatment. He could then make an
informed decision to change treatment or not.
Although all participants were overwhelmingly in favour of BNP monitoring, they did acknowledge that
this was in part a reflection of their current health status. They agreed that deteriorating health and
potentially severe side effects resulting from more intensive medication may well cause their views to
differ. For one of the participants this was a real concern, as he had experienced incapacitating side
effects. Nobody else spoke about experiencing adverse side effects: the other three participants had all
experienced only benefits from their prescribed HF medications.
All participants in the group were focused on ‘maintaining’ their current, relatively healthy status and
prolonging life. BNP testing was viewed in this context, as a tool to achieve this goal. The potential for
being prescribed more intensified treatment was not seen as a deterrent, primarily reflecting the fact that
they had not experienced side effects with their current medications; rather, BNP testing was perceived as
a means of making more informed choices.
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Other comments arising from the discussion
l Participant B said that, since his discharge from hospital, his medications had not been changed.
l Participant C felt that there had been a pattern of poor communication between the consultants/
specialists and the GPs involved in his care.
l Some of the participants asked if they would be able to go to the GP and ask for the testing to be done.
l Participant D asked that, if this is a test for diagnosis of HF, why is it not offered to everyone with a
history of HF?
l Demographics of participant groups in studies were discussed in relation to the kinds of patients who
would be likely to be most assertive about requesting treatment/tests not routinely offered; it was
suggested that patients with a lower level of education would be less likely push for testing. In this
context, participants reflected on the composition of the focus group, noting that they perceived
themselves to be an intelligent, well-read/informed and mostly healthy group of people. They discussed
how their perspectives might have differed had they had a different socioeconomic profile. All participants
felt that their demographic characteristics had the potential to impact on their responses to questions, as
did their current health status.
l Subsequently, the group requested that any report resulting from the focus group should be
transparent about the health status and demographic composition of the group, particularly that no
participant had ‘end-stage’ HF.
Dissemination of the results of the study
The focus group discussed dissemination at two levels, namely with respect to general information level
about HF and information specific about the research.
At the general level, it was suggested that the leaflets available in British Heart Foundation (BHF) shops
were an excellent resource and that this information was of high quality. Participants talked about the
ways in which they used the BHF website and their booklets to keep up to date with news relating to their
condition and as a source of general information. All participants were keen to find ways of keeping up to
date with literature about HF, treatments and relevant research.
It was pointed out that general awareness of HF is poor. The consequence of this poor awareness is that
people are not aware of the signs and symptoms of HF so do not go to their GPs and are not diagnosed.
Participants viewed this as a bigger problem than the specific issue of interest, that is BNP testing.
The group pointed out that, apart from information provided by the BHF, it was not easy to find
appropriate literature on specific research or literature relating to issues of specific interest. A comment
was made that ‘in clinic there are 1000 different leaflets and you don’t know what you are looking for’.
With respect to specific research information, one participant had come with newspaper clippings about HF
research that had been published in the media and spoke about being keen to be as informed as possible.
The companions of the participants with HF also played a key role in gaining information about their
partner’s conditions. Three of the participants came with a companion and all three companions were very
well-informed about their partner’s condition and were clearly keen to learn more. The companions
discussed how they kept up to date with literature about HF, treatments and research: this largely involved
following leads from the BHF.
Other ways of disseminating information were suggested:
l Leaflets in GP surgeries, cardiology clinics, etc.
l Coverage on television, radio and in other media; dissemination in these fora is always popular and is
also very achievable, particularly radio and newspapers.
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l Posters were highlighted as a way of increasing general awareness about HF. Participants also
suggested that posters are a way to engage with the public about research-specific topics.
l Public lectures/workshops (group meetings to disseminate research). One participant talked about a
conference that they went to where there were stands and professionals presenting their work. He said
that the conference was very well-attended by the general public and something that he really enjoyed.
Another participant had also attended similar events but felt that the lack of inclusion of the patients
had had an impact on its success from their perspective.
Each of the participants fed back that they had enjoyed participating in the group and concluded that they
had particularly enjoyed meeting the other participants and talking about their health experiences together.
Next steps
Each participant was sent a thank you letter after the meeting. Participants were also invited to join an
ongoing patient advisory group about early-phase research in the Cardiovascular Biomedical Research Unit.
One of the participants agreed to join this group.
Dissemination of the findings of the study to patients and the public will draw on the points made by
participants and the continuing input of Peter Billingham, who will help us to disseminate our findings
through the Cardiac and Stroke Network.
Conclusion
Some key points emerged from focus group participants’ accounts of their medical histories in relation
to HF:
l they reported not being actively managed for HF by their GPs
l the lack of active management in primary care extended to diagnosis of HF; two of the four participants
reported being diagnosed only after referral or admission to hospital
l they actively sought out specialist hospital-based care, through specialist clinics or by participating
in research.
It is difficult to generalise from these accounts, as the participants were not representative and appeared
to be very engaged in managing their own conditions. Nevertheless, their accounts are consistent with
management in primary care being suboptimal, as reported by the BATTLESCARRED trial.64
Participants said that the principle of BNP monitoring, with regular blood tests, was acceptable and that
they would welcome an objective way of monitoring whether their HF medications were working or not.
With respect to an increased risk of side effects, it was felt that more information about HF status could
only be helpful in making difficult decisions about whether or not to opt for more intensive medication.
BNP testing was perceived as a means of making more informed choices.
Strengths and limitations of the study
Systematic review and meta-analysis
The present meta-analysis has several strengths. The review team systematically identified all RCTs that
used BNP-guided therapy in patients with HF and conducted the meta-analysis in accordance with a
prespecified protocol35 and published guidelines. All trials identified for which data were available (IPD or
aggregate) were included. There was no evidence of bias due to small study effects. The analysis plan
was prespecified.
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The main weakness was the inability to obtain IPD from most of the trials included in the meta-analysis by
Troughton et al.25 because of the differing view about the appropriateness of combining data for trials
when a BNP/NT-proBNP target was not set. This limitation constrained the subgroup analyses that could be
conducted. Unfortunately, it was not possible to combine the IPD subgroup estimates in our study with
other reported subgroup effects for all subgroups; the meta-analysis by Troughton et al.25 did not quantify
the age subgroup effect and the subgroup analysis based on the same set of trials33 quantified the age
subgroup effect within HFrEF and non-HFrEF strata. We asked Troughton et al. for their subgroup
estimates to allow us to carry out more detailed analyses but they did not respond.
Other limitations are inherent to the design of the RCTs: heterogeneity in how BNP-guided therapy was
administered; the recruitment of certain types of patients with HF (younger patients with HFrEF and
without comorbidities), which makes it difficult to generalise the results to the broader population with HF;
and the potential for bias, as clinicians and patients were not blinded to treatment allocation in most of
the trials. In addition, despite combining results from 13 RCTs, the pooled sample size (up to 3074 patients
with HF) was relatively small in comparison with sample sizes in other meta-analyses in this patient
population (some of which included > 13,000 patients)99 and multiple estimates have been reported with
95% CIs; therefore, chance may explain some of the apparently significant findings.
Cohort study of patients with incident heart failure
This cohort study had several strengths with respect to the descriptive objectives. We identified a large
cohort of patients newly diagnosed with HF, rather than a combination of incident and prevalent patients,
reducing the potential for bias and reflecting the most current population diagnosed with HF. We used
three different algorithms for identifying HF in the CPRD. Algorithms 2 and 3 included HF Read Codes and
the presence of HF-related investigations and HF medications. Although we did not validate our algorithms
(e.g. by requesting additional data from GPs for a subset of patients), results for the SA did not find
differences between the algorithms with intermediate (2) and least sensitivity (3). Similar findings have
been reported in other studies using CPRD data to identify different conditions,100–102 which suggests that
CPRD Read Codes can be used to identify a representative sample of patients with a particular condition in
the UK. Our study was conducted and reported in accordance with recent guidelines for studies conducted
using observational routinely collected health data (REporting of studies Conducted using Observational
Routinely collected health Data, RECORD guidelines103), which recognise the additional challenges of
conducting research using routinely collected data obtained for administrative and clinical purposes rather
than research.
In the context of the overall study, the main limitation was our lack of confidence that the patients
identified as BNP monitored were in fact monitored, as there was large diversity in the patterns of BNP
tests recorded in the CPRD data set. For example, some patients had numerous tests for a short period of
follow-up and no other tests recorded for the remainder of follow-up, there were irregular time intervals
between tests for different patients and there was no clear pattern of repeated BNP testing among most
of the 71 patients classified as BNP monitored. In addition, a proportion of patients did not have sufficient
observation time in the cohort study for the algorithm to discriminate between BNP tested and BNP
monitored. Ideally, we should have conducted a validation study (sending questionnaires to GPs for a
sample of the cohort to verify the diagnosis and the timing of the diagnosis)100 on the exposure algorithm
but this was difficult given the lack of consensus about what BNP monitoring should constitute and the
limited time frame of the project.
We were also aware at the outset that BNP monitoring, such as it was implemented in RCTs, is unlikely to
exist in ‘real-life’ practice. We were unable to establish if the serial BNP tests in the CPRD represented
clinicians ordering these tests and using BNP values to check that patients were stable (or adjust their
medications), indicated different clinicians ordering BNP tests at particular points in time to check the
severity of HF (in effect, cross-sectional testing), or represented tests ordered around hospital admissions or
following a cardiologist’s request after an outpatient appointment. Certainly, given that patients we
identified as monitored in the present study had poorer outcomes, it seems likely that BNP tests were
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ordered for the sickest patients to check the severity of their HF. These patients were on average older and
had a lower BMI, factors which are both associated with disease severity and poor outcome in chronic HF.104
Furthermore, with respect to investigating the mechanism of any effect of BNP monitoring, we could not
determine whether or not there was a relationship between BNP testing and changes in medications
because medication dose could not be determined accurately in the CPRD therapy data set (there were
many missing data on doses of medications). Evidence for such a relationship would have increased our
confidence that the serial testing represented monitoring. Collectively, these limitations led to our decision
not to report analyses of clinical outcomes according to BNP test exposure (BNP monitored vs. BNP tested
vs. never tested).
Other limitations of the cohort study include our inability to distinguish patients with HFrEF and HFpEF
because specific codes for the two types of HF were not used consistently. We were also unable to
perform the linkage between CPRD GOLD and the NHFA, which would have provided more detailed
information on unscheduled hospital admissions for patients in the cohort. A final point is that not all HF
patients in the UK are treated by GPs; some are treated in community HF clinics and at home by HF
specialist nurses. Community care databases are not linked with CPRD GOLD and, therefore, a substantial
proportion of data relating to some patients’ care pathways will be missing from the CPRD.
Model-based cost-effectiveness analysis
Our primary analyses were based on the IPD analyses of Troughton et al.25 and Brunner-La Rocca et al.33
including approximately 2000 patients participating in several RCTs. We were able to investigate the
cost-effectiveness of BNP-guided therapy in subgroups of patients that were not reported in all the original
RCT publications. The use of both previously published IPD meta-analyses25,33 and the meta-analyses
conducted in this report using an overlapping set of RCTs provided further confirmation of the probable
cost-effectiveness of BNP-guided therapy in younger patients. We conducted a PSA that allowed us to
identify patient subgroups (e.g. HFpEF patients aged < 75 years and HFrEF patients aged ≥ 75 years) for
which further evidence is needed. We did not extend this to estimate expected value of information.105
Expected value of information would estimate the costs of benefits of future RCTs in these patient
subgroups but was beyond the remit of this research grant. We conducted deterministic SAs to explore the
influence of selected assumptions on the model. This allowed us to demonstrate that plausible changes to
assumptions about the sustained benefit of BNP-guided therapy do not alter conclusions that BNP-guided
monitoring is cost-effective in younger patients with HFrEF but that they are influential in estimating the
absolute health benefit for patients.
We used a highly simplified two-state Markov model to track costs and patient outcomes. A more complex
model tracking dysfunction (e.g. through NYHA class) and making the probability of hospitalisation and
death dependent on dysfunction would provide a more realistic representation of disease progression. For
example, Ieva et al.106 have used routine administrative data to model the decrease in time to readmission
with each successive admission and the association between age, sex and readmission. The simplicity of
our model might lead to poor estimates of cost-effectiveness if BNP-guided therapy has a large effect
(positive or negative) on functional decline among survivors. However, evidence from several RCTs59,62–64
that have measured quality of life indicates no difference between patients with BNP-guided versus CG
treatment. One exception is the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT)
trial,107 which found greater improvement in quality-of-life scores among patients with HFrEF and who
received BNP-guided therapy. Our analyses focus on costs to the health service, rather than wider costs
falling on social care or patients and families. BNP-guided therapy may be more cost-effective from a
broader societal perspective if, for example, it results in fewer admissions to residential or nursing homes.
The conclusions of our study are limited by the quality of available evidence. In some patient subgroups
(i.e. HFpEF patients aged < 75 years and HFrEF patients aged ≥ 75 years), too little evidence exists to reach
definitive conclusions about cost-effectiveness. There was no evidence on all-cause hospitalisation stratified
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by patient subgroup, therefore we assumed that the HR reported for all HF patients could be applied to all
patient subgroups. Although this parameter was not very influential in our model, additional evidence on
this is needed for the patient subgroups (i.e. HFrEF patients aged ≥ 75 years) for which cost-effectiveness is
most marginal.
Lessons for the future: implications for clinicians and policy-makers
The present meta-analysis suggests that BNP-guided therapy improves clinical outcomes. However, the
applicability of this conclusion to all health settings is not clear. The RCTs included mainly patients < 75
years of age with HFrEF and who were treated by cardiologists in dedicated HF clinics. By contrast, across
many European countries, including the UK, cardiologists do not lead the management of patients with HF
and about half of all patients have HFpEF. There are significant gaps and variation in the medical care of
HF patients and there is evidence that not all patients are receiving optimal treatment according
to guidelines.11
The lack of evidence supporting plausible mechanisms by which BNP guiding might have an effect is also a
concern. The reduction in BNP levels and the increase in the doses of most medications in both treatment
groups reported in the RCTs suggest that patients in both groups were treated more aggressively
(according to trial protocols optimising symptom-guided therapy or clinical guidelines). Thus, our results
suggest that the first priority should be to ensure adherence to guidelines for managing HF. Despite the
apparent efficacy of BNP monitoring, its usefulness in guiding up-titration of therapy is not clearly
established, given the lack of relationship between the change in BNP levels between groups and
improved outcome.
B-type natriuretic peptide testing is recommended by NICE as an essential part of the diagnostic pathway
for HF.8 We have shown that ordering of BNP tests has increased to some extent over time, as would be
expected, but there is no hard evidence that BNP monitoring is currently happening in the UK, given the
small proportion of the cohort who had serial BNP tests. The introduction of a Read Code to indicate that
serial BNP testing is being carried out explicitly to guide up-titration of HF medications, and consistent use
of the code, would facilitate a future similar investigation using the CPRD data.
The National Institute for Health and Care Excellence also advised clinicians to consider specialist
monitoring of BNP in some patients, for example those recently admitted to hospital, but also
recommended further research on cost-effectiveness.8 It has been suggested that the guidelines did not
recommend routine use of BNP monitoring because of uncertainties about the impact of this monitoring in
older patients who represent the majority of patients with HF.32 The NICE clinical guidelines are scheduled
to be updated in 2018. Our results indicate that BNP-guided therapy conducted by a specialist team is
cost-effective in younger patients with HFrEF and who have recently been discharged from hospital after
an acute episode. However, more evidence is required to decide whether or not it is cost-effective in
younger patients with HFpEF and older patients with HFrEF, particularly with respect to the setting, the
frequency, duration and BNP target for monitoring.
Although BNP tests are relatively cheap, there will be logistical and financial challenges to routine
implementation in the UK. If, as in most RCTs, BNP monitoring is conducted in an outpatient setting by
physicians skilled in HF care, existing gaps between guidelines and current practice need to be bridged:
many patients in the UK do not receive follow-up by a cardiologist or HF specialist nurse.108 The
BATTLESCARRED trial64 compared BNP-guided and CG care in a specialist clinic with usual primary care
and found that usual primary care resulted in inferior survival at 1 year. Therefore, ensuring that more
patients with acute HF episodes get specialist follow-up is a necessary first step to using BNP-guided
monitoring to improve care for younger patients with HFrEF in a cost-effective way.
Furthermore, the SIGNAL-HF trial,63 which recruited patients with stable HF in primary care, found no
important improvements in clinical outcomes for patients with BNP-guided therapy in primary care. This
suggests that the clinical effectiveness and cost-effectiveness results cannot be generalised from specialist
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to primary care. Another hurdle to implementing BNP-guided treatment is that there is little consensus on
the optimal frequency, duration and BNP target for monitoring.
The frequency and duration of BNP-guided therapy and the algorithm used to titrate therapy are important
considerations for clinicians and policy-makers. Statistically, there was relatively little variation in the
mortality outcomes of RCTs; however, there were important differences in the BNP-guided monitoring
protocols used. TIME-CHF,86 which has provided the best evidence to date of a sustained effect in younger
patients with HFrEF, scheduled visits at 1, 3, 6, 12 and 18 months with the aim of rapidly up-titrating
therapy within 6 months. However, other protocols may be more cost-effective.
Future research recommendations
The present systematic review and meta-analysis have not been able to draw inference of an optimal
BNP-monitoring strategy and no group of researchers has defined one. An important area of future
research should, therefore, be an initiative to define an optimal BNP monitoring strategy, for example
through a formal consensus process involving researchers, cardiologists, GPs and patients. This initiative
may also consider which patient subgroups are likely to benefit from BNP monitoring and whether or not a
single optimal strategy should apply to all patient subgroups.
A striking feature of the trials is that HF medications increased in both BNP-monitored and CG groups,
strongly suggesting that HF management outside of the RCTs was suboptimal; this is also implied by the
comparison between participants managed in specialist clinics versus primary care in the BATTLESCARRED
trial.64 This evidence suggests that interventions are needed to optimise management of HF in accordance
with current guidelines.8 It is not clear whether or not this can be achieved through the commissioning
process (i.e. implementing incentives for practitioners to implement existing knowledge and expertise in HF
management), upskilling of practitioners (i.e. giving practitioners the knowledge and expertise to achieve
HF management consistent with the guidelines) and transferring care to a specialist setting (i.e. because
the setting of primary care does not allow HF management consistent with the guidelines). Understanding
which of these alternative reasons applies at present may require qualitative research with different types
of practitioner providing care for HF patients.
Depending on the findings from the two pieces of research described above, there might be a case to
commission a large pragmatic RCT of BNP monitoring in the UK in a primary care setting but with
improved adherence to existing HF management guidelines.
With respect to the cost-effectiveness model, most of the uncertainty is caused by wide CIs surrounding
the effect size of BNP-guided therapy, particularly in patient subgroups that are not well-represented in
RCTs. The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) trial,109 which
aimed to randomise 1100 patients with HFrEF to BNP-guided or symptom-guided therapy, was terminated
by the Duke Clinical Research Institute on 23 September 2016 (https://dcri.org/dcri-announces-halt-guide-
trial/; accessed 19 April 2017) having randomised 894 patients (https://clinicaltrials.gov/ct2/show/
NCT01685840?term=guide-it&rank=1; accessed 19 April 2017) because of a lack of difference in the
primary outcome between the treatment groups. No results from the trial are available yet but, when
published, the trial should contribute important new evidence about BNP-guided therapy in older patients
with HFrEF and help to support or refute existing evidence from smaller RCTs for younger patients with
HFrEF. Larger numbers of RCT participants would also enable more detailed exploration into further patient
subgroups. For instance, it has been suggested that comorbidities may explain the lower efficacy of
BNP-guided monitoring in older patients.33 This could be substantiated in future updated IPD meta-analyses
incorporating the GUIDE-IT findings, providing the collaboration of the triallists could be obtained.
The sustainability of any treatment effect guided by BNP is likely to be important in patient subgroups for
whom the economic case for monitoring is more marginal. In TIME-CHF,59,86 a non-statistically significant
trend for improved survival among older patients with HFrEF at 18 months was no longer evident at
5 years. Similar research collecting routine data on long-term mortality and hospitalisation among
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participants in other completed and ongoing RCTs would greatly enhance their value to clinicians and
policy-makers. Despite the high prevalence of HF, there is surprisingly little research on the economic
impact on health systems, families and societies.10 Future research, particularly on residential care needs,
informal care needs and productivity losses due to HF, is needed in order to better judge the economic
case for interventions such as BNP-guided monitoring.
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Chapter 6 Conclusion
This study has shown that BNP-guided therapy, as implemented in RCTs in specialist HF clinics, appearsto be efficacious and cost-effective in patients who have predominantly been recruited to the RCTs,
namely those who are < 75 years of age and with HFrEF. The conclusions about the efficacy of BNP-guided
therapy are uncertain because the findings are of borderline statistical significance and the majority of trials
contributing to the findings were judged to have high risk of bias.
The application of this evidence to HF patients in the UK is also uncertain. First, none of the RCTs on BNP
monitoring was conducted in the UK. Second, there is no consensus about the optimal BNP-monitoring
strategy. Third, patients with HF in the UK are not predominantly managed in specialist clinics and there
is evidence that HF management in primary care has worse clinical outcomes. Finally, the mechanism
through which BNP monitoring reduces all-cause mortality is unclear as, in the RCTs, BNP monitoring did
not result in notable differences in BNP levels or HF medications between groups.
DOI: 10.3310/hta21400 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 40
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121

Acknowledgements
The authors would like to thank the patient and public contributors for sharing their experiences of theircare and contributing their opinions in relation to interpretation of the findings.
Contributions of authors
Maria Pufulete (Research Fellow) was lead researcher. She managed the team, established the
collaboration, designed the search strategy and extracted data for the systematic review, organised
approvals for the CPRD linked cohort and co-ordinated the analyses of the cohort and drafted the
final report.
Rachel Maishman (Research Associate) was statistician. She carried out the meta-analyses and cohort
study analyses, with advice from Julian Higgins and Chris A Rogers, and drafted some of the results
sections for the final report.
Lucy Dabner (Clinical Trial co-ordinator) screened the abstracts and extracted data for the systematic
review, liaised with IPD collaborators and drafted some sections of the final report.
Syed Mohiuddin (Research Associate) was health economist. He developed the cost-effectiveness model
in collaboration with William Hollingworth.
William Hollingworth (Professor of Health Economics) was senior health economist. He developed the
cost-effectiveness model in collaboration with Syed Mohiuddin.
Chris A Rogers (Reader in Medical Statistics) was senior statistician. She advised on meta-analyses and
cohort study analyses.
Julian Higgins (Professor of Evidence Synthesis) was senior statistician with expertise in evidence synthesis.
He advised on the systematic review and meta-analyses.
Mark Dayer (Consultant Cardiologist) was clinical advisor. He advised about secondary care aspects of HF
management and interpretation of the findings.
John Macleod (Professor of Primary Care) was GP advisor with expertise in using CPRD data for research.
He advised about analyses of CPRD data, primary care aspects of HF management and interpretation of
the findings.
Sarah Purdy (Professor of Primary Care) was GP advisor. She advised about primary care aspects of HF
management and interpretation of the findings.
Theresa McDonagh (Professor of Cardiology) was clinical advisor with responsibility for the NHFA.
She advised about the NHFA data, secondary care aspects of HF management and interpretation of
the findings.
Angus Nightingale (Consultant Cardiologist and Senior Clinical Lecturer in Clinical Science) was clinical
advisor. He advised about secondary care aspects of HF management and interpretation of the findings.
Rachael Williams (Senior Researcher, CPRD) assisted with the data specification and advised about the
CPRD GOLD and linked HES data sets throughout the project.
DOI: 10.3310/hta21400 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 40
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
Barnaby C Reeves (Professor of Health Services Research) was chief investigator with overall responsibility
for the project and guarantor. He provided strategic direction for the systematic review and cohort study
and interpretation of the findings and edited the final report.
Publications
Hollingworth W, Biswas M, Maishman RL, Dayer MJ, McDonagh T, Purdy S, et al. The healthcare costs of
heart failure during the last five years of life: a retrospective cohort study. Int J Cardiol 2016;224:132–8.
Pufulete M, Higgins JPT, Rogers CA, Dreyer L, Hollingworth W, Dayer M, et al. Protocol for a systematic
review and individual participant data meta-analysis of B-type natriuretic peptide-guided therapy for heart
failure. Syst Rev 2014;3:41.
Mohiuddin S, Reeves BC, Pufulete M, Maishman R, Dayer M, Macleod J, et al. A model-based
cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure.
BMJ Open 2016;6:e014010.
Data sharing statement
Data for the IPD meta-analysis were requested from triallists under the terms of a data collaboration
agreement. Key terms of this agreement prevent further data sharing of the IPD with third parties:
l to use the data only for the purposes stated in the study protocol and in the analyses set out in the
analysis plan
l to store data submitted for the IPD meta-analysis in password-protected files on a secure University of
Bristol computer that will only be accessible by members of the management committee
l to deposit the anonymised data sets and the final individual patient data set in a data archive in
accordance with patient data archiving procedures required by the UK NHS
l all data will remain the property of the original researchers and can be withdrawn from the analyses at
any time, if they so wish
l all data will be held securely and will not be shared with anyone other than the research team
assembled for this project without the permission of the original researchers.
The data for the cohort study from NHS Digital were also obtained under an agreement with the Secretary
of State for Health, which stipulated that:
The licence granted in clause 3.1 is subject to the use of the Dataset or any other information
obtained by the Customer or its Affiliated Companies (if any) in accordance with this Agreement being
restricted to carrying out the Study for Medical and Health Research Purposes and any other use of the
Dataset, that is not expressly specified in the Protocol, is strictly prohibited.
We regret that these agreements preclude us from sharing the data sets.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
References
1. Townsend N, Bhatnagar P, Wilkins E, Wickramasinghe K, Rayner M. Cardiovascular Disease
Statistics 2015. London: British Heart Foundation; 2015.
2. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877–89. https://doi.org/10.1016/
S0140-6736(05)66621-4
3. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, et al. Prevalence of left-ventricular
systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study:
a population based study. Lancet 2001;358:439–44. https://doi.org/10.1016/S0140-6736(01)
05620-3
4. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC. Survival of
patients with a new diagnosis of heart failure: a population based study. Heart 2000;83:505–10.
https://doi.org/10.1136/heart.83.5.505
5. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R, Midlands Research Practices Consortium
(MidReC). Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction:
5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES).
Eur Heart J 2007;28:1128–34. https://doi.org/10.1093/eurheartj/ehm102
6. Sharma A, Ezekowitz JA. Similarities and differences in patient characteristics between heart
failure registries versus clinical trials. Curr Heart Fail Rep 2013;10:373–9. http://dx.doi.org/
10.1007/s11897-013-0152-x
7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines
for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the
Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of
Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
Eur Heart J 2012;3:1787–1847.
8. NICE. Chronic Heart Failure. National Clinical Guideline for Diagnosis and Management in Primary
and Secondary Care. NICE Guideline number 108. London: NICE; 2010.
9. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart
failure. Int J Cardiol 2014;171:368–76. http://dx.doi.org/10.1016/j.ijcard.2013.12.028
10. Hollingworth W, Biswas M, Maishman RL, Dayer MJ, McDonagh T, Purdy S, et al. The healthcare
costs of heart failure during the last five years of life: a retrospective cohort study. Int J Cardiol
2016;224:132–8. https://doi.org/10.1016/j.ijcard.2016.09.021
11. Healthcare Commission. Pushing The Boundaries: Improving Services For People With Heart
Failure. London: Healthcare Commission; 2007.
12. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart
failure in primary care: qualitative study. BMJ 2003;326:196. https://doi.org/10.1136/bmj.326.
7382.196
13. Hancock HC, Close H, Fuat A, Murphy JJ, Hungin AP, Mason JM. Barriers to accurate diagnosis
and effective management of heart failure have not changed in the past 10 years: a qualitative
study and national survey. BMJ Open 2014;4:e003866. http://dx.doi.org/10.1136/bmjopen-
2013-003866
DOI: 10.3310/hta21400 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 40
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
14. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, et al. National Academy
of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage
Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure.
Circulation 2007;116:e95–8. https://doi.org/10.1161/CIRCULATIONAHA.107.185266
15. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid
measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J
Med 2002;347:161–7. https://doi.org/10.1056/NEJMoa020233
16. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict
death and cardiac events in patients with heart failure: systematic review. BMJ 2005;330:625.
https://doi.org/10.1136/bmj.330.7492.625
17. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357–68. https://doi.org/
10.1016/j.jacc.2007.09.021
18. White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, et al. Effects of combined
candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and
glucose regulation in patients with symptomatic heart failure. J Card Fail 2007;13:86–94.
https://doi.org/10.1016/j.cardfail.2006.10.013
19. Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic
heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158:422–30.
http://dx.doi.org/10.1016/j.ahj.2009.06.018
20. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided
heart failure therapy: a meta-analysis. Arch Intern Med 2010;170:507–14. http://dx.doi.org/
10.1001/archinternmed.2010.35
21. Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, et al. Natriuretic
peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12
randomized trials. PLOS ONE 2013;8:e58287. http://dx.doi.org/10.1371/journal.pone.0058287
22. Li P, Luo Y, Chen YM. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-
analysis of 11 randomised controlled trials. Heart Lung Circ 2013;22:852–60. http://dx.doi.org/
10.1016/j.hlc.2013.03.077
23. Xin W, Lin Z, Mi S. Does B-type natriuretic peptide-guided therapy improve outcomes in patients
with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials.
Heart Fail Rev 2015;20:69–80. http://dx.doi.org/10.1007/s10741-014-9437-8
24. De Vecchis R, Esposito C, Di Biase G, Ariano C, Giasi A, Cioppa C. B-type natriuretic peptide-
guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic
review with meta-analysis. J Cardiovasc Med 2014;15:122–34. http://dx.doi.org/10.2459/
JCM.0b013e328364bde1
25. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, et al.
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality
and hospitalization: an individual patient meta-analysis. Eur Heart J 2014;35:1559–67.
http://dx.doi.org/10.1093/eurheartj/ehu090
26. Cochrane IPD Meta-analysis Methods Group. Resources. URL: http://ipdmamg.cochrane.org/
resources (accessed 1 December 2016).
27. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct,
and reporting. BMJ 2010;340:c221. http://dx.doi.org/10.1136/bmj.c221
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
28. Adlbrecht C, Huelsmann M, Berger R, Moertl D, Strunk G, Oesterle A, et al. Cost analysis and
cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based
nurse care. Eur J Clin Invest 2011;41:315–22. http://dx.doi.org/10.1111/j.1365-2362.2010.
02412.x
29. Sanders-van Wijk S, van Asselt AD, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, et al.
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure
patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly
Patients with Congestive Heart Failure). JACC Heart Fail 2013;1:64–71. http://dx.doi.org/10.1016/
j.jchf.2012.08.002
30. Moertl D, Steiner S, Coyle D, Berger R. Cost-utility analysis of NT-proBNP-guided multidisciplinary
care in chronic heart failure. Int J Technol Assess Health Care 2013;29:3–11. http://dx.doi.org/
10.1017/S0266462312000712
31. Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T. Is B-type natriuretic peptide-guided heart
failure management cost-effective? Int J Cardiol 2004;96:177–81. http://dx.doi.org/10.1016/
j.ijcard.2003.05.036
32. Laramée P, Wonderling D, Swain S, Al-Mohammad A, Mant J. Cost-effectiveness analysis of serial
measurement of circulating natriuretic peptide concentration in chronic heart failure. Heart
2013;99:267–71. http://dx.doi.org/10.1136/heartjnl-2012-302692
33. Brunner-La Rocca HP, Eurlings L, Richards AM, Januzzi JL, Pfisterer ME, Dahlström U, et al. Which
heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from
individual patient data of randomized trials. Eur J Heart Fail 2015;17:1252–61. http://dx.doi.org/
10.1002/ejhf.401
34. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of
individual patient data from randomized trials: a review of methods used in practice. Clin Trials
2005;2:209–17. https://doi.org/10.1191/1740774505cn087oa
35. Pufulete M, Higgins JP, Rogers CA, Dreyer L, Hollingworth W, Dayer M, et al. Protocol for a
systematic review and individual participant data meta-analysis of B-type natriuretic peptide-
guided therapy for heart failure. Syst Rev 2014;3:41. http://dx.doi.org/10.1186/2046-4053-3-41
36. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
http://dx.doi.org/10.1136/bmj.d5928
37. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions.
Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. URL: http://handbook.
cochrane.org/ (accessed 1 December 2016).
38. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous
outcome data from individual patients. Stat Med 2001;20:2219–41. http://dx.doi.org/10.1002/
sim.918
39. Thompson SG, Higgins JP. Treating individuals 4: can meta-analysis help target interventions at
individuals most likely to benefit? Lancet 2005;365:341–6. https://doi.org/10.1016/S0140-6736
(05)70200-2
40. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators.
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J
2006;27:2338–45. https://doi.org/10.1093/eurheartj/ehl250
41. Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Töpper A, Mehrhof F, et al. Titration to target
dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J
Heart Fail 2011;13:670–80. http://dx.doi.org/10.1093/eurjhf/hfr020
DOI: 10.3310/hta21400 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 40
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
42. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital
admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–25.
https://doi.org/10.1093/eurheartj/ehi115
43. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in
patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–67.
http://dx.doi.org/10.1056/NEJMoa0805450
44. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan
versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study,
ELITE). Lancet 1997;349:747–52. https://doi.org/10.1016/S0140-6736(97)01187-2
45. Fisher DJ. Two-stage individual participant data meta-analysis and generalized forest plots.
Stata J 2015;15:369–96.
46. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med 1998;17:2815–34. https://doi.org/10.1002/
(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
47. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
https://doi.org/10.1136/bmj.b2535
48. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of
methodological quality associated with estimates of treatment effects in controlled trials.
JAMA 1995;273:408–12. https://doi.org/10.1001/jama.1995.03520290060030
49. Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J 2004;4:127–41.
50. Troughton R, Brunner-La Rocca HP, Frampton CM, Berger R, Persson H, O’Connor CM, et al.
B-type natriuretic peptide guided treatment of heart failure and all cause mortality: an individual
patient data meta-analysis. Proceedings of the ESC Congress 27–31 August 2011, Paris, France,
abstract no. 3002. URL: http://eurheartj.oxfordjournals.org/content/ehj/32/suppl_1/313.full.pdf
(accessed 2 December 2016).
51. Brunner-La Rocca HP. Which heart failure patients profit from natriuretic peptide guided therapy? A
meta-analysis from individual patient data of randomised trials. Eur Heart J 2014;35(Suppl. 1):1180.
URL: https://eurheartj.oxfordjournals.org/content/ehj/35/suppl_1/local/front-matter.pdf
52. Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, et al. The STARBRITE trial:
a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced
heart failure. J Card Fail 2011;17:613–21. http://dx.doi.org/10.1016/j.cardfail.2011.04.012
53. Anguita M, Esteban F, Castillo JC, Mazuelos F, López-Granados A, Arizón JM, Suárez De Lezo J.
[Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the
treatment monitoring of patients with heart failure.] Med Clin 2010;135:435–40. http://dx.doi.org/
10.1016/j.medcli.2009.11.048
54. Karlstrom P, Alehagen U, Boman K, Ulf D, on behalf of the UPSTEP-study group. Brain natriuretic
peptide-guided treatment does not improve morbidity and mortality in extensively treated patients
with chronic heart failure: responders to treatment have a significantly better outcome. Eur J
Heart Fail 2011;13:1096–103. https://doi.org/10.1093/eurjhf/hfr078
55. Schou M, Gustafsson F, Videbaek L, Andersen H, Toft J, Nyvad O, et al. Adding serial N-terminal
pro brain natriuretic peptide measurements to optimal clinical management in outpatients with
systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). Eur J
Heart Fail 2013;15:818–27. http://dx.doi.org/10.1093/eurjhf/hft037
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128
56. Shochat M, Shotan A, Dahan I, Shochat I, Levy Y, Asif A, et al. NT-proBNP-Guided Preemptive
Treatment of Outpatients with Chronic Heart Failure Followed in a Out Hospital Clinic. J Card Fail
2012;18:S58. https://doi.org/10.1016/j.cardfail.2012.06.198
57. Koshkina D, Skvortsov A, Narusov O, Protasov V, Nasonova S, Masenko V, Tereschenko S.
NT-proBNP-guided treatment of high risk heart failure patients after acute decompensation.
Eur Heart J 2015;36(Suppl. 1):153–54. Proceedings of the ESC Congress 29 August –
2 September 2015, London, UK, abstract no. P879.
58. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of
heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.
Lancet 2000;355:1126–30. https://doi.org/10.1016/S0140-6736(00)02060-2
59. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-
guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly
Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009;301:383–92.
http://dx.doi.org/10.1001/jama.2009.2
60. Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, et al. N-terminal pro brain
natriuretic peptide-guided management in patients with heart failure and preserved ejection
fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients
with congestive heart failure (TIME-CHF). Eur J Heart Fail 2013;15:1148–56. http://dx.doi.org/
10.1093/eurjhf/hft076
61. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, et al. N-terminal pro-B-type
natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care
in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol
2010;55:645–53. http://dx.doi.org/10.1016/j.jacc.2009.08.078
62. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, et al.
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic
peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic
heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol
2010;56:2090–100. http://dx.doi.org/10.1016/j.jacc.2010.07.030
63. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U. Improved pharmacological
therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided
Management of Heart Failure – SIGNAL-HF (Swedish Intervention study – Guidelines and NT-proBNP
AnaLysis in Heart Failure). Eur J Heart Fail 2010;12:1300–8. http://dx.doi.org/10.1093/eurjhf/hfq169
64. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al.
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from
the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and
Death) trial. J Am Coll Cardiol 2009;55:53–60. http://dx.doi.org/10.1016/j.jacc.2009.02.095
65. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic
peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.
J Am Coll Cardiol 2007;49:1733–9. https://doi.org/10.1016/j.jacc.2006.10.081
66. Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-
terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left
ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881–9. http://dx.doi.org/10.1016/
j.jacc.2011.03.072
67. Karavidas A, Konstantinou K, Nikolaou M, Matzaraki V, Papoutsidakis N, Pyrgakis, Parissis J.
Guiding decongestion treatment in chronic heart failure patients. Clinical assessment or serial
laboratory evaluation? Eur J Heart Failure 2013:34(Suppl. 1):126.
DOI: 10.3310/hta21400 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 40
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
68. Krupicka J, Janota T, Hradec J. Optimalization of Heart Failure Therapy Guided by Plasma BNP
Concentrations. Proceedings of the European Society of Cardiology Congress, Stockholm,
Sweden, 31 August 2010, Eur Heart J 2010;31(Suppl. 1):859–60.
69. Karlström P, Johansson P, Dahlström U, Boman K, Alehagen U. Can BNP-guided therapy improve
health-related quality of life, and do responders to BNP-guided heart failure treatment have
improved health-related quality of life? Results from the UPSTEP study. BMC Cardiovasc Disord
2016;16:39. http://dx.doi.org/10.1186/s12872-016-0221-7
70. World Health Organization. International Classification of Diseases. Tenth Revision. Geneva: World
Health Organization; 2016.
71. Clinical Codes.org. An Online Clinical Codes Repository to Improve Validity and Reproducibility of
Medical Database Research. https://clinicalcodes.rss.mhs.man.ac.uk/ (accessed 1 May 2016).
72. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/
OXMIS coded databases. BMC Fam Pract 2010;11:1. http://dx.doi.org/10.1186/1471-2296-11-1
73. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the
appropriate approach. J Health Serv Res Policy 2004;9:110–18. http://dx.doi.org/10.1258/
135581904322987535
74. Goehler A, Geisler BP, Manne JM, Jahn B, Conrads-Frank A, Schnell-Inderst P, et al. Decision-
analytic models to simulate health outcomes and costs in heart failure: a systematic review.
PharmacoEconomics 2011;29:753–69. http://dx.doi.org/10.2165/11585990-000000000-00000
75. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009;12(Suppl. 1):5–9.
http://dx.doi.org/10.1111/j.1524-4733.2009.00515.x
76. NICE. Guide To The Methods Of Technology Appraisal 2013. London: NICE; 2013. URL: www.
nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-
200797584378 (accessed 2 December 2016).
77. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ
2004;329:224–7. http://dx.doi.org/10.1136/bmj.329.7459.224
78. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry
2005;187:106–8. https://doi.org/10.1192/bjp.187.2.106
79. ONS. National Life Tables, United Kingdom, 1980-82 to 2012-14. Newport; ONS: 2015.
80. van Jaarsveld CH, Ranchor AV, Kempen GI, Coyne JC, van Veldhuisen DJ, Sanderman R.
Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years:
incidence and long-term survival. Eur J Heart Fail 2006;8:23–30. https://doi.org/10.1016/j.ejheart.
2005.04.012
81. Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW. Comparison of risk of re-hospitalization,
all-cause mortality, and medical care resource utilization in patients with heart failure and preserved
versus reduced ejection fraction. Am J Cardiol 2015;116:1088–92. http://dx.doi.org/10.1016/
j.amjcard.2015.07.018
82. Reed SD, Kaul P, Li Y, Eapen ZJ, Davidson-Ray L, Schulman KA, et al. Medical resource use, costs,
and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF.
J Card Fail 2013;19:611–20. http://dx.doi.org/10.1016/j.cardfail.2013.07.003
83. Department of Health (DH). NHS Reference Costs 2013 to 2014. London: DH; 2014.
84. NICE. Chronic Heart Failure Shared Learning: Use of The Scenarios Simulation in the Introduction
of Serum Natriuretic Peptide Testing. London: NICE; 2011.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
85. Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure
with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.
Eur Heart J 2012;33:1750–7. https://doi.org/10.1093/eurheartj/ehr254
86. Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, et al. Long-term
results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided
treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Circ Heart Fail
2014;7:131–9. http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000527
87. Claxton K. Exploring uncertainty in cost-effectiveness analysis. PharmacoEconomics
2008;26:781–98. https://doi.org/10.2165/00019053-200826090-00008
88. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain
natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976–82.
https://doi.org/10.1016/S0735-1097(02)02059-4
89. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on
plasma natriuretic peptide levels. Circulation 2004;109:594–600. http://dx.doi.org/10.1161/
01.CIR.0000112582.16683.EA
90. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common
variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet
2009;41:348–53. http://dx.doi.org/10.1038/ng.328
91. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the
diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology
(ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Eur J Heart Fail 2016;18:891–975. https://doi.org/10.1002/ejhf.592
92. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure.
Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The
CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–35.
93. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival
in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD
Investigators. N Engl J Med 1991;325:293–302.
94. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the
angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75.
http://dx.doi.org/10.1056/NEJMoa010713
95. Neubauer S, Schilling T, Zeidler J, Lange A, Engel S, Linder R, et al. [Impact of guideline
adherence on mortality in treatment of left heart failure.] Herz 2016;41:614–24. http://dx.doi.org/
10.1007/s00059-016-4401-0
96. Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and unavailable data
in meta-analyses using individual participant data: a database survey. BMJ 2012;344:d7762.
http://dx.doi.org/10.1136/bmj.d7762
97. Burdett S, Stewart LA, Tierney JF. Publication bias and meta-analyses: a practical example. Int J
Technol Assess Health Care 2003;19:129–34. https://doi.org/10.1017/S0266462303000126
98. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart
failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92. http://dx.doi.org/
10.1056/NEJMoa1313731
99. Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, et al. Effect of age and sex on
efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction:
individual patient data meta-analysis. BMJ 2016;353:i1855. http://dx.doi.org/10.1136/bmj.i1855
DOI: 10.3310/hta21400 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 40
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131
100. Kang EM, Pinheiro SP, Hammad TA, Abou-Ali A. Evaluating the validity of clinical codes to
identify cataract and glaucoma in the UK Clinical Practice Research Datalink. Pharmacoepidemiol
Drug Saf 2015;24:38–44. http://dx.doi.org/10.1002/pds.3726
101. Quint JK, Müllerova H, DiSantostefano RL, Forbes H, Eaton S, Hurst JR, et al. Validation of chronic
obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD).
BMJ Open 2014;4:e005540. http://dx.doi.org/10.1136/bmjopen-2014-005540
102. Rothnie KJ, Müllerová H, Hurst JR, Smeeth L, Davis K, Thomas SL, Quint JK. Validation of the
Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records.
PLOS ONE 2016;11:e0151357. http://dx.doi.org/10.1371/journal.pone.0151357
103. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of
studies Conducted using Observational Routinely-collected health Data (RECORD) statement.
PLOS Med 2015;12:e1001885. https://doi.org/10.1371/journal.pmed.1001885
104. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass
index and mortality in heart failure: a meta-analysis. Am Heart J 2008;156:13–22. http://dx.doi.org/
10.1016/j.ahj.2008.02.014
105. Campbell JD, McQueen RB, Libby AM, Spackman DE, Carlson JJ, Briggs A. Cost-effectiveness
uncertainty analysis methods: a comparison of one-way sensitivity, analysis of covariance, and
expected value of partial perfect information. Med Decis Making 2015;35:596–607. http://dx.doi.org/
10.1177/0272989X14556510
106. Ieva F, Jackson CH, Sharples LD. Multi-state modelling of repeated hospitalisation and death in
patients with heart failure: the use of large administrative databases in clinical epidemiology.
Stat Methods Med Res 2015;26:1350–72. https://doi.org/10.1177/0962280215578777
107. Bhardwaj A, Rehman SU, Mohammed AA, Gaggin HK, Barajas L, Barajas J, et al. Quality of life and
chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient
Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J 2012;164:793–99 e1.
108. British Society for Heart Failure. National Heart Failure Audit: April 2013 – March 2014. London:
British Society for Heart Failure; 2015.
109. Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, et al. Rationale and
design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified
Treatment in Heart Failure. JACC Heart Fail 2014;2:457–65. http://dx.doi.org/10.1016/j.jchf.2014.
05.007
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Appendix 1 Literature searches
2012 search
Database: MEDLINE (via Ovid) 1950 to present
Search strategy
1. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (732)
2. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw. (462)
3. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (22)
4. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw. (650)
5. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial or
series)).tw. (153)
6. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or treat$ or therap$ or strateg$)).tw. (863)
7. or/1-6 (2266)
8. exp Heart Failure/ (77,650)
9. heart failure.tw. (88,345)
10. cardiac failure.tw. (9104)
11. HF.tw. (15,642)
12. CHF.tw. (9142)
13. or/8-12 (132,395)
14. Natriuretic Peptide, Brain/ (8154)
15. Monitoring, Physiologic/ (42,028)
16. ‘Predictive Value of Tests’/ (121,365)
17. ‘Health Status Indicators’/ (17,985)
18. or/15-17 (179,642)
19. 14 and 18 (1234)
20. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (732)
21. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw. (462)
22. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (22)
23. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw. (650)
24. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial or
series)).tw. (153)
25. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or therap$ or strateg$)).tw. (461)
26. or/20-25 (1923)
27. 19 or 26 (2616)
28. 13 and 27 (1471)
29. randomized controlled trial.pt. (330,201)
30. controlled clinical trial.pt. (84,375)
31. randomized.ab. (233,876)
32. placebo.ab. (132,230)
33. drug therapy.fs. (1,543,331)
34. randomly.ab. (168,558)
35. trial.ab. (242,070)
36. groups.ab. (1,106,725)
37. or/29-36 (2,867,649)
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38. exp animals/ not humans/ (3,736,636)
39. 37 not 38 (2,435,187)
40. 28 and 39 (506)
Database: EMBASE (via Ovid) 1980 to 2012 Week 26
Search strategy
1. exp heart failure/ (240,304)
2. heart failure.tw. (125,430)
3. cardiac failure.tw. (11,574)
4. CHF.tw. (13,935)
5. HF.tw. (26,271)
6. or/1-5 (284,966)
7. brain natriuretic peptide/ (13,290)
8. monitoring/ (68,421)
9. predictive value/ (18,283)
10. ‘disease course’/ (253,029)
11. ‘symptom’/ (82,438)
12. disease course/ (253,029)
13. ‘pathophysiology’/ (552,261)
14. patient monitoring/ (57,907)
15. biological monitoring/ (11,401)
16. hemodynamic monitoring/ (11,474)
17. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (1,015,916)
18. 7 and 17 (2351)
19. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (1252)
20. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw. (813)
21. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (111)
22. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw. (894)
23. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial or
series)).tw. (236)
24. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or treat$ or therap$ or strateg$)).tw. (1373)
25. or/19-24 (3676)
26. 18 or 25 (5641)
27. 6 and 26 (3599)
28. random$.tw. (734,627)
29. factorial$.tw. (18,994)
30. (crossover$ or cross-over$).tw. (61,441)
31. placebo$.tw. (175,748)
32. (doubl$ adj blind$).tw. (128,507)
33. (singl$ adj blind$).tw. (12,267)
34. assign$.tw. (204,642)
35. allocat$.tw. (68,787)
36. volunteer$.tw. (157,058)
37. Crossover Procedure/ (34,246)
38. Double-blind Procedure/ (109,462)
39. Randomized Controlled Trial/ (324,293)
40. Single-blind Procedure/ (16,047)
41. or/28-40 (1,210,587)
42. (animal/ or nonhuman/) not human/ (4,452,630)
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43. 41 not 42 (1,063,367)
44. 27 and 43 (461)
45. limit 44 to embase (395)
The Cochrane Library
#1 MeSH descriptor Heart Failure explode all trees
#2 ‘heart failure’
#3 ‘cardiac failure’
#4 CHF
#5 HF
#6 (#1 OR #2 OR #2 OR #4 OR #5)
#7 MeSH descriptor Natriuretic Peptide, Brain, this term only
#8 (BNP near/5 (guide* or monitor* or target* or predict*))
#9 (NTproBNP near/5 (guide* or monitor* or target* or predict*))
#10 ((‘natriuretic peptide’) near/5 (guide* or monitor* or target* or predict*))
#11 ((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) near/5 (retest* or
serial or series))
#12 (‘natriuretic propeptide’ near/5 (guide* or monitor* or target* or predict*))
#13 (NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP):ti
#14 (NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) near/5 (manag* or
tailor* or therap* or strateg*)
#15 (proBNP near/5 (guide* or monitor* or target* or predict*))
#16 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17 (#6 AND #16)
Web of Science (Citations Index and Conference Proceedings)
#18 #17 AND #16
#17 TS=(random* or trial or placebo* or groups (double same blind*) or (single same blind*))
#16 #15 AND #1
#15 #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
#14 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (strateg*))
#13 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (therap*))
#12 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (tailor*))
#11 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (manag*))
#10 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR series)
#9 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR serial*)
#8 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR retest*)
#7 TS=(‘natriuretic propeptide’ NEAR (guide* or monitor* or target* or predict*))
#6 TS=(‘natriuretic peptide’ NEAR (guide* or monitor* or target* or predict*))
#5 TS=(NTproBNP NEAR (guide* or monitor* or target* or predict*))
#4 TS=(proBNP NEAR (guide or monitor* or target* or predict*))
#3 TS=(BNP NEAR (guide* or monitor* or target* or predict*))
#2 TS=(‘natriuretic peptide’ NEAR target*) or TS=(‘natriuretic propeptide’ NEAR target*)
#1 TS=(‘heart failure’ or ‘cardiac failure’ or CHF or HF)
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2014 updated search
The original search was rerun from 2012 to January 2014 (date of search 11 January 2014) using the
above listed strategies (but please see below for correction to MEDLINE strategy text – there were some
duplicated lines in the original MEDLINE search).
Database: MEDLINE 1950 to present
Search strategy
1. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (875)
2. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw. (585)
3. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (30)
4. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw. (770)
5. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial or
series)).tw. (177)
6. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or treat$ or therap$ or strateg$)).tw. (1034)
7. or/1-6 (2734)
8. exp Heart Failure/ (88,614)
9. heart failure.tw. (103,737)
10. cardiac failure.tw. (9777)
11. HF.tw. (19,875)
12. CHF.tw. (10,524)
13. or/8-12 (152,446)
14. Natriuretic Peptide, Brain/ (9880)
15. Monitoring, Physiologic/ (45,222)
16. ‘Predictive Value of Tests’/ (145,475)
17. ‘Health Status Indicators’/ (21,035)
18. or/15-17 (209,672)
19. 14 and 18 (1512)
20. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (875)
21. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw. (585)
22. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw. (30)
23. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw. (770)
24. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial or
series)).tw. (177)
25. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or therap$ or strateg$)).tw. (540)
26. or/20-25 (2324)
27. 19 or 26 (3187)
28. 13 and 27 (1767)
29. randomized controlled trial.pt. (390,995)
30. controlled clinical trial.pt. (90,070)
31. randomized.ab. (288,395)
32. placebo.ab. (157,299)
33. drug therapy.fs. (1,772,029)
34. randomly.ab. (200,079)
35. trial.ab. (303,857)
36. groups.ab. (1,280,166)
37. or/29-36 (3,308,511)
38. exp animals/ not humans/ (4,066,609)
39. 37 not 38 (2,817,704)
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40. 28 and 39 (622)
41. (‘2012$’ or ‘2013$’ or ‘2014$’).ed. (1,700,243)
42. 40 and 41 (105)
2016 updated search
Search date: 8 June 2016.
Summary of search results (1 January 2014–8 June 2016)
l MEDLINE, n = 141
l MEDLINE In-Process & Other Non-Indexed Citations, n = 22
l EMBASE, n = 160
l Web of Science (Core Collection), n = 161.
Total = 484.
De-duplicated (against each other and 2014 search results), n = 367
l The Cochrane Library (all years to 8 June 2016):
¢ Cochrane Central Register of Controlled Trials, n = 834 (216)
¢ Cochrane Database of Systematic Reviews, n = 6
¢ Database of Abstracts of Reviews of Effects, n = 49
¢ Health Technology Assessment database, n = 20
¢ NHS Economic Evaluation Database, n = 25.
All years total = 934.
De-duplicated (against each other and 2014 search results), n = 217.
Total number of ‘new’ references to screen, n = 584.
MEDLINE, MEDLINE & Other Non-Indexed Citations (via Ovid)
Search strategies
1. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw.
2. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw.
3. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw.
4. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw.
5. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial
or series)).tw.
6. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or treat$ or therap$ or strateg$)).tw.
7. or/1-6
8. exp Heart Failure/
9. heart failure.tw.
10. cardiac failure.tw.
11. HT.tw.
12. CHF.tw.
13. or/8-12
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14. Natriuretic Peptide, Brain/
15. Monitoring, Physiologic/
16. ‘Predictive Value of Tests’/
17. ‘Health Status Indicators’/
18. or/15-17
19. 14 and 18
20. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw.
21. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw.
22. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw.
23. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw.
24. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial
or series)).tw.
25. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or therap$ or strateg$)).tw.
26. or/20-25
27. 19 or 26
28. 13 and 27
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. randomized.ab.
32. placebo.ab.
33. drug therapy.fs.
34. randomly.ab.
35. trial.ab.
36. groups.ab.
37. or/29-36
38. exp animals/ not humans/
39. 37 not 38
40. 28 and 39
41. (‘2014$’ or ‘2015$’ or ‘2016$’).ed,yr.
42. 40 and 41 [n=141] [n=22 (MEDLINE-in-Process)]
EMBASE (via Ovid)
1. exp heart failure/
2. heart failure.tw.
3. cardiac failure.tw.
4. CHF.tw.
5. HF.tw.
6. or/1-5
7. brain natriuretic peptide/
8. monitoring/
9. predictive value/
10. ‘disease course’/
11. ‘symptom’/
12. ‘pathophysiology’/
13. patient monitoring/
14. biological monitoring/
15. hemodynamic monitoring/
16. or/8-15
17. 7 and 16
18. (BNP adj5 (guide$ or monitor$ or target$ or predict$)).tw.
19. (proBNP adj5 (guide or monitor$ or target$ or predict$)).tw.
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20. (NTproBNP adj5 (guide$ or monitor$ or target$ or predict$)).tw.
21. ((natriuretic peptide or natriuretic propeptide) adj5 (guide$ or monitor$ or target$ or predict$)).tw.
22. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (retest$ or serial
or series)).tw.
23. ((NTproBNP or Natriuretic Peptide or natriuretic propeptide or BNP or proBNP) adj5 (manag$ or tailor$
or treat$ or therap$ or strateg$)).tw.
24. or/18-23
25. 17 or 24
26. 6 and 25
27. random$.tw.
28. factorial$.tw.
29. (crossover$ or cross-over$).tw.
30. placebo$.tw.
31. (doubl$ adj blind$).tw.
32. (singl$ adj blind$).tw.
33. assign$.tw.
34. allocat$.tw.
35. volunteer$.tw.
36. Crossover Procedure/
37. Double-blind Procedure/
38. Randomized Controlled Trial/
39. Single-blind Procedure/
40. or/27-39
41. (animal/ or nonhuman/) not human/
42. 40 not 41
43. 26 and 42
44. limit 43 to embase
45. (2014$ or 2015$ or 2016$).em,yr.
46. 44 and 45 [n=160]
Web of Science Core Collection
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=2014-2016 [n=161]
#1 TS=(‘heart failure’ or ‘cardiac failure’ or CHF or HF)
#2 TS=(‘natriuretic peptide’ NEAR target*) or TS=(‘natriuretic propeptide’ NEAR target*)
#3 TS=(BNP NEAR (guide* or monitor* or target* or predict*))
#4 TS=(proBNP NEAR (guide or monitor* or target* or predict*))
#5 TS=(NTproBNP NEAR (guide* or monitor* or target* or predict*))
#6 TS=(‘natriuretic peptide’ NEAR (guide* or monitor* or target* or predict*))
#7 TS=(‘natriuretic propeptide’ NEAR (guide* or monitor* or target* or predict*))
#8 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR retest*)
#9 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR serial*)
#10 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR series)
#11 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (manag*))
#12 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (tailor*))
#13 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (therap*))
#14 TS=((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) NEAR (strateg*))
#15 #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
#16 #15 AND #1
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#17 TS=(random* or trial or placebo* or groups (double same blind*) or (single same blind*))
#18 #17 AND #16
#19 TS=(((clinical near trial* or crossover or cross over) or ((single* or doubl* or trebl* or tripl*) near
(blind* or mask* or dummy)) or (singleblind* or doubleblind* or trebleblind* or tripleblind* or placebo* or
random*))) or TI=(((clinical near trial* or crossover or cross over) or ((single* or doubl* or trebl* or tripl*)
near (blind* or mask* or dummy)) or (singleblind* or doubleblind* or trebleblind* or tripleblind* or
placebo* or random*)))
The Cochrane Library
#1 MeSH descriptor: [Heart Failure] explode all trees
#2 ‘heart failure’
#3 ‘cardiac failure’
#4 CHF or HF:ab (Word variations have been searched)
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Natriuretic Peptide, Brain] this term only
#7 (BNP near/5 (guide* or monitor* or target* or predict*))
#8 (NTproBNP near/5 (guide* or monitor* or target* or predict*))
#9 ((‘natriuretic peptide’) near/5 (guide* or monitor* or target* or predict*))
#10 ((NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) near/5 (retest* or
serial or series))
#11 (‘natriuretic propeptide’ near/5 (guide* or monitor* or target* or predict*))
#12 (NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP):ti
#13 (NTproBNP or ‘Natriuretic Peptide’ or ‘natriuretic propeptide’ or BNP or proBNP) near/5 (manag* or
tailor* or therap* or strateg*)
#14 (proBNP near/5 (guide* or monitor* or target* or predict*))
#15 (#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14)
#16 #5 and #15
#17 (2014 or 2015 or 2016)
#18 #16 and #17
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Appendix 2 List of data items requested
Study-level data
Country in which study was carried out
Number of participants randomised
Number allocated to the BNP group
Number allocated to the standard care group
Setting (primary care, hospitals, specialist clinics)
Date first patient randomised
Date last patient randomised
Date of final follow-up
Did the study measure quality of life (state tool that was used)
Did the study measure HF risk score (state tool that was used)
Details of intervention (frequency of testing, actions, etc.)
Details of comparator (frequency of review, actions, etc.)
IPD Variables collected at study entry
Demography Age
Sex
Weight
Height
BMI
Smoking status
Medical history Cause of HF
Previous myocardial infarction
Previous intervention (PCI/CABG)
Previous stroke
Previous angina pectoris
Previous peripheral artery disease
Diabetes status (including type)
History of hypertension
History of atrial fibrillation
History of chronic obstructive pulmonary disease
Pacemaker in situ
Cardiac resynchronization therapy device in situ
Implantable cardioverter defibrillator in situ
IPD
Variables collected at each visit – data required for
all visits including baseline visits
Clinical NYHA class
LVEF
Resting heart rate
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IPD
Variables collected at each visit – data required for
all visits including baseline visits
SBP
DBP
HF score
Laboratory BNP/NT-proBNP
Creatinine
Sodium
Potassium
Blood urea nitrogen
Haemoglobin
Drug treatment ACEis
ARBs
Beta blockers
Mineralocorticoid receptor antagonists
Loop diuretic
Thiazide diuretics
Vasodilator
Other potassium sparing diuretic
Ivabradine
Aspirin
Other antiplatelet agent
Oral anticoagulant
Digoxin
Amiodarone
Other antiarrhythmiac
Calcium-channel blocker
Statin
Quality of life
IPD
Clinical outcomes – data required for all deaths,
hospital admissions or cardiovascular events
Date of death
Cause of death
Date of hospital admission/cardiovascular event
Date of hospital discharge
Details of reason for admission/cardiovascular event
(e.g. HF, non-fatal myocardial infarction, non-fatal stroke,
new atrial fibrillation, fitting of pacemaker/cardiac
resynchronization therapy device/implantable cardioverter
defibrillator)
DBP, diastolic blood pressure.
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Appendix 3 Data extraction form
B-type natriuretic peptide-guided therapy in heart failure
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